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This thesis is about neovascularization in the eye including neovascularization on the ocular 
surface and the retina. The pathogenesis of the neovascularization is similar in different tissues 
of the eye. Ischaemia of tissues results in production of vascular endothelial growth factor 
(VEGF) which in turn leads to growth of abnormal neovessels which can lead to complications 
by leakage or bleeding.  
Chapter one discusses in details the anatomy of the ocular surface and retina and the 
pathogenesis of neovascularization as well as the mediators involved in the complex process of 
neovascularization.  
Chapter two discusses a clinical trial that studies the effect of combined Anti-VEGF injection 
(Avastin) and Anti-fibrosis injection (5 Fluorouracil) on pterygium. Pterygium is a condition that 
affects the conjunctiva due to degenerative changes and can affect vision by causing 
astigmatism and blocking the visual axis. Pterygium has both vascular and fibrous elements and 
hence the idea of injecting it with 2 agents. It was found via previous studies that the release of 
several mediators is responsible for the formation and growth of pterygium. Of these 
mediators, VEGF is the main inducer of the vascular component of the pterygium and its 
receptors are blocked by Avastin while the fibrotic component is blocked by 5 fluorouracil (5 
FU) injections. Pterygium is mainly treated by surgical excision with the draw back of 
recurrence. Several studies were conducted and investigated the use of Avastin and 5FU 
separately but never combined. This clinical trial was designed to evaluate the effect of 
combined injections of 5FU and bevaciazumab in patients presenting with pterygium.  This 
approach resulted in reduction in the clinical grade, thickness and vascularity of the pterygium. 
This two pronged approach addressing both the main pathological processes may work 
synergistically affecting thickness and vascularity of the pterygium. This medical approach will 
also reduce the need for surgery in many patients in whom injections alone might be an option 
to stop the progression of pterygium.  
Chapter three is an observational study to observe the healing of grafts in patients who 
underwent surgical excision of pterygium and had autologous conjunctival grafts to cover the 
defect. The healing of the donor site was also observed. Such an observational study 
monitoring the graft and donor site was never carried out before. The results were very 
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interesting as it was found that the graft showed signs of reperfusion injury during the early 
stages of healing, a phenomenon which also occurs in organs like kidneys during renal 
transplantation surgery. Reperfusion injury happens due to sudden ischaemia caused by 
severed blood supply but is essential as it induces healing to start in the tissue which in this 
study was the autoconjunctival graft. These findings are specifically useful for clinical follow up 
and differentiation from early signs of recurrence of pterygium which may clinically look very 
similar to the normal healing signs of the graft.  
Chapter four studies a different component of the ocular surface which is the cornea. The 
cornea is responsible for the major proportion of refraction. A retrospective study was 
conducted to evaluate the effect of different techniques to treat active and established corneal 
neovessels which can cause inflammation and severe visual impairment. The techniques used 
were fine needle diathermy, Anti-VEGF injections or both. All patients who received both fine 
needle diathermy and injections had complete regression of the corneal neovessels for the 
whole study period.  
Chapter five was about the HOLOCORE study, a multi-center prospective study across several 
centers in Europe for exvivo limbal stem cell expansion. It involved evaluating the results of 
Holoclar product- a small limbal biopsy specimen from the unaffected eye or from a normal 
limbal zone in case of bilateral burns, followed by in vitro expansion to generate a sheet of 
corneal epithelial cells including both differentiated and stem cells resting on a supportive 
fibrin layer and kept in a nutrient transport medium- on the corneal neovessels regression and 
epithelial defect healing in patients with unilateral or bilateral partial chemical or physical burn.  
Two patients were recruited  after meeting the eligibility criteria of the clinical trial. According 
to the outcome measures of the trial, one patient was considered a success as there was 
complete regression of the corneal neovessels and healing of the epithelial defect. The second 
patient failed as the vessels have failed to regress and the epithelial defect failed to heal. The 
patient underwent other different procedures for treating the neovessels and the defect.  
Finally, chapter six was about retinal neovascularization. It was a single centre prospective cross-
sectional study to investigate corneal neuropathy in the different stages of diabetes with and without 
retinopathy and the effect of anti-VEGF and PASCAL laser photocoagulation on corneal nerves in eyes 
with diabetic macular oedema in non-proliferative diabetic retinopathy and proliferative diabetic 
retinopathy. This was the first study that has evaluated corneal innervation following anti-VEGF 
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therapy in a large number of diabetic eyes at different stages of diabetic retinopathy. The results 
showed that PASCAL is a safe modality of treatment for patients who need focal, macular grid or PRP 
laser treatment. It also showed that anti-VEGF injections might be implicated in the damage of corneal 
nerves seen in diabetic eyes especially at the non-proliferative diabetic retinopathy stage. In eyes with 
proliferative diabetic retinopathy, it is most probable that the long-standing diabetes rather than the 
laser treatment or anti-VEGF injections are responsible for reduced corneal nerve parameters. 
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CHAPTER 1: GENERAL INTRODUCTION 
 
 
1.1 Ocular surface anatomy 
 
The ocular surface consists of the corneal epithelium, the limbal epithelium and the 
epithelial lining of the conjunctiva and lid margins. The transparent cornea is the part of the 
ocular surface that is responsible for 65% of refraction in the eye allowing the light to pass 
and focus on its way to the retina. 
1.1.1 Corneal layers 
 
The cornea consists of 6 layers: epithelium which is the outer most layer with its basement 
membrane. Posterior to the epithelial basement membrane lies the Bowman’s membrane 
which is a condensation of types 1 and 4 and proteoglycans. The stroma which forms 90% 
of the corneal thickness is formed of stromal fibers, extracellular matrix and keratocytes. 
The stromal fibers are mainly made of collagen type 1 but also contain types 4 and 12 
collagen. Pre- Descemet’s layer (Dua’s layer) lies posterior to the stroma and is formed of 
collagen fibers(1). Descemet’s membrane lies posterior to Dua’s layer and contains type 4 
collagen and laminin and is acellular. The endothelium which is the inner most layer is a 
single layer of hexagonal cells (Figure 1.1). The corneal epithelium is a uniform non-
keratinised stratified squamous epithelium extending from limbus to limbus and is 
continuous with the limbal epithelium. It is made of 4 to 6 layers and has 3 types of cells 
which are the superficial flat cells, wing cells and basal cells. The transparency of the cornea 
is attributed to the extremely well organised epithelium and organisation of the collagen 
fibres which lie parallel to each other and to the plane of the cornea within the stroma as 
well as corneal lack of vascularity (2). The basement membrane is secreted by the basal 
epithelial cells and is made of different proteins mainly type IV collagen, fibrin, fibronectin 













1.1.2 Limbal structure 
 
The palisades of Vogt with their interpalisade rete ridges, the specialized connective tissue 
architecture, the various epithelial immunophenotypes and the limbal epithelial crypts; as 
well as a highly organized vascular and nervous supply provide the physiological 
microenvironment and the anatomical support for the limbus (corneoscleral junction) to 
maintain and sustain the limbal epithelial stem cells. Stem cells (SC) are progenitor cells with 
the role of tissue regeneration and cells replacement. SC are slow cycling and live as long as 
the organ they serve and constitute a very small part of the total cell mass of the organ. 
They are the source from which almost all other cells arise that constitute a given organ 
served by the SC. Corneal epithelial stem cells are committed progenitors and their 
physiological role is to only differentiate to corneal epithelial phenotype, though in 
experimental conditions can be made to transdifferentiate to hair follicles (4, 5). SC play a 
major role in healing and regeneration of epithelium after injury but have a minimal role in 
physiological homeostasis of the corneal epithelium (6, 7). Limbal stem cells reside in a well- 
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protected microenvironment called the niche. The niche surrounds stem cells and 
modulates their function and fate through internal and external factors. They are protected 
from Ultraviolet radiation by melanocytes that reside in the basal layers of the limbal 
epithelium and by the upper and lower eyelid that act as a protective cover to the superior 
and inferior limbus (8-10). It acquires its oxygen supply, cytokines, growth factors and other 
several nutrients from the limbal stromal blood vessels and mesenchymal cells (2, 11-13). 
The niche also regulates the limbal stem cell cycle to keep them in an undifferentiated 
resting state (11, 14). The inter palisade rete ridges of the palisades of Vogt constitute the 
limbal SC niche (4, 5, 15, 16). 
The palisades of Vogt are radially oriented fibrovascular ridges and are very prominent along 
the upper and lower limbus. They are visible in pigmented individuals due to the high 
melanin content of the epithelial cells. The ‘valley’ between the adjacent palisades is packed 
with epithelial cells that form the interpalisade (epithelial) rete ridge. Impression cytology 
studies show that the limbal epithelial cells are smaller, with a higher cell density and a 
greater nucleus to cytoplasm ratio compared to central corneal epithelial cells (17, 18). The 
connective tissue of the palisade is rich in arteries, veins, nerves and lymphatics. The arterial 
supply is from the anterior ciliary arteries derived from arteries of the rectus muscles. The 
epithelium covering the palisade is 2 to 3 cells thick. The epithelial cells in inter palisade rete 
ridges are 10 to 15 cells thick (19). 
Limbal epithelial crypts (LEC) are solid cords of epithelial cells that arise from the posterior 
end of the inter palisade rete ridge and extend into the surrounding substantia propria 
peripherally, centrally towards the cornea or circumferentially in a clockwise or 
anticlockwise direction (18, 20). LEC could be minor and major, with the major ones ranging 
from 40 to over 200 microns. The average number of LEC is 9 per eye. LEC are packed with 
epithelial phenotype of cells, basal, suprabasal and central. The cell membrane of the basal 
cells in contact with the basement membrane have complex finger-like processes with 
special hemidesmosomes, allowing for a strong attachment between these putative SC and 
the substrate. The peripheral corneal basal cell attachments are also firmer than the central 
epithelial attachments. Hence following injury, a peripheral rim of corneal epithelium (and 
the limbal epithelium) remain attached even when a large area of the central cornea is lost. 
Cells from this rim migrate centripetally as convex sheets that close the defect and restore 
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epithelial integrity. Lines of contact between these sheets stain with fluorescein and appear 
as the pseudo dendrites seen during healing of corneal epithelial defects (21). 
 
 
Figure 1.2: A cross-sectional diagram of the human corneal limbus. (corneal epithelial stem cells, deficiency and 




The conjunctiva is the highly specialised mucosal lining of the ocular surface and it extends 
from the lid margin, posterior to the grey line and lines the posterior aspect of the lids 
forming the palpebral or tarsal conjunctiva. It then folds over to cover the eye ball as the 
bulbar conjunctiva. The folds between the bulbar and palpebral conjunctiva are called 
superior, inferior, lateral and medial fornices. The conjunctiva is made of epithelial cells and 
substantia propria which is loose connective tissue underlying the epithelium. The 
conjunctival epithelium is squamous, non-keratinized, with goblet cells which are found all 
over the conjunctiva especially in the nasal palpebral and forniceal areas. The conjunctival 
cells are rich in cytoplasmic organelles. The substantia propria is very rich in blood vessels 
and contains lymphoid tissue made of plasma cells, lymphocytes, neutrophils and mast cells 
(22-24). 
1.1.4 Blood supply and lymphatics 
5  
 
The cornea is an avascular structure and acquires nutrients from the peri-corneal limbal 
vasculature, the aqueous humour and the tear film (25-27). 
Limbal vessels consist of basement membrane and endothelial cell lining. The basement 
membrane is made of fine filaments with embedded collagen fibrils. The filaments are 
arranged in alternating layers, each layer is less than 0.1 microns thick. The endothelial cells 
form the vessel wall and are organised in a single layer attached to their basement 
membrane (28). 
Two types of capillaries have been described in the limbus; muscle type capillaries with thick 
endothelium and fenestrated visceral type capillaries. There is no gap between the 
endothelial cells in most of the capillaries. However, a thin membrane covering this gap was 
described in some localised areas where the vessel appears to be fenestrated. Pericytes 
were seen on the outer surface of the arterial capillaries and in proximity to the endothelial 
cells (29). Pericytes have similar structure to the endothelial cells but are functionally 
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different (30). It is commonly believed that pericytes are one major source of mesenchymal 
stem cells (31-34). 
Pericytes also lead to specific induction of fibronectin and nidogen-1 (i.e., matrix-bridging 
proteins that link together basement membrane components) as well as perlecan and 
laminin isoforms (35). 
The cornea is normally devoid of lymphatic vessels thus allowing for its unique immune 
privileged status. Corneal neovascularisation is usually associated with lymphatics- 
subsequent studies of vascularised corneas supported the presence of lymphatic vessels in 
the cornea using lymphatic specific markers which augment the afferent arc of the immune 






1.1.5 Corneal innervation 
 
 
The cornea is a highly innervated structure and has both sensory and autonomic nerves and 
is mainly vasomotor in function (38). Corneal innervation is mainly sensory form the 
ophthalmic division of the trigeminal nerve via the long posterior ciliary nerves. These 
nerves branch forming the peri-limbal plexus(39). 
The autonomic nerve fibers have sympathetic fibers that originate from the superior 
cervical ganglion as well as parasympathetic fibers that come from the ciliary ganglion. 
Demylinated radial nerves emerge from the peri-limbal plexus and enter the cornea at mid 
stromal level. There are about 11 radial nerves in each quadrant. They run towards the 
centre and superficially to form the Bowmans plexus. Smaller branches penetrate Bowmans 
membrane ending in the sub-basal plane of the epithelium, in terminal bulbs which are 20 
to 40 micrins in diameter. The penetration sites are mainly situated in the mid-peripheral 
cornea. Finer neurites arise from the bulbs as naked endings (without Schwan cells) forming 
the sub-basal plexus (40). Terminal nerves from the sub-basal nerve plexus enter the 




Figure 1.3:  A three-dimensional section of the human cornea showing the corneal nerves distribution and their density and 






1.2 Corneal angiogenesis 
 
1.2.1 Epidemiology and risk factors 
 
 
Corneal neovascularization (NV) is a condition that can result in severe visual impairment 
and represents a major public health problem (42). It is estimated that for a given year, 1.4 
million patients in the US may develop corneal NV; and 20% of corneal samples taken during 
corneal transplantation revealed histopathologic evidence of vascularization (43). Recently, 
it was found to affect up to 4.14% of patients coming for eye care (44). The rate of corneal 
NV may be as high as 60% in patients with inflammatory disorders such as atopic 
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keratoconjunctivitis (45). A study was performed to assess corneal NV after penetrating 
keratoplasty in patients without active inflammation, previous corneal NV or persistent 
epithelial defects. The study reported a remarkably higher risk of corneal NV when suture 
knots were buried in the host stroma, when a large recipient was used or when active 
blepharitis was present. They also reported that 41% of eyes receiving corneal grafts 
developed corneal NV 6 to 9 months after the corneal transplant (46). The most common 
cause for corneal neovascularisation was found to be herpes simplex keratitis and it remains 
to be the most common cause of recurrence of NV after corneal grafting (47, 48). 
1.2.2 Causes 
 
Corneal neovascularisation could occur due to the following disorders (44, 49, 50): 
 
1. Hypoxia due to contact lens wear 
2. Infectious keratitis due to viral, bacterial, fungal and parasitic infections 
3. Limbal stem cell deficiency 
4. Trauma 
5. Ocular surface neoplasia such as conjunctival, corneal intraepithelial neoplasia and 
papilloma. 
6. Inflammatory ocular surface disorders such as Steven-Johnson syndrome, atopic 
conjunctivitis, Rosacea and Mucous membrane pemphigoid. 
 
 
1.2.3 Mechanism of angiogenesis 
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In corneal angiogenesis, corneal NV sprout mainly from the venules and capillaries of the 
limbal plexus. Depending on the underlying pathology, corneal NV are present clinically in 
three different forms (1) stromal NV mainly correlated with stromal keratitis, (2) deep NV 
overlying Descemet’s membrane in herpetic keratitis and (3) vascular pannus which is 
associated with connective tissue growing in the superficial periphery of the cornea and is 
seen mainly in ocular surface disorders (46, 51). 
Insults to the cornea activate inflammatory and immune-mediated pathways leading to an 
imbalance between angiogenic and antiangiogenic factors and this balance may be tilted in 
favour of NV due to the upregulation of angiogenic factors and/or the downregulation of 
antiangiogenic factors (52-55). The angiogenic factors include vascular endothelial growth 
factor (VEGF), fibroblast growth factor, platelet derived growth factor, inflammatory 
mediators and angiopoietins with VEGF being the most prominent molecule involved in the 
promotion of NV. Antiangiogenic factors are pigment epithelium–derived factor, VEGF 
Receptor-2, endostatin and angiostatin (56). MMPs can act as a stimulator or inhibitor of 
angiogenesis in different circumstances (57, 58). 
The antiangiogenic molecules were found to work together to maintain the cornea in an 
avascular state. Alternatively, it was mentioned that molecules can act individually to 
suppress corneal vascularisation. 
Corneal NV can be superficial or deep. Superficial NV is either localized or diffuse (pannus). 
Pannus is fibrovascular tissue that separates the epithelium from Bowman’s membrane, 
occasionally extending than Bowman’s membrane. With trachoma it tends to involve the upper 
part of the cornea while in in exposure or bullous keratopathy it involves the lower part of the 
cornea. In chemical burns, it is massive and covers the whole cornea. Each vessel of a pannus 
consists of a small arteriole forming a loop with one large venule or more via a small capillary 
bed. The vessels move by simple migration of the loop. On the other hand, localized superficial 
NV consists of a layer of vessels that includes interstitial and superficial vessels. These vessels 
are directed towards a specific lesion and is most commonly seen in recurrent herpetic keratitis. 
Histologically, superficial NV are located under the epithelium and are associated with 
inflammatory cells during their active progression. Pannus wll be associated with plenty of 
connective tissue. Deep NV tends to occur between the corneal stroma and Descemet’s 
membrane. They tend to occur following interstitial keratitis (Corneal vascularization, David G. 
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Cogan, IOVS, 1962) 
1.2.4 Suppressors of corneal angiogenesis 
 
A) VEGF Receptors 
 
Multiple VEGEF receptors are expressed by the cornea and these act as “decoy” receptors 
for the proangiogenic VEGF molecules. These receptors are soluble VEGF-1 and soluble 
VEGF-2. Soluble VEGF-1 suppresses angiogenesis via sequestration of VEGF-A molecules (56, 
59). The corneal epithelium is responsible for expressing membrane bound VEGF-3 which in 
turn sequesters VEGF-C and VEGF-D (60).This leads to indirect suppression of angiogenesis 
by inhibiting the recruitment of VEGF secreting macrophages (61). 
B) Pigment epithelium–derived factor (PEDF) 
 
PEDF is thought to act individually to maintain the cornea in an avascular state (62). PEDF is 
found in large amounts in the corneal stroma, iris and retinal pigment epithelium (63, 64). 
When an antibody that suppresses the action of PEDF was delivered to the cornea, it was 
found that the cornea became invaded with blood vessels. On delivery of large amounts 





Angiostatin is present in the tear fluid and the corneal epithelium (66). Angiostatin 
suppresses corneal NV via binding to integrin αvβ3 (67), vascular endothelial cell surface- 
expressed F1-F0 ATP synthase R (68, 69)and hepatocyte growth factor receptor (c-met) (70- 




Angiogenin is present in tears and reduces the inflammation caused by tumour necrosis 
factor-alpha or lipopolysaccharide in human corneal fibroblasts by suppressing IkappaB 
kinase-epsilon mediated activation of nuclear factor-kappaB (74), 
 
 
E) Matrix metalloproteinases (MMPs) 
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MMPs play a query role in corneal vascularization as the same molecule is capable of being 
a stimulator or inhibitor of angiogenesis in different circumstances (57, 58). MMP-7 
(matrilysin) promotes vascularization by stimulating the production of VEGF and promoting 
proliferation of vascular endothelial cells (75, 76). MMP-7 produced by the corneal basal 
epithelial layer is believed to play a role in suppressing angiogenesis and this is evidenced by 
the massive increase of the angiogenic response to corneal trauma when MMP-7 becomes 
deficient (77, 78). This may be a function of the MMP-7-mediated cleavage of type XVIII 




Endostatin is a proteolytic portion of collagen XVIII and suppresses angiogenesis by 
inhibiting the VEGF and fibroblast growth factor (81, 82). Collagen XVIII is present in lens 
capsule, lens and cornea (50). 
1.2.5 Stimulators of corneal angiogenesis 
 
A) Vascular Endothelial Growth Factors (VEGF) 
VEGF are secreted growth factor peptides generated by alternative splicing in five isoforms 
(VEGF 115, VEGF 121, VEGF 165, VEGF 189 and VEGF 206). The members of the VEGF family 
are VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PlGF) (83). VEGFs bind to 
tyrosine kinase receptor VEGF-1, VEGF-2 and VEGF-3 (83, 84). 
VEGF is produced by T cells, pericytes, smooth muscle cells, astrocytes, retinal pigment 
epithelial cells and macrophages secondary to inflammation and hypoxia. Hypoxia is the 
main regulator of VEGF gene expression. VEGF expression is also regulated by several 
cytokines such as epidermal growth factor, prostaglandin E2, interleukin 1a, interleukin 6 
and transforming growth factor-B (85, 86). 
VEGF is a peptide present massively in the epithelium of vascularized corneas secondary to 
inflammation(87)and is a strong promoter of corneal inflammation induced by hypoxia and 
angiogenesis(88). VEGF is also produced in the stromal keratocytes and endothelium (89). 
VEGF-A is the most important member of VEGF family regarding angiogenesis (90, 91).VEGF- 
A binds to VEGF-2(92) resulting in vascular endothelial cell proliferation, migration and 
increased vascular permeability and dilation (86, 93, 94). Moreover, VEGF attracts 
inflammatory cells (e.g. macrophages) chemically leading to production of more 
proangiogenic molecules(95).When VEGF-C or VEGF-D bind to VEGF-2 or -3 




B) Inflammatory Mediators 
 
All causes of corneal angiogenesis result from inflammation. Inflammatory cells are 
abundant in VEGF molecules and thus encourage angiogenesis (98). 
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Inflammatory mediators such as chemokines can promote angiogenesis either directly or by 
recruiting inflammatory cells (99). Integrins help with the migration of vascular endothelial 
cells and inflammatory cells (100). Interleukin 6, transforming growth factor and tumour 





C) Fibroblast Growth Factors (FGFs) 
 
There are 18 types of FGs that bind to FGF receptors (105, 106). FGF1 and FGF 2 are strong 
stimulators of angiogenesis (107, 108). FGF2 is produced by corneal epithelial cells and 
released as a result to injury to the epithelium (50, 109) and binds to receptors on the 
epithelial basement membrane, Bowman membrane and Descemet membrane (110, 111) 
thus promoting vascular endothelial cell proliferation and migration (112, 113). 
 
D) Platelet-derived growth factors (PDGFs) 
 
PDGF and VEGF are related both in structure and function (114). Humans have four PDGF 
chains (PDGF-A, -B, -C, and –D) that bind to tyrosine kinase receptor complexes of PDGFR-α 
or PDGFR–β(115). PDGF-A and –B are present in corneal endothelial cells, epithelial cells and 
stromal fibroblasts (116). PDGFR-α and PDGFR–β are expressed by corneal epithelial cells, 




E) Angiopoietins (Ang) 
 
Once vessels are formed, Ang family including Ang1, 2, and 4 ((118) come into place in the 
process of angiogenesis. Ang-1 induces maturation of blood vessels and this is evidenced by 
an increase in vessels perfusion and density. The role of Ang-2 has remained controversial, 
however, with recent reports suggest that in some circumstances, it may be pro-angiogenic 
via promoting a rapid increase in capillary diameter, remodelling of the basal lamina, 
proliferation and migration of endothelial cells and stimulating the sprouting of new blood 
vessels (119). 
1.2.3 Quantification of Corneal NV 
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Faraj et al. (47) have recently carried out a study with the aim of clinically characterizing the 
corneal NV in 165 patients with various causes of corneal pathologies. They assessed the 
vessels location, depth, length, branching pattern, colour, lipid leakage, blood flow and 
presence or absence of haemorrhage and developed a clinical grading system for corneal 
NV. They staged the vessels into five categories based on their morphological characteristics 
and created a system for the quantification of NV as follows (Please see Chapter 4, figure 
4.1): 
1. Active young vessels: Newly formed vessels that contain a lot of blood, bright red 
with minimal fibrous tissue layering . They are seen to be actively  progressing in the 
cornea and a well- defined network of fine capillary vessels. The corneal stroma 
surrounding the vessels shows signs of leakage  
2. Active old vessels: These are vessels that reach and surround or cover the lesion in 
the cornea. Their progression stops but the fibrosis will keep progressing. They are 
less bright than the young vessels and still have an active circulation 
3. Partially regressed: These vessels are present when corneal pathology has stopped 
due to therapy or the arrival of corneal vessels or following fine needle diathermy of 
corneal vessels. The blood circulation is slow, the vessels are less dilated and some 
parts of the complex become less visible or reduced. Both active old vessels and 
partly regressed vessels show arborizing pattern from the limbus towards the centre, 
with the vessels becoming narrower towards the centre 
4. Mature: These are larger vessels, with less branching and regressed or absent 
capillary networks, seen to persist in scar tissue or in the corneal stroma after the 
corneal pathology has abated. These vessels maintain a blood circulation 
5. Regressed (ghost vessels): These can be seen as fine white lines mirroring the 
morphology of the original vessels and are seen as ‘ghost vessels’. These do not 
contain a circulation and the surrounding cornea is not swollen. Ghost vessels are 
situated in the stroma 
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1.3 Management of corneal vascularisation 
 
Choosing the appropriate method for managing the corneal neovascularisation is dependent 
on the state of maturity of these vessels. Mature vessels are not dependent on angiogenic 
mediators and thus surgical interventions such as fine needle diathermy are the most 
effective method for treating them, while actively growing vessels indicate an underlying 
ongoing pathology which is best treated by anti-VEGF in the form of drops or 
subconjunctival injections (120). 




The impact of corticosteroids in inhibiting the corneal vessels both in clinical and 
experimental conditions is well documented especially topical and subconjunctival 
Triamcinolone (121, 122) . Their anti-angiogenic effect is a result of their anti-inflammatory 
properties, which includes the suppression of inflammatory cellular chemotaxis, the 
inhibition of synthesis of pro-inflammatory cytokines as well as direct suppression of 
vascular endothelial cell migration and proliferation (122-124) . Ashton N et al reported 
that moderate doses of systemic (IM) and subconjunctival steroids have remarkably 
decreased the corneal NV in rabbits and that subconjunctival injection was found to be 
more superior than systemic treatment, They also found that subconjunctival steroid 
injection has caused a remarkable reduction in the corneal opacity(125). Another study has 
shown that adding heparin to steroid can greatly improve its efficacy in reduction of corneal 
NV (126). However, the long term use of steroids can result in several complications such as 
posterior subcapsular cataracts, glaucoma and enhancement of infection especially herpes 
simplex and its inhibitory effect is incomplete (127). 
 
B) Anti VEGFs 
 
 
VEGF is the most fundamental molecule that promotes and controls major steps in the 
process of corneal angiogenesis. When hypoxia or inflammation occur, endothelial cells 
lining the limbal vessels together with corneal epithelial and endothelial cells release VEGF 
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(60). Anti-VEGFs will suppress the process of angiogenesis thus preventing and reducing the 




Ranibizumab (Lucentis®) is a recombinant humanized monoclonal antibody directed against 
human VEGF-A. It is produced in Escherichia coli using recombinant DNA technology and has 
a molecular mass of 48 kDa and a single antigen binding site. Ranibizumab neutralizes all 
active forms of VEGF-A. It has been genetically engineered via a process of selective 
mutation to increase its affinity for binding and suppressing the growth factor (128). 
Ranibizumab was developed specifically for intraocular use and was approved by the FDA in 
2006 for the treatment of neovascular age related macular degeneration (NVAMD) (129). 
The indications for ranibizumab have expanded to include macular oedema following retinal 
vein occlusion and diabetic macular oedema. Ranibizumab has greater pharmacokinetic 
properties than bevacizumab as it is a smaller molecule and hence has better corneal 
bioavailability (89). 
 
A combined in vivo and in vitro study showed that ranibizumab had dual antiangiogenic 
mechanisms via simultaneous inhibition of blood and lymphatic vessels, highlighting its 
therapeutic role in corneal NV. A study in rabbits was conducted and showed a reduction of 
VEGF concentration in the bulbar conjunctiva, cornea, aqueous humor and iris following 
subconjunctival ranibizumab injections indicating high bioavailability (130). 
Several studies were conducted for the clinical evaluation of ranibizumab. One study used 
topical ranibizumab as 1% solution, 4 times a day in eyes with stable NV. The results showed 
that ranibizuamb is effective in controlling stable NV by narrowing of vessels but not by 
reduction of the corneal area invaded by NV (131). 
 
Another randomized clinical trial compared subconjunctival and intralesional injections of 
bevacizumab and ranibizumab. It was suggested that corneal NV management was better in 
the bevacizumab group than in those treated with ranibizumab (132). This was contradicted 
by another study which showed that subconjunctival and intrastromal ranibizumab 
injections were successful in treating a case with NV due to herpetic keratoconjunctivitis 
after failure to treat her with bevacizumab injections by the same route of delivery (133). 
17  
 
Bevacizumab (Avastin®) is a full-length humanized monoclonal anti-VEGF antibody that 
binds all VEGF-A isoforms thus blocking the VEGF-/VEGF receptor interaction thereby 
suppressing the role of VEGF in angiogenesis. It is a recombinant IgG1 antibody that is 
produced in Chinese Hamster Ovary mammalian cell expression system and its molecular 
weight is 149kD. It was initially designed as an anti-angiogenic therapy to treat solid 
tumours (134). In 1997, phase 1 trials of bevacizumab for the treatment of cancer was 
started and it was established that it had minimal toxicity (135). Phase 2 and 3 trials were 
carried out later and their results led to the approval of the U.S. Food and Drug 
Administration (FDA) of bevacizumab as therapy of colon cancer along with chemotherapy 
(136, 137). 
 
Although bevacizumab was initially approved for treating colorectal cancer, it has been used 
off-label to treat several ophthalmic conditions (138, 139). It has been first introduced as an 
intravitreal injection for treating ocular diseases in July 2005 (140). 
 
Several clinical cases have been published showing dramatic resolution of macular fluid in 
central retinal vein occlusion and NVAMD (140). Other studies showed the ability of 
bevacizumab to penetrate the retina after being injected intravitreally (141, 142). 
Bevacizumab has also been used for the treatment of other ophthalmological conditions 
such as juxtafoveal telengectasia (142-144), myopic choroidal neovascularization (CNV) 
(145, 146) and CNV secondary to angioid streaks (147, 148)and has shown promising results. 
Many retina specialists have also noted impressive results in the setting of CNV, proliferative 
diabetic retinopathy, neovascular glaucoma, diabetic macular oedema, retinopathy of 
prematurity and macular oedema secondary to retinal vein occlusions (149). 
 
The comparison of Age related Macular Degeneration Treatments Trials is one of the largest 
studies that has been conducted with the aim of evaluating the relative efficacy and safety 
of treatment of NVAMD. It was concluded that Avastin and Lucentis had the same effect on 
visual acuity over a 5 year period. There were no differences between the 2 drugs in rates of 
death or arteriothrombotic events (150). 
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A systematic review and meta-analysis was done with the objective of evaluating the 
efficacy and safety in treatment of ocular neovascularization by bevacizumab versus 
ranibizumab. The results showed that bevacizumab has equal efficacy and safety to 
ranibizumab in treatment of ocular neovascularization (151). 
 
Anti-VEGFs have been first used to treat corneal neovascularization in a rat model. Corneal 
injury was induced to in order to stimulate VEGF release, and the resulting NV were 
subsequently blocked by anti-VEGF antibodies (85). Another animal trial conducted later 
demonstrated that corneal vessels secondary to herpes simplex virus were reduced by 
suppressing VEGF via the delivery of a murine soluble VEGF receptor protein, mFlt (1–3)- 
immunoglobulin G (152). These studies led to the hypothesis that anti-VEGFS might be an 
effective treatment option for active corneal NV (153). 
 
Several studies have been conducted to evaluate the efficacy and safety of bevacizumab 
when used as subconjunctival injections to treat corneal NV. They showed that the 
treatment of active corneal NV with subconjunctival injections of bevacizumab could be of 
great benefit as they noted either a regression or stabilization of the corneal NV and this 
effect was also associated with improved lipid deposition in cases with lipid keratopathy. 
The intervention was well tolerated without adverse ocular or systemic effects (154-158). 
However, there has been reports that it could delay epithelial wound healing (159).This was 
contradicted by another group who used similar doses of bevacizumab (1%, twice daily for 2 
months) but instilled the drops in the reservoir of a Boston Ocular Surface Prosthesis. This 
indirect drug application may have resulted in quite low drug concentrations at the corneal 
surface (160). 
Other studies also reported improved mean visual acuity at the final follow up and also 
reported that the injections were beneficial and effective in high-risk keratoplasty, with 
regards to preventing corneal NV after keratoplasty with improvement of graft survival 
(161-164). 
Bevacizumab 1% eye drops used 4 times/day showed remarkable decrease in superficial and 
deep stromal neovascularization in a number of pilot studies (165, 166) (167). 
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C) Topical therapeutics 
 
New topical therapeutics are being developed and might be used clinically in the future for 
treatment of corneal NV (168). These are protein phosphatase magnesium dependent-1, 
melatonin, omentum, 0.5% ketorolac tromethamine, Rho-associated protein kinase 




1.3.2 Surgical treatment 
 
A) Laser photocoagulation 
 
Argon laser has been first described by Cherry PM in treating corneal NV on 4 human 
patients. There was 1 success, one partial regression of NV and two failures (177).In 1976 
Cherry and Garner used 11 rabbits to test the impact of argon laser in obliterating corneal 
vessels. They concluded that the obliteration of corneal vessels by argon laser was 
successful as long as there was no stimulus for vascularisation. There was slight iris damage 
in their experiment but they did not think that this could necessarily contradict the laser 
usage on humans(178).The argon laser was used further in treatment of lipid keratopathy 
by Marsh RJ. The lipid deposition was reduced in more than half of the cases, however there 
were complications such as iris damage, peaking of pupil and corneal thinning(179). Yellow 
dye laser 577 nm was used by Baer and Foster to treat corneal NV in 25 eyes of 23 patients 
(180). They reported a significant decrease in the vascularised region from 46.4% to 27.3% 
in 9 patients who had lipid keratopathy. They also reported reversal of graft rejection and a 
marked reduction in the vascularisation area (68% decrease in the vascularised area). 
However, patients with severe corneal neovascularisation did not show improvement. 
 
B) Photodynamic Therapy (PDT) 
PDT is a potential treatment for the management of corneal NV. The idea of PDT is to 
administer systemic porphyrin derivatives which will build up in the replicating endothelial 
cells. This is followed by laser energy application which will activate those derivatives 
resulting in the release of cytotoxic oxygen free radicals leading to corneal vessels 
obliteration (181-184). Several porphyrin derivatives were used such as verteporfin(185) 
and diheamtoporphyrin ether(182). A clinical trial was carried out using PDT with 
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verteporfin to treat corneal neovascularisation and showed that it is a safe and effective 
method of reducing corneal neovascularization (186) . Other trials used a combination of 
PDT and subconjunctival bevacizumab and showed that this combination can effectively 
inhibit corneal neovascularization (187, 188). 
C) Fine needle diathermy (FND) 
 
Fine needle diathermy(FND) is a method for occluding corneal vessels that has been 
developed by Professor Harminder Dua (189). FND was found to be superior to the methods 
mentioned earlier in terms of being an effective, simple and inexpensive method of 
occluding mature vessels. FND can be used as a preconditioning and/or post-conditioning 
treatment of high-risk corneal grafts (190). It can be one element of an overall plan to 
reduce the risk of graft rejection or deal with refractory episodes of rejection (120). 
The procedure involves the insertion of stainless steel 3/8 needle attached to a 10–0 
monofilament black nylon suture close to the limbus, parallel to and at approximately the 
same depth as the blood vessel(s) to be occluded than the needle is touched with a 
monopolar cautery at low power (Covidien Force X) to produce the coagulation (120). 
Several studies were carried out to evaluate the safety and efficacy FND for occlusion of 
corneal vessels (189, 191). They concluded that FND is a safe, inexpensive and effective 
treatment option for the occlusion of corneal blood vessels both before and after 
penetrating keratoplasty. It can be done repeatedly and is also beneficial in stopping the 
progress of lipid keratopathy. However, it was noted that the deposited lipids did not 
regress any faster by the occlusion of the corneal vessels (189). 
In 2014, a study was carried out by Faraj et al in the same centre where FND technique was 
first described more than a decade ago(120). 
The study has shown that FND was the method of choice in occlusion of active old and 
mature vessels. It was also found that FND was very effective in treating lipid keratopathy. 
Another important conclusion that was drawn out from the study, was that active young 
vessels were usually a sign of underlying continuous pathology which keeps on inducing 
more vascularisation. It was pointed out that such eyes will require treatment with anti- 
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VEGF subconjunctival injections or eye drops and several studies have been conducted to 
assess the efficacy and safety of combined FND with adjuvant anti-VEGF bevacizumab eye 
drops, subconjunctival or intrastromal injections in both adults and children (192, 193). 
The studies concluded that applying combined FND and bevacizumab is both successful and 




1.4 Consequences of corneal vascularization 
 
In the presence of corneal pathology, NV’s are necessary to mount a host defence reaction, 
promote healing of the cornea, get rid of toxic material and transfer medications to the 
inflammation site(194, 195).However, when the pathology is no longer active, the blood 
vessels formed may remain in the cornea and the vessels are tortuous, leaky and wide 
resulting in infiltration of corneal stroma with inflammatory cells and cytokines due to loss 
of pericytes and separation of endothelial cells. Keratocytes proliferate and transform into 
fibroblasts which secrete fibrin leading to scarring. All these events will eventually lead to 
corneal opacity and haze which will consequently reduce vision. This opacification is a result 
of circulation of blood cells in the blood vessels, changes in the spaces between stromal 
collagen, chronic or recurrent inflammation, scarring, higher order aberrations caused by 
irregular vessel wall and lipid leakage and deposition in the cornea (50),(49, 196). Lipid 
keratopathy was related to mature and partially regressed vessels. The most common 
aetiology of lipid keratopathy was found to be secondary to viral keratitis (47). 
 
Corneal vessels promote easy lipid access to the cornea(197). Lipids become deposited by 
lipid overloaded fibroblasts in the corneal stroma in the form of droplets of cholesterol 
crystals(198). Corneal NV may as well cause bleeding intraoperatively and hyphema. Corneal 
NV affect the corneal immunological privilege which may eventually lead to graft rejection 
(199, 200)as it provides an efferent arm in the immune reflex arc and accelerates immune 
reaction by facilitating access for immune effector cells to the graft and thereby resulting in 
corneal rejection(49, 50). Lymphatic vessels that are microscopically undetectable have 
been detected with blood vessels in high-risk vascularized corneas (201). These lymphatic 
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vessels facilitate the access of host and donor antigen-presenting cells (APCs) to regional 
lymph nodes thereby accelerating sensitization to the graft antigens and causing further 
disruption of the immune privilege status of the cornea. Lymphatics represent the afferent 
arm of the immune reflex arc (201-203). A meta-analysis of 19 studies reporting on a total of 
24,944 grafts undergoing keratoplasty was done. It was found that the chances of graft 
failure due to rejection becomes higher with increasing number of corneal quadrants that 




1.5 Pterygium: demographics, role of vessels and vascular factors 
 
Pterygium is a potentially sight threatening condition that originates from the bulbar 
conjunctiva as fleshy fibrovascular tissue and grows centripetally most often from the nasal 
conjunctiva although it can occur temporally. It can be bilateral and asymmetric with one 
eye affected by a larger pterygium, encroaching on the cornea which could result in corneal 
scarring, chronic ocular surface inflammation, irregular astigmatism as well as restriction of 
ocular motility (204-206). Although the etiology of pterygium remains an enigma and is so 
complex, environmental factors such as chronic exposure to ultraviolet light, dryness, 
genetic and immunological factors play a big role in its formation (207-209). It is more 
prevalent within the peri-equatorial latitudes” 37 degrees north and south”, where the 
ultraviolet radiation intensity is strongest. Recently, other important factors such as 
fibrovascular proliferation, inflammation and vascularisation and localised stem cell 
deficiency have been implicated in the pterygium pathogenesis and progression (210, 211). 
Pterygium can be classified as quiescent or progressing and active (212, 213). 
 
Many studies have also demonstrated that the pathogenesis and recurrence of pterygia is 
highly attributed to the increased expression of molecules such as vascular endothelial 
growth factor (VEGF), transforming growth factor, platelet derived growth factor and basic 
fibroblast growth factor(214-216). The most prominent of these was found to be VEGF 
molecule and it was found to be highly increased in pterygia as well as being involved 
directly or indirectly in formation of pterygia by inducing the formation of blood vessels. It 
has also been postulated that the development of pterygia depends on a disturbed 
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angiogenic stimulator to inhibitor ratio (216-219). Moreover, further immunochemistry 
studies have shown that immunostaining of VEGF in pterygial sections was much stronger 
than normal conjunctival sections(216). Based on these findings, several clinical studies 
aimed to reduce the vascular density and prevent its recurrence using anti-VEGFs (207, 210). 
In many of these cases, there was a brisk reduction of inflammation and vascularization 
when pterygia where injected subconjunctivaly with anti-VEGF which gives more evidence 
of the role of VEGF in pterygium angiogenesis(208, 210); (216);(219). Studies have also 
shown that in anti-VEGFs suppress fibroblast proliferation and induce fibroblast apoptosis in 
addition to its effect on angiogenesis. In one study, injection of bevacizumab with a 
concentration greater than 7.5 mg/ml had a remarkable effect on the anti-fibrotic effect, 
changes in morphology, and reduction in the collagenase activity of human Tenons’ 













Figure 1.5: Slit-lamp anterior segment photograph of a recurrent pterygium 
 
1.6 Pterygium recurrence 
 
Recurrence of pterygium is the most common complication after surgical excision and it has 
been found that recurrent pterygia are more difficult to manage than primary ones as the 
underlying cornea could be thinner(222). Several factors raise the chances of recurrences 
after surgery such as young age, family history and concurrent ocular surface inflammation 
(223, 224). According to a grading system developed by Tan et al, a fleshy-like aspect of the 
pterygium is correlated with high recurrence rates, especially after bare sclera excision 
(223). Race plays an important role as well in defining the recurrence rates. Hispanic and 
black race have a higher rate of recurrence compared to white (225). 50% of the 
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recurrences appear in the first 4 months while 97% appear within the first 12 months (226). 
 
Surgical technique of pterygium excision also attributes to the rate of recurrence. High 
recurrences rates were reported in patients who had pterygium excision by bare sclera 
technique with no adjuvants or radiotherapy alone and this was attributed to the fact that 
small tissue residues may be left in the scleral bed leading to higher recurrence rates which 
ranged from 38 and 88 % in many publications (227-229). Adjuvant amniotic membrane 
transplantation has also high rate of recurrence which can be up to 28.1 % but no 
postulations were given regarding the high recurrence rate (230). 
 
The recurrence of pterygium has been also attributed to fibroblast migration and 
proliferation, therefore 5 fluorouracil is being injected subconjunctivally in the recurrent 
pterygium body to reduce or inhibit the activity of fibroblasts (231). 
 




A) 5 Flouorouracil (5 FU) 
 
 
5 fluorouracil (5FU) is a pyrimidine analogue that inhibits thymidylate synthetase and hence 
DNA and RNA synthesis, suppresses proliferating fibroblasts and promotes apoptosis of 
Tenon’s fibroblasts. It is widely used in ophthalmology especially in glaucoma surgery with 
favourable outcomes due to its anti-fibrotic characteristics.(232, 233). A number of pilot 
studies were conducted to study the efficacy of intra-lesional injection of 5FU in primary 
pterygium. They reported cosmetic and clinical improvement. One study reported no 
statistically significant changes of corneal astigmatism after the injections (234, 235). 
 




Several studies demonstrated that vascularization and inflammation were rapidly controlled 
by subconjunctival bevacizumab injections in many patients, and this provided more 
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evidence for the role of increased VEGF in pterygium (153, 208, 215, 216, 219, 236-238). 
However, some reported that the changes were clinically insignificant as they were clinically 
not obvious with no beneficial effect on the regression of the vessels (239, 240) and one 




One study used 2 different doses of topical bevacizumab and compared them to a control 
group and reported good results in the group with higher bevacizumab dose. They had 




1.7.2 Surgical excision 
 
There are several techniques for surgical management of primary pterygium. 
 
 
Bare sclera technique: This technique involves complete excision of the pterygium head, 
removal of some of the surrounding nasal bulbar conjunctiva as well as excision of Tenon’s 
capsule resulting in a bare sclera. The recurrence rate for this method is quite high 30% to 
80%). That is why some of the surgeons will combine this technique with other adjunctive 
therapies to reduce the recurrence rate (229, 242, 243). 
 
Aminiotic membrane graft Transplantation (AMT): Human aminiotic membrane inhibits 
inflammation and formation of fibrovascular tissues, provides numerous growth factors and 
promotes proliferation of epithelial cells without the risk of immunological reactions (244, 
245). Due to these properties, it has been used as a graft to cover the bare sclera after 
pterygium excision, typically with the basement membrane facing up and the stroma facing. 
It has the advantage of short surgical time, fast recovery, less post-operative pain and better 
cosmetic outcome following surgery (as no donor site is injured)(246). However, it has 
higher recurrence rates when compared to the conjunctival autograft technique (247, 248). 
AMT effectiveness is improved by using fibrin glue to promote aminiotic membrane graft 
fixation to the underlying sclera. It is useful in situations such as covering large conjunctival 
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defects after pterygium excision and to preserve conjunctiva in glaucomatous patients. 
Combining AMT with intra-operative Mitomycin-C improves the outcome of the surgery and 
reduces the recurrence rate (249) . AMT has been used in combination with conjunctival 
autograft to reduce the recurrence rate especially in cases with large or severely inflamed 
pterygia or persistent recurrence (250). 
 
Conjunctival autograft: This technique involves covering the bare sclera by using autologous 
conjunctival tissue. The free graft is obtained from the superior bulbar conjunctiva and 
sutured or more preferably, glued to the bare scleral defect after pterygium excision. 
Additional use of intra-operative Mitomycin-C reduces the recurrence rate (251). 
Recurrence rates range from 3.3% to 13.5% (252-255). Higher recurrence rates have been 
reported in cases of recurrent pterygium (31.3% to 33.3%) (253). It is considered to be one 
of the most effective method for management of pterygium (256). Conjunctival autografts 
can be fixed to the scleral bed using sutures or fibrin glue. Sutures are associated with 
inflammation, discomfort and granuloma formation (257). Fibrin glue is used as an 
alternative and remains the most effective method for conjunctival autograft fixation in 
pterygium surgery due to reduced operative time, reduced postoperative discomfort and 
lower recurrence rate (258). 
 
Conjunctival transpositional flap 
Rotational conjunctival flaps have been employed since the 40’s to cover the pterygium 
excision site with different recurrence rates ranging from 3.2% as reported by McCoombes 
et al. (259) to 33.33% as reported by Alpay (227). Bilge compared this technique to 
conjunctival autografting and reported that both procedures had low recurrence rates 
without severe complications (253). This procedure is useful in patients with insufficient 
conjunctiva (260). 
 
Mitomycin C (MMC) is an antineoplastic drug that has been suggested as an adjuvant for 
pterygium surgery in the 60’s (261). Intraoperative application of 0.02% MMC had a positive 
outcome as it has been reported that recurrence in primary pterygium was as low as 7% 
after use of MMC while rates after recurrent pterygia were reduced to 9%. When applied 
for 5 minutes with bare sclera technique, the recurrence rate was as low as 5% (262). When 
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combined with rotational conjunctival flap approach, no differences have been noted 
between postoperative 0.02% MMC drops for 5 days or intraoperative MMC at different 
dosages (263-268). However, it has been shown that combining intraoperative MMC with 
conjunctival autografting is associated with remarkably lower recurrence rates regardless of 
the application technique or dosage (269-271). The most common used concentration of 
MMC is 0.02% (0.2 mg/ml) and the most common application time length is three minutes 
(229). 
 
1.7.1.3 Anti-VEGF as Adjuvant to surgery 
 
 
Numerous clinical trials studied the effect of bevacizumab as an adjunct to surgery, however 
the trials employed different surgical techniques. 
Two studies were conducted using bevacizumab as an adjunct to pterygium excision using 
bare sclera technique. One reported that subconjunctival bevacizumab injections before and 
after surgical excision, were a safe and valid option in preventing recurrence after bare scleral 
procedures (272), however the other study showed no changes and that was attributed to 
the low dose of bevacizumab injected. 
 
Trials have demonstrated reduced vascularity of pterygium as well as reduced recurrence rate 
after using subconjunctival bevacizumab injections with conjunctival autografts for primary 
pterygium (273-275). 
 
Karlezli et al. (276) used topical bevacizumab after pterygium excision with conjunctival 
autografting for 1 month after surgery and compared to them to a control group who were 
only given steroids and antibiotics and reported no significant difference in the recurrence 











Local subconjunctival steroid injections have shown efficacy in about 50% of the cases of 
recurrence but no large randomized controlled clinical trials have been carried out to 
confirm their efficacy (278) . 
 
B) 5 fluorouracil 
 
 
The effective role of 5FU in halting pterygium recurrence and further progression has been 
studied by many (279, 280). 
 
Pherwani at al. (281) reported a single case of multiple post-surgical recurrences of 
pterygium in an Afro-Caribbean lady who was successfully treated with intra-lesional 5FU 
injections following the fourth operation. Other studies have also reported the safety and 
efficacy of 5FU in limiting the progression and inducing the regression of recurrent 
pterygium and that the number of injections can be tailored according to clinical need. They 
have also shown that by avoiding repeated surgery for recurrent pterygium by injecting 5FU, 
less fibrosis occurred and the risk of intra and post-operative complications has decreased 
(231, 282, 283). 
 
C) Anti-VEGF (no surgery) 
 
 
Subconjunctival injections of bevacizumab were used safely and effectively for treatment of 
recurrent pterygia (207, 236, 284, 285). 
 
1.8.2 Surgical excision 
 
Recurrent pterygia are more difficult and challenging to excise due to the scarring already 
present which increases the risk of damage to the extraocular muscles and obliterates the 
tissue planes. In cases of extensive scarring, primary closure techniques are unreliable. 
Pedicle or sliding flaps can be used (278). 
 
 
Surgical management is the first line management for aggressive pterygium recurrences or 
recurrent pterygia that extend more centrally than the initial pterygia, with 4 to 6 months 
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form the primary surgery. Conjunctival flaps, conjunctival or limbal autograft 
transplantation have been used for management of recurrent pterygium (286). 
 
1.8.3 Anti-VEGF as Adjuvant to surgery 
 
In 2013, Ozgurhan et al. used topical application of bevacizumab 4 times daily for 2 months 
after excision of recurrent pterygium. This technique had less recurrence rate compared to 
the control group (287). Similarly, Nava Castaneda at al. (275) reported reduced vascularized 
area as well as reduced corneal opacification area in all recurrent pterygia and the effect 
remained until the end of the study. 
 
1.9 Limbal stem cell deficiency 
 
Limbal stem cell deficiency (LSCD) could be congenital as in cases of aniridia or acquired 
secondary to ocular burns (chemical and thermal), chronic immune-mediated inflammatory 
diseases (Ocular cicatricial pemphigoid and Stevens Johnson syndrome), contact lens related 
pathology and ocular surface malignancy. Ocular burns have the most devastating impact in 
relation to visual impairment, quality of life and ability to work. LSCD has several sequeal 
which include superficial and deep corneal neovascularisation, recurrent and /or persistent 
epithelial defects, development of fibrovascular pannus, stromal scarring, 
conjunctivalization of the cornea, symblepharon formation and ultimately corneal melting 
(288, 289). 
There are several management options for LSCD and it all begins with a thorough 
assessment of the diagnosis, patient factors and the extent of deficiency. The diagnosis 
depends mainly on the history and the clinical signs of which conjunctivalization of the 
cornea is the hallmark. Impression cytology and/or biopsy and invivo confocal microscopy 
are done to demonstrate the conjunctival epithelial cells and goblet cells on the cornea and 
these procedures can be performed to complement the clinical diagnosis (6, 288-291). LSCD 
can be partial or total, unilateral or bilateral (290). 
Ideally all abnormalities related to the lds and fornices should be addressed and intraocular 
pressure should be controlled before considering limbal transplantation. 
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Partial SC deficiency with conjunctivalized epithelium on the cornea; where the visual axis is 
not involved, requires no surgical intervention. When the visual axis is involved and vision is 
affected, the first line of management should be Sequential Sector Conjunctival 
Epitheliectomy (SSCE). SSCE involves brushing off the conjunctival epithelium away from the 
corneal surface so that the healthy corneal epithelium from the surviving limbus can 
repopulate the denuded area. As the cells derived from the corneal epithelium cover the 
denuded area, the conjunctival epithelial cells will be also invading the corneal surface, 
usually faster than the corneal epithelial cells. That is why brushing should be repeated 
every 24 to 48 hours as often as required to keep the advancing conjunctival sheet in check 
and to allow the corneal surface to be covered by cells migrating from the remaining intact 
limbal epithelium. 
Partial SC deficiency with fibrovascular pannus over the cornea may require sector limbal 
transplant, although SSCE could help (292, 293). 
For cases with total unilateral SC deficiency, the procedure of choice is auto limbal 
transplantation (AL) (17, 294). In total bilateral SC deficiency, the only treatment option 
would be the use of allografts from a living donor (LRD) or a cadaver donor (CD). Living non- 
related donor tissue can be potentially used as well. The advantage of using autologous and 
LRD tissue is that they are very fresh and of younger age, on the other hand CD is available 
in abundance but is usually between 24 to 48 hours old (post death). Screening tests for HIV, 
HTLV, syphilis and Hepatitis B and C must be done for all donors (294-296). Both AL and LRD 
should not be considered in the acute stage of the disease as there is ongoing 
inflammation.CD is associated with very high failure rate, systemic immunosuppression is 
required in LRD and CD transplantation for at least 18 months after the transplantation or 
from the last rejection episode (297-299). 
SSCE can also be applied in association with AL transplants and LRD transplants as often the 
conjunctival epithelium from the peritomised conjunctiva migrates at a rapid pace and 
crosses the limbus to cover the corneal surface resulting in conjunctivalisation of the 
cornea. SSCE is used successfully to prevent this from occurring (293, 294, 300). However 
there are limitations in these circumstances which are bleeding form surface vessels, pain 
and multiple visits required for treatment and observation. Based on that Dua et al. (301) 
have devised an approach, using amniotic membrane, to redirect conjunctival epithelium on 
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to the membrane allowing the corneal surface to be covered by explant-derived epithelium, 
thus completely avoiding admixture of limbal/corneal and conjunctival epithelium and 
avoiding the need for SSCE. This procedure has been termed amnion-assisted conjunctival 
epithelial redirection (ACER) and is a useful adjuvant in the management of patients 
undergoing limbal transplantation for LSCD. 
Exvivo expansion of limbus derived cells methods are an essential option in the surgical 
management of total LSCD whether unilateral or bilateral. These methods will be discussed 
in details in Chapter 5. 
1.10 Retinal anatomy 
 
1.10.1 Retinal layers 
 
The retina is the neurosensory part of the eye. It is formed of multiple layers of 
photoreceptors and neuronal cells with a complex structure. The adult posterior pole, also 
known as the anatomical macula, is about 4.5 to 6 mm in diameter and lies between the 
superior and inferior temporal arcades and the fovea lies in its center . The macula, also 
known as the anatomical fovea centralis, is located approximately 3 mm temporal to the 
optic disc and is about 1.5 mm in diameter. The macula has a disproportionately big 
density of cones which are responsible for hyperacuity and colour differentiation. The 
fovea represents the retinal region of greatest visual acuity. It is thinner than the rest of 
the retina and is seen as a dip (foveal pit) in cross sectional view. The central 500 µm of the 
fovea contains no retinal capillaries (the foveal avascular zone) and the fovea receives its 
blood supply from the choriocapillaris. The foveola has the highest density of cone 
photoreceptors (199,000/mm2). The foveola consists of cone photoreceptors and some 
Muller cells (302, 303). 
The peripheral retina is the part of the retina that lies outside the temporal retinal arteries. 
The peripheral retina is made of one layer of ganglion cells. The long posterior ciliary 
arteries and nerves mark the horizontal meridian, while the ampullae of the vortex are 
located posterior to the equator (Figure 1.6). 
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Retinal Pigment Epithelium (RPE) 
 
There are about 3.5 million RPE cells and they interdigitate with the outer segments of the 
photoreceptors (304). The density of RPE cells is greater in the fovea (5000 cells/ mm2) than 
in the periphery (2000 cells/ mm2) RPE cells contain melanin and that is the reason they are 
pigmented. RPE cells are essential for recycling of the visual pigments necessary for the 
photoreceptor to function normally as well as removing the debris from the degenerating 
photoreceptors, pumping fluid out of the retina, forming the outer blood retinal barrier due 
to the tight junctions between adjacent RPE cells (preventing flow of fluid out of choroidal 
blood vessels into the retina) and secretion of anti-angiogenic factors. RPE cells lie on a thick 
basement membrane called Bruchs membrane. Bruchs membrane contains collagen 5 and 
probably originates from the overlying RPE cells and the underlying choriocapillaris. It acts 
as a water impermeable membrane between the overlying RPE and retina and the 
underlying vascular choroid (303). 
Photoreceptor layer 
 
Photoreceptors act as the sensors of the visual system and are responsible for converting 
photons to a nerve signal in a process called phototransduction (305). It is  the only light 
sensitive part of the neuroretina. The nerve signals generated will be transmitted by all the 
other layers of the neuroretina. There are approximately 4 to 5 million cones and 77 to 107 
million rods in the human retina (305-307). The foveola contains only cones , whereas rods 
are dominant in the rest of the fovea and the peripheral retina. Each photoreceptor is made 
of an outer segment, inner segment, a nucleus, an inner fibre and a synaptic terminal (308). 
The outer segment contains photopigment that captures the photon. The outer and inner 
segments are connected by non-mobile cilia. The inner segment is full of mitochondria that 
produces ATP and rough endoplasmic reticulum for synthetic activity as well as 
microtubules for transport within the cell. The nucleus contains nonmitochondrial DNA. The 
inner fibre acts as the axon of the photoreceptor cell and is responsible for the transmission 
of photoreceptors signals to the outer plexiform layer via its synaptic terminals. 
 
 
External Limiting Membrane 
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The external limiting membrane is not a real membrane, it is made of junctional complexes 
between adjacent Muller cells as well as between Muller cells and photoreceptor cells. The 
subretinal space is a potential space between the outer blood retina barrier and the 
external limiting membrane (309, 310). 
Outer Nuclear Layer 
 
The outer nuclear layer is made of the nuclei of the photoreceptor cells and is thickest in the 
foveolar area (305-307). 
Outer Plexiform Layer (OPL) 
 
In the OPL, photoreceptor cells of the outer nuclear layer form connections with the 
horizontal and bipolar cells of the inner nuclear layers. The OPL consists of 2 parts: the 
axons of photoreceptor, bipolar and horizontal cells and their synaptic connections 
(307, 311). 
Inner Nuclear Layer 
 
This layer contains the nuclei of five different types of cells: the bipolar, the amacrine, the 
horizontal, the interplexiform and Muller cells. The amacrine cells face the inner plexiform 
layer while the horizontal cells are situated along the outer limit of the inner nuclear layer 
facing the OPL (307, 311, 312). 
 
 
Inner Plexiform Layer (IPL) 
 
The IPL contains the connections between amacrine, bipolar and ganglion cells. The IPL is 
further divided into six layers which is imperative for the processing of the photoreceptor 
input through highly specialized interactions between the bipolar, amacrine, and ganglion 
cells in each of the six layers of the IPL (313). 
 
 
Ganglion cell Layer 
 
There are 1.2 million ganglion cells in in the ganglion cell layer in addition to other cells 
including astrocytes, pericytes and endothelial cells. The ganglion cell layer is thickest in the 
perifoveal macula where it is made of  8 to 10 rows of nuclei and becomes only one raw 
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outside the macular area. It is not present in the foveola. The small midget and larger 
parasol cells make up 80% of the ganglion cell layer (306, 307, 313). 
Nerve Fibre Layer 
 
The nerve fibre layer has the ganglion cell axons travelling within it towards the optic nerve 
head. The nerve fibre layer is thick towards the disc due to the convergence of all retinal 
ganglion axon fibres on the optic disc and becomes thinner towards the periphery. The 
axons are associated with astrocytes and are separated into small bundles by the cellular 




Figure 1.6: Illustration of retinal layers(adapted from retinal imaging and image analysis, biomedical engineering, Michael 
Abramoff et al, 315) 
 
1.11 Retinal vascular structure and blood supply 
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The inner two thirds of the retina receives its oxygen supply and nutrients form the retinal 
vascular circulation via a network of blood vessels that emanates from the central retinal 
artery at the optic nerve head. The central retinal artery is a branch from the ophthalmic 
artery which is ultimately a branch of the internal carotid artery. The central retinal artery 
branches into four arterioles at the optic nerve head which further subdivide to supply each 
retinal quadrant via a network of capillaries. Each arteriole is associated with a 
corresponding venule which carries deoxygenated blood back to the optic nerve head and 
into the central retinal vein. The choroidal circulation supplies the outer one third of the 
retina (photoreceptor cell bodies, photoreceptor inner segments, and photoreceptor outer 
segments). Each person’s retinal vasculature is said to be unique and may provide a form of 







Figure 1.7: Anatomy of ocular circulation (a-artery, b-vein, n-nerve). A, Cut away drawing along the superioreinferior axis of 
the human eye through the optic nerve, showing the vascular supply to the retina and choroid. B, Drawing showing 
vasculature of the retina and choroid. (adapted from Dave Schmick et al, 317 ) 
 
1.12 Retinal neovascularisation 
 
Retinal neovascularization occurs due to ischemic retinopathy changes in which damage to 
retinal vessels leads to retinal ischemia. In diabetic retinas, leukocytes form adhesions and 
infiltrations causing physical occlusion of capillaries and hence damage to the vascular 
endothelial cells and neuroglial cells. There is also release of inflammatory mediators and 
superoxide in diabetic retinas hence leading to more retinal ischemia. Severe retinal 
ischemia results in retinal neovascularization which might bleed leading to pre-retinal or 
vitreous hemorrhage and /or grow into the vitreous cavity causing tractional retinal 
detachment. There are several ischemic retinopathies that lead to retinal 
neovascularization and the most prevalent of these are diabetic retinopathy and retinal vein 
occlusions (317). 
1.13 Diabetic retinopathy (DR) 
 
1.13.1 Epidemiology and risk factors 
 
Diabetic retinopathy (DR) is the most common microvascular complication in diabetic 
patients, with a higher incidence in type 1 compared with type 2 diabetes mellitus (318). DR 
is the fundamental cause of loss of vision globally in working middle aged adults which is 
consistent with the increasing prevalence of diabetes in developing and developed 
countries. Diabetic macular edema (DME) affects central vision at any stage of DR. Among 
the diabetic populations, the estimated prevalence of any type of DR is 34.6% and those of 
PDR and DME are 6.96% and 6.81%, respectively (318). A major risk factor for DR is 




1.13.2 DR forms 
 
Diabetic retinopathy is divided clinically into non-proliferative (NPDR) and proliferative 
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(PDR) forms (319, 320). NPDR is classified into mild, moderate or severe based on the 
severity of the retinal vascular lesions. Severe NPDR is associated with more distinct 
features of retinal ischaemia such as intra-retinal microvascular abnormalities and venous 
beading that are adjacent to non-perfusion areas. PDR has the defining features of 
neovascularization of optic disc or elsewhere, pre-retinal hemorrhage or vitreous 
hemorrhage (319, 320). 
1.13.3 Pathophysiology of DR 
 
Diabetic mouse modules were frequently employed to gain insights into the molecular and 
cellular mechanisms that underlie the pathophysiology of DR. Optical coherence 
tomography (OCT), Optical coherence tomography angiography (OCTA) and 
electroretinography (ERG) have been used to monitor the structure and function of mouse 
retinae (321-323). In vivo imaging of retinal cell dynamics of anesthetized diabetic mice has 
been made possible using 2-photon and confocal laser scanning fluorescence microscopy, 
combined with a cataract-preventing contact lens (324). The metabolic changes caused by 
diabetes induce excessive production of mitochondrial superoxide in vascular endothelial 
cells which results in activation of protein kinase C pathway and over activity of the 
hexosamine pathway. These pathways increase the levels of intracellular reactive oxygen 
species leading to irreversible cell destruction through epigenetic changes such as DNA 
methylation, non-coding RNAs and histone changes (325, 326). 
Continuous hyperglycemia and oxidative stress induce inflammation (325-327). The levels of 
pro-inflammatory cytokines and chemokines, such as monocyte chemoattractant protein 1, 
interleukin1B, interleukin 6 and tumor necrosis factor are increased in eyes with DR (328). In 
diabetic retinas, the infiltration and adhesion of leukocytes might destruct the vascular 
endothelial cells and neuroglial cells via obstruction of capillaries and release of 
inflammatory mediators and superoxide (329). Although it is still not known why retinal 
microvascular abnormalities occur over years of hyperglycemic periods (more than five 
years in type 2 diabetes mellitus), experimental and clinical evidence has shown irreversible 
loss of neurons preceding the vascular damage in diabetic retinas (330-333). 
After the discovery of VEGF in the 1980s (334, 335), elevated VEGF levels were reported in 
eyes with PDR (336). Following that, VEGF injections were used in monkeys’ eyes and led to 
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the formation of retinal vascular abnormalities that were seen in NPDR and PDR (337). 
During ischemic conditions, several VEGFA isoforms are generated such as VEGFA121, 
VEGFA165, VEGFA189 in humans (338-340). VEGFA isoforms have binding affinities to 
extracellular matrices, VEGFR2 co-receptor and neuropilin-1. VEGFA in vascular endothelial 
cells bind to VEGFR2, activating several signal transduction cascades, as well as the 
phosphatidyl inositol 3-kinase (PI3K)/Akt pathway and the mitogen-activated protein kinase 
pathway, thereby inducing cell proliferation and migration and the subsequent formation of 
new blood vessels (338, 339). Moreover, VEGFA-VEGFR2 signal damages the endothelial 
cells’ tight junctions resulting in fluid extravasation and vascular hyperpermeability (338, 
339). Thus, VEGF-VEGFR2 signal is essential in vascular leakage and retinal angiogenesis in 
DR (340, 341). Angiopoietin 1 (Ang1) stabilizes vessels integrity by promoting endothelial 
cells survival, inhibiting inflammatory pathways and preventing vascular permeability (342). 
Angiopoietin 2 (Ang2) renders the vascular endothelial cells more sensitive to pro- 
inflammatory, pro-angiogenic and pro-permeable stimuli such as VEGFA. Further, Ang2 is 
upregulated by ischemia, hyperglycemia and VEGFA. These findings signify that Ang2 
facilitates vascular permeability, inflammation and retinal angiogenesis under specific 
disease conditions. Ang2 is upregulated in eyes with ischemic conditions such as DR, retinal 
vein occlusion and age related macular degeneration (343). 
1.13.4 Consequences of PDR 
 
New blood vessels that protrude from the ischemic retina cause vitreous hemorrhages 
(344). 8% of PDR patients will have a fibrovascular membrane growth accompanying the 
aberrant neoangiogenesis, inducing retinal detachment (345). Retinal ischemia persistence 
results in neovascularization of the iris and refractory glaucoma (344). 
 
 
1.14 Aims and Objectives  
 
This thesis contains several studies to evaluate the effect of different modalities of treatment on ocular 
neovessels in the ocular surface which includes the cornea and conjunctiva as well as observational studies 
that observe the effect of treatment modalities such as surgery, laser and injections on ocular surface 
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neovascularization and retinal neovascularization secondary to proliferative diabetic retinopathy. 
Chapter’s 2 aim was to evaluate the effect of combined injections of 5FU and      
bevaciazumab in patients presenting with pterygium which is a condition that is mainly 
treated surgically. This would reduce the need to perform surgery for excision of the 
pterugium.  
Chapter’s 3 aim was to study of the healing of conjunctival autograft and the donor site 
after pterygium excision surgery. This would have implications for clinical follow‐up and 
differentiation from signs of early recurrence of pterygium. 
Chapter’s 4 aim was to compare the effects of FND alone, subconjunctival 
bevacizumab alone and the combined FND and subconjunctival bevacizumab 
injections on the corneal NV.  
Chapter’s 5 aim was to evaluate the effect of LSCT using an exvivo method for patients 
who had extensive LSCD and NV. This was done as as part of a multi-center study 
(HOLOCORE). The success was measured by reduction of corneal NV and healing of 
corneal epithelial defect.  
 
Chapter’s 6 aim was to investigate corneal neuropathy in the different stages of diabetes with 
and without retinopathy and the effect of anti-VEGF and Pattern Scanning Laser 









CHAPTER 2: MANAGEMENT OF PRIMARY PTERYGIUM WITH 
INTRA-LESIONAL INJECTION OF 5 FLUROURACIL AND 






Pterygium is an elastotic degeneration of the subconjunctival tissue that affects the 
exposed bulbar conjunctiva, nasally more than temporally. It affects sight when the fleshy 
fibrovascular tissue advances across the limbus and encroaches on to the visual axis of the 
cornea. It may result in corneal scarring, chronic ocular surface inflammation and irregular 
astigmatism and can restrict ocular movement (204). Although the aetiology of the 
pterygium remains an enigma, environmental factors such as ultraviolet light, dryness, 
genetic and immunological factors play a big role in its occurrence (209). Other important 
factors such as fibrovascular proliferation, inflammation and angiogenesis have been 
implicated in the pathogenesis and progression of pterygium (211). Increased expression of 
several growth factors, such as epidermal growth factor (EGF), vascular endothelial growth 
factor (VEGF), basic fibroblast growth factor (bFGF), transforming growth factor-beta, 
connective tissue growth factor, insulin-like growth factor and nerve growth factor has 
been reported in primary and recurrent pterygia (346). VEGF, VEGF receptors and other 
molecules that play a role in angiogenesis are particularly expressed in pterygium (347-
349). 
The gold standard for treatment of primary pterygium is surgical excision with an 
autoconjunctival graft (350). Recurrence rates of 0 to 14.29 % have been reported (351). 
Recently Said et al (282) emphasised the importance of recognising conjunctival recurrence 
of pterygium and demonstrated that intralesional 5 fluorouracil (5FU) could arrest 
progression of pterygium avoiding need for surgery. This has also been the experience of 
others (235). Studies have also shown that intralesional injection of bevacizumab can treat 
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recurrent pterygium (275, 352). 
Taking a cue from the above reports, investigators looked at treating primary pterygium in a 
similar manner. Two studies were carried out in 2016 to study the effect of intralesional 5FU 
injection in primary pterygium and reported good results (234, 235). Further studies were 
carried out on the use of bevacizumab in primary pterygium and also reported good results 
(273, 352). 
We conducted a clinical trial to evaluate the effect of combined injections of 5FU and 
bevaciazumab in patients presenting with primary pterygium. Immunohistology for different 
growth factors and markers for blood vessels and lymphatics was carried out in tissue 
samples obtained after excision of injected pterygia. Our results have implications for 
clinical application of these injections to arrest progression and reduce vascularity of 
pterygium as the only treatment or prior to surgical excision. This chapter has been 
published by Dr Ghoz et al and is her own work (Please refer to list of publications).  
2.2 Methods 
 
2.2.1 Ethical issues 
 
The study adhered to the tenets of the Declaration of Helsinki. The study proposal with the 
relevant forms and documents were approved by the Nottingham research ethics service 
committee II, Medicines & Healthcare products Regulatory Agency MHRA, the Health 
Research Authority HRA and local NHS Research and Innovation authorities (Eudract 
Number: 2015-003217-20), (REC reference Number: 16/EM/0002). It was registered online 
and adopted by National Institute for Health Research. 
 
 
The ethical approval application process involved the submission of the project proposal 
and completed IRAS form to all parties (Research ethics committee, MHRA, NUH NHS trust 
R&I and HRA), the ethics committee reviewed the application on 22nd February 2016 and 
was approved on 14th March 2016. MHRA approved the study on 23rd March 2016. Four 
substantial amendments were applied for and they were all approved. The first patient was 
recruited on 10th January 2017. 
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2.2.2 Patient recruitment 
 
Whilst the recruitment target was extended to 40 participants, the decision was taken to 
complete recruitment at 20 as we have collected sufficient data to achieve the protocol 
objectives. Participants were recruited from specialist cornea and ocular surface clinics at 
the Queen’s Medical Centre, Nottingham University Hospitals NHS Trust under the 
supervision of Professor Harminder Dua (Consultant Ophthalmologist). 11 patients were 
retrospectively recruited into the study. 
Inclusion criteria 
- Patients over the age of 18. 
- Patients able to give informed consent. 
- Patients with progressive primary pterygium. 
 
- Patients with early recurrent pterygium within 6 months of original excision (conjunctival 
recurrence or recurrence extending just across the limbus). 
Recurrence will be defined as follows: 
 
1. Increased vascularity of the conjunctiva at the site of original excision and 
autologous conjunctival grafting, showing tortuous and dilated vessels associated with 
thickening/oedema of the conjunctiva appearing after the initial redness and swelling 
related to surgery had settled. 
2. Clinically documented progression of fibrovascular tissue over two or more follow-up 
visits with or without frank encroachment on to the cornea, which did not settle with 
increased doses of topical steroids 




- Patients under 18 years of age. 
- Patients unable or refusing to provide informed consent. 
- Patients who are needle phobic. 
- Pregnant women, women aiming for conception and breastfeeding women. 
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- Patients with hypersensitivity to the active substance or to any of the excipients. 
- Patients with active or suspected ocular or periocular infections. 
- Patients with active severe intraocular inflammation. 
- Patients with raised intraocular pressure or on glaucoma medication. 
 
 
2.2.3 Clinical intervention and follow up 
 
A complete eye examination at base line and after injections was carried. Visual acuity was 
assessed using LogMAR charts followed by pupil reaction, anterior segment biomicroscopic 
examination, corneal topography (Oculus Pentacam HR, Oculus Optikgerate GmbH, Wetzlar, 
Germany) to assess corneal astigmatism, Optical coherence tomography (OCT) (Spectralis 
Heidelberg engineering, Heidelberg, Germany) to assess thickness, intraocular pressure 
measurement and fundal examination. Demographic data were documented. A 
standardised protocol was followed for anterior segment photography. The patient was 
asked to look straight and ×10 and ×16 images were taken. Brightness, colour and 
background illumination were always set at the standard chosen for the study for all 
patients at all time-points. The ×10 magnification image was used for length measurement. 
Images were imported to a PC and measurements were taken with the Neuron J software 
(ImageJ V.1.31, Maryland, USA) that was calibrated in accordance with the pixel resolution 
of the images as detailed in instructions. The pterygium length, from limbus to apex was 
measured before and after injections. A standardised protocol was followed for optical 
coherence tomography. The Spectralis Heidelberg OCT was used in all patients at all time- 
points. The patient was asked to look at a predefined fixation target (looking straight) and a 
vertical scan was performed at two pre-determined points corresponding to anatomical 
landmarks in the body of the pterygium. The landmark corresponded to the bifurcation of a 
major vessel. From previous validation studies it was noted that this landmark did not shift 
in position with treatment though the ‘redness’ and thickness of the vessels changed. The 
thickness was measured from the epithelial surface to the surface of the underlying scleral 
reflection on OCT. The Spectralis Heidelberg software was used to measure the thickness in 
microns. Any complications and adverse events were noted and recorded. Anterior segment 
photographs were taken at every follow up visit to assess response to treatment in terms of 
47  
redness and progression. The pterygium was graded as severe (red areas more than white 
(heavily vascularized with dilated and full vessels and fleshy); moderate (more white areas 
then red, (intermediate vascularization with thin and narrow vessels and not fleshy), and 
mild (atrophic and thin with minimal vasculature). A score of 3, 2 and 1 was ascribed to the 
three grades respectively. Astigmatic changes were analysed using Vector Analyzer software 
(VectorAnalyzer 1.2, Dr.Peyman) and the magnitude of difference vector was measured. 
Injections were administered every 2 weeks for a maximum of 5 injections or until the 
desired endpoint was achieved (atrophic pterygium, mild grade). Further follow up was at 
monthly intervals for three months (Table 2.1). 
Injection method 
 
All injections were given in the outpatient clinic using a slit lamp. Topical anaesthesia 
(tetracaine minims 1% w/v, Bausch & Lomb, UK) and Povidone iodine (5% w/v, Bausch & 
Lomb, UK) eye drops were instilled in the eye 10 minutes prior to the injection. With a pre- 
loaded 1 ml syringe of 5FU (0.3 ml of 2.5mg 5FU per 0.1ml) 0.1 to 0.2 ml of 5FU (2.5 to 5 mg) 
was injected into the body of the pterygium using a 30 gauge needle (Sterican, B. Braun, 
Hessen, Germany). Formation of a bleb indicated intra-lesional injection of drug (Fig. 1). This 
was followed by injection of bevacizumab, which too was delivered in a pre-loaded 1 ml 
syringe containing 0.2 ml of 5 mg bevacizumab. 0.1 to 0.2 ml of bevacizumab (2.5mg to 
5mg) was injected in the body of the pterygium. Post-injection, 1–2 drops of 
chloramphenicol 0.5% (preservative free minims, Bausch and Lomb, UK) were instilled 
topically and continued four times a day for 3 days after each injection. All patients had the 
ability to access the 24 hour on call emergency eye service and contact the investigators for 
any queries during the study period. 
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Table 2.1: Follow up scheme of REPEAT. 
 
Table giving details of the follow up scheme of recruited patients. 
 
 
Name and code of visit Interpretation 
Visit 01 Date of recruitment 
Visit 02 Date of first treatment 
Visit 03 Two weeks from first treatment and 
possibly date of second treatment 
Visit 04 Two weeks from second treatment and 
possibly date of third treatment 
Visit 05 Two weeks from third treatment and 
possibly date of fourth treatment 
Visit 06 Two weeks from fourth treatment and 
possibly date of fifth treatment 
Post-injection visit 01 1 month from last treatment 
Post-injection visit 02 2 months from last treatment 
Post-injection visit 03 3 months form last treatment 
 
 
2.2.4 Laboratory study method 
 
The laboratory part complements the clinical study. This clinical study was published and 
I contributed for three-quarters of the work. The cases in the study were my patients and 
I was the first author on the publication. The laboratory team carried out the laboratory 
part of the study.  
Four patients returned for excision of pterygium for cosmetic reasons, 5 months after last 
injection. Pterygium tissue from these patients and from three non-injected controls 
matched for severity (controls) were subjected to immunohistological examination. 
Pterygium tissue was fixed in 4% paraformaldehyde for 2 hours and embedded in paraffin. 
Thin sections (4 um) were cut, deparaffinized and antigen retrieval carried out by incubating 
slides in 10mM sodium citrate solution, pH 6.0 (IHC antigen retrieval solution – low pH; 
Thermofisher Scientific, UK) for 15 minutes at 60oC. The slides were then incubated with 5% 
normal donkey serum in 0.03% Triton-X100 for 1 hour to block any non-specific binding 
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sites. Sections were stained with specific primary antibodies (Table 1) or negative control 
(no primary or normal mouse IgG1) overnight at 4oC followed by secondary antibody 
staining (alexa fluor 488 or 594 conjugated donkey anti rabbit IgG or donkey anti mouse IgG, 
Thermofisher scientific) at room temperature for 1 hour. The stained sections were 
mounted in DAKO fluorescent mounting media and examined using fluorescent microscope 
(B51X Olympus, Japan) and processed with Adobe Photoshop CS4 (Adobe Systems, CA). 
Histological sections in duplicate, from each of the three control samples and four injected 
pterygia were used for each of the seven antibodies indicated in table 2.2. 
 









bFGF IgG Goat Polyclonal R&D Systems 
AF-233- 
NA 
1 in 200 
VEGF- 
189 





1 in 100 
EGF IgG1 Mouse 10825 R&D Systems MAB236 1 in 100 
Collagen- 
I 
IgG Rabbit Polyclonal Abcam AB34710 1 in 200 
vWF IgG Rabbit Polyclonal Dako A0082 1 in 400 
LYVE-1 IgG Goat Polyclonal R&D Systems AF2089 1 in 200 
Isotype IgG1 Mouse 11711 R&D Systems MAB002 1 in 100 
 
 
2.2.5 Outcome measurements 
 
The primary efficacy measures were arrest of progression and reduction of vascularity 
(redness) of lesion. The secondary efficacy measures were cosmetic improvement as 
perceived by the patient, improvement in symptoms of irritation, reduction in thickness and 
effect on astigmatism. All patients were clearly informed that the treatment would not 
cause the lesion to disappear and that for cosmetic or other reasons surgery to remove the 
lesion might still be required. 
Safety measurements were specifically investigated with reporting any adverse events 
related to the injections. Patients had the ability to access the 24 hour on call emergency 
eye service, and at the same time were provided with contact numbers for investigators for 






2.2.6 Statistics and Data analysis 
 
Statistical analysis was performed by using GraphPad Prism 7.03 (GraphPad Software La 
Jolla, CA, USA). Wilcoxon adhoc test was used to analyse the data for pterygium length and 





We were able to recruit 20 patients to the study (study is completed). The demographic 






















1 REPEAT01 64 (M) Primary 10.01.2017 Left 5 11.04.2017 
2 REPEAT02 72 (M) Primary 12.01.2017 Right 5 09.05.2017 
3 REPEAT03 64 (F) Primary 24.01.2017 Right 2 07.02.2017 
4 REPEAT04 34 (M) Recurrent 05.03.2017 Left 5 30.01.2018 
5 REPEAT05 38 (M) Primary 14.03.2017 Left 5 17.10.2017 
6 REPEAT06 55 (M) Primary 23.03.2017 Left 5 25.10.2016 
7 REPEAT07 63 (F) Primary 28.03.2017 Left 5 09.11.2016 
8 REPEAT08 57 (M) Primary 11.04.2017 Left 5 17.10.2017 
9 REPEAT09 22 (M) Primary 11.04.2017 Left 5 09.11.2017 
10 REPEAT11 56 (F) Primary 24.05.2017 Right 5 28.12.2016 
11 REPEAT13 83 (M) Recurrent 07.06.2017 Left 5 20.03.2018 
12 REPEAT14 37 (F) Primary 21.06.2017 Right 3 06.12.2016 
13 REPEAT15 63 (F) Primary 22.06.2017 Left 5 23.01.2018 
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14 REPEAT16 49 (M) Primary 28.06.2017 Left 5 17.01.2017 
15 REPEAT17 54 (M) Primary 05.07.2017 Left 5 21.02.2017 
16 REPEAT18 53 (F) Recurrent 15.08.2017 Left 2 15.08.2017 
17 REPEAT19 70 (M) Primary 29.08.2017 Right 5 16.01.2018 
18 REPEAT20 42 (F) Primary 11.10.2017 Left 4 27.02.2018 
19 REPEAT22 37 (F) Primary 03.11.2017 Right 5 10.04.2018 
20 REPEAT23 69 (M) Recurrent 09.11.2017 Left 5 09.11.2017 






16 patients had primary pterygium and 4 patients had recurrent pterygium. A total of 20 
eyes of 20 patients received 5 FU and bevacizumab injections. Of the twenty patients, 8 
were females (40%), and 12 were males (60%). Mean age was 54 years (range was from 22- 
83 years). Sixteen patients received 5 injections, 1 received 4 injections, 1 received 3 
injections and 2 received 2 injections. All patients experienced stinging during injection of 
bevacizumab but not with 5FU. All patients showed subconjunctival and/or intra-lesional 
haemorrhage after injection (Figure 2.1), which resolved in two weeks. All patients showed 




Figure 2.1: Slit lamp anterior segment photograph of a pterygium post injection. 
 




There was a mean reduction of 0.10 mm+/-0.1 in pterygium length in 56% of the patients 
while the rest did not show any change ( p=0.0039, Wilcoxon test, median= 0.041, 95% 
confidence interval (CI) = 0.024-0.177). Twenty two percent of the patients showed a 
reduction in astigmatism (mean magnitude of difference vector was 10.1), 11% showed no 
difference (mean magnitude of difference vector was 1) while 67% had increased 
astigmatism (mean magnitude of difference vector was 5) following the injections. The 
mean magnitude of difference vector was 5.7 and the range of astigmatic change was from 
0.8-19.4. Eighty nine percent of patients had reduced thickness of pterygium as evidenced 
by difference in OCT measurements while the rest had no change. The mean reduction in 
thickness was 35.8 µm+/- 31.29, (p=0.0078, Wilcoxon test, median= 29 µm, 95% CI= 11.7- 
59.9). 
 
The clinical grade of the pterygium had significantly reduced in 62.5 % while it remained the 
same in 37.5%. No patient showed an increase in clinical grade of pterygium. Ninety percent 
of the patients who showed reduction of clinical grade had one clinical grade improvement 
while 10% had a 2 clinical grades improvement (Figures 2.2-2.4) (Mean pre-injection grade 
was 2.313, mean post-injection grade was1.625, p=0.0004, paired-test, 95% CI= 0.367 to 
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1.008). Two patients developed superficial punctate keratitis after the 4th and 5th injection. 
This resolved on cessation of injection. 
 
 
Figure 2.2: Slit-lamp anterior segment photograph of REPEAT09 before and after 5 injections. 
A, C: Pre-injection image of pterygium with patient looking straight (A) and temporally (C). The lesion 
appears fleshy with dilated and full vessels. B, D: Post-injection images with patient looking straight (B) 




Figure 2.3: Slit lamp anterior segment photographs of REPEAT14 before and after 3 injections. 
A, C: Pre-injection images of pterygium with patient looking straight (A) and temporally (C). The lesion 
appears fleshy with dilated and full vessels (arrow). B, D: Post-injection images show reduction in 
vascularity with patient looking straight (B) and temporally (D). The arrow in (D) points to a vessel that 
has attenuated with barely visible branches. 
 
 
Figure 2.4: Slit lamp anterior segment photographs images of REPEAT16 before and after 5 injections. 
A: The pterygium before injections is fleshy and vascular obscuring the underlying limbus (arrow). B: 
The pterygium after injections is atrophic as evidenced by increased visibility of the outline of the 
underlying limbus especially inferiorly (arrow). 
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2.3.3 Laboratory study results 
 
Atypical fibroblast cells and vascular endothelium showed positive staining for bFGF in 
control pterygium samples (Figure 2.5A), whereas in injected pterygium (Figure 2.5B) weak 
bFGF immunoreactivity was noted only at the basal aspect of vascular endothelium. 
Monoclonal antibody against VEGF showed positive immunoreactivity in control pterygium 
samples (Figure 2.5C) and a significantly reduced staining in injected samples (Figure 2.5D). 
EGF (epidermal growth factor) was abundantly present in pterygium epithelium and around 
basal aspects of vascular endothelium of control samples (Figure 2.5E), but in injected 
samples it was only detected at low levels around basal aspect of vascular endothelium 
(Figure 2.5F). Reactivity of collagen-I was moderately reduced in injected samples (Fig. 5H) 
compared to control samples (Figure 2.5G). SPARC (secreted protein acidic and cysteine 
rich) was shown to be positively expressed in all control samples but unlike bFGF, it 
remained unchanged in sections of injected samples (Figure 2.6). Antibodies against von- 
Willebrand factor (vWF) were used to detect blood vessels, and against lymphatic vessel 
endothelial hyaluronan receptor (LYVE-1) to detect lymphatic vessels. Some vascular 
structures showed dual staining for both vWF and LYVE-1 in sections of control samples 
(Figure 2.7) whereas reduced expression was noted in injected samples. This amounted to 





Figure 2.5: Immunofluorescence analysis of control and injected pterygium samples. 
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Representative sections of sample from control (A, C, E, G; n=3) and injected (B, D, F, H; n=4) groups. 
Positive immunoreactivity for bFGF in fibroblast cells (A); VEGF in vascular endothelium and 
extracellular matrix (C), EGF in epithelial cells (E) and Collagen-I in vascular basement membrane (G) 
are demonstrated in the control sections. Reduced or weakened staining for these proteins is seen in 




Figure 2.6: Representative sections of sample from control (n=3) and injected (n=4) groups (Double 
labeling of bFGF and SPARC). 
Labeling for bFGF is demonstrated by red fluorescence (A and D) and SPARC by green fluorescence (B 
and E) in multiple sections of the same pterygium vessel in control and injected samples. Overlay 
micrographs indicate double labeling for bFGF and SPARC (orange/yellow fluorescence; C and F). The 
staining for bFGF is markedly reduced in the injected sample but that of SPARC is unchanged. Scale bar 




Figure 2.7: Representative micrographs of control (n=3) and injected (n=4) samples. (Co-localization of 
vWF (vascular) and LVYE-1 (lymphatic) channels). 
vWF is indicated in green (A and D) and LYVE-1 in red (B and E). Overlay micrograph of control 
section (C) indicates co-localisation of vWF and LYVE-1. In injected sample (F), LYVE-1 stained cells 








 vWF LYVE-1 
Control (n=3) 28 21 
Injected (n=4) 10 8 






Recurrence of pterygium is the major complication after surgical excision of the lesion. The 
two main pathological processes in pterygium are fibroblast proliferation and angiogenesis. 
Many studies have demonstrated that the pathogenesis and recurrence of pterygia can be 
attributed to the increased expression of molecules such as VEGF, transforming growth 
factor, platelet derived growth factor and bFGF (236). VEGF was found to be highly 
increased in pterygia and is believed to be involved directly or indirectly in formation of 
pterygia (215). 
Intervention to reduce incidence of recurrence following surgery for primary or recurrent 
pterygia include the use of autologous conjunctival graft and application of antimetabolites 
either 5FU or MMC intraoperatively. Intra lesion injection of antimetabolites and anti-VEGF 
drugs have also been used to treat recurrent pterygium (235, 275, 282, 352). Encouraged by 
the beneficial effects of treating recurrence, both agents have also been used individually in 
treatment of primary pterygium with considerable success (349). 5FU inhibits DNA synthesis 
and proliferation of fibroblast (353). Anti-VEGF antibodies bind to isoforms of VEGF and 
inhibit the VEGF-receptor interaction preventing angiogenesis (352). 
In our study we injected both agents together, for the treatment of primary pterygium. We 
found that this approach resulted in reduction in the clinical grade, thickness and vascularity 
of the pterygium. This two pronged approach addressing both the main pathological 
processes may work synergistically affecting thickness and vascularity of the pterygium. 
Some patients also showed a slight reduction in the length of the pterygium. This is most 
likely due to the reduction in thickness at the apex, but in any case was less than 0.2mm and 
clinically insignificant. Significantly, the progression of pterygium was arrested in all cases 
and the cosmesis too had improved in 62.5% with 56% of the concerned patients noticing 
the difference subjectively. Some of these individuals are unlikely to proceed to surgery 
making the study clinically more relevant. Interestingly however, the astigmatism increased 
in 67% of patients post-injection. This could be related to the retraction of the fibrotic tissue 
post-injection exerting a greater force on the cornea inducing further deformation. Malik et 
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al (235) compared the mean change in corneal astigmatism and clinical appearance after 
intralesional injection of 5FU in primary and recurrent pterygia. They treated all patients 
with 0.1 ml of 5FU (5mg) weekly injections for four weeks and demonstrated a reduction of 
the astigmatism. However, Singh et al (273) use only bevacizumab injection and showed not 
difference in astigmatism. Unlike these studies, we injected both 5FU and bevacizumab, 
which could account for the increased astigmatism we noted, probably as a consequence of 
fibrous tissue contraction. Most studies that have used either 5FU or bevacizumab (234, 
236, 273) concluded that improvements in appearance, colour and surface area of 
pterygium could be safely achieved. 
 
 
Despite anaesthesia, all patients complained of a stinging sensation during injection of 
bevacizumab but not with 5FU. Hence we injected the latter before the former. 
Bevacizumab solution is acidic (pH 6.13) and 5FU is alkaline (pH 8.89), which could explain 
the difference in patient experience. Apart from mild punctate keratitis, no adverse events 
were recorded. Post-injection, four patients requested surgery to remove the residual 
pterygium. Intraoperative bleeding was much less compared to previous experience with 
un-injected lesions. This is an anecdotal observation as the study was not designed to pick 
up this difference. These four samples were examined by immunohistology. 
Immunohistology: 
 
Immunohistochemical studies have shown increased expression of VEGF in pterygium 
compared to normal conjunctiva (215, 349). VEGF receptors 2 and 3 are also increased in 
pterygium (349). Mohamed et al (353) conducted a randomised control study with one 
group receiving a single bevacizumab injection while the other did not receive any. Similar 
to our results, they found a reduced mean vessel count and a significant reduction in VEGF 
expression in injected pterygium samples. vWF is one of the proteins involved in blood 
vessel function. It has been demonstrated in the pterygial blood vessel walls and could be 
involved in pterygial angiogenesis (354). Lymphatic vessel endothelial cells express specific 
proteins including LYVE-1 (201). Our study demonstrated that there was a reduction in both 
vWF and LYVE-1 in the injected samples indicating decreased angiogenesis and 
lymphangiogenesis, which is a novel finding. Interestingly, in control pterygium samples 
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there was a close localisation of both vWF and LYVE-1 in relation some vessels, which could 
be related to immature vessels or proximity of mononuclear cells (355). 
 
 
Detorakis et al (356) found that levels of bFGF were higher in pterygium than normal 
conjunctiva. Collagen types I, III and IV were found in normal conjunctiva and pterygium 
(357). In our injected samples both bFGF and Collagen I were reduced, which is more likely 
to be due to the effect of 5FU as it primarily targets the proliferation of fibroblasts. SPARC, 
is a matrix protein which has several roles in wound remodelling and modification of 
collagen production as well as in angiogenesis and high levels have been reported in 
pterygium (349). We were not able to demonstrate any effect of our injections on the 
SPARC expression despite reduction in vascularity and collagen suggesting that bFGF plays a 
greater role in the pathophysiology of pterygium. Pterygium epithelium and fibroblasts 
derived from pterygia also express epidermal growth factor receptors (EGFR) (358). We 
detected EGF at the basal aspect of pterygium vascular endothelium, which was reduced 
after injections suggesting that EGF also contributed to angiogenesis in pterygium. 
This study demonstrates that proliferative activity in pterygium and its progression can be 
modified by drugs targeting the various growth factors and cells involved in the 
pathogenesis of pterygium. Such a medical approach in the management of pterygium, the 
treatment of which is essentially surgical, is a viable option to consider for both recurrent 
and primary pterygia. 
 
 
The strong point in this clinical study is using 2 different types of combined injections to determine their effect 
on the arrest of pterygium progression as all previous studies investigated one type of injection only. The 
limitation in this study was the sample size. In the future, a bigger sample size would give more data and also 
another clinical study could be carried out to follow up the patients who required surgery despite of injections to 
look into the rate of recurrence to determine whether the multiple combined injections reduced the recurrences 
rates or not .
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CHAPTER 3: HEALING OF AUTOLOGOUS CONJUNCTIVAL 




Pterygium is a common ocular disorder which presents as a progressive triangular growth 
encroaching on the cornea from the bulbar conjunctiva. It consists of fibrovascular 
subconjunctival tissue with elastotic degeneration and conjunctival epithelial 
hypertrophy(359). It typically affects inter‐palpebral conjunctiva, nasal more than temporal. 
It can affect vision by direct obstruction of the passage of light or induce corneal distortion 
and irregular astigmatism. In advanced cases, it can affect ocular movements with 
symptoms of diplopia. For many patients, it is a cosmetic blemish (204, 360-363). There is 
no medical therapy for pterygium. When indicated for the above reasons, surgical excision 
with autologous conjunctival graft is the intervention of choice with intraoperative use of an 
anti‐metabolite such as Mitomycin‐C (MMC) as an adjunct, especially in recurrent cases. 
Traditionally the autologous graft was secured in place with sutures but in many parts of the 
world sutures have been replaced with tissue glue (fibrin glue) or its variations such as 
autologous blood (364-366). 
Both occurrence and recurrence of pterygium after surgery are related to race, skin colour 
and geographic location (207-209). The surgical success rate (lack of recurrence) following 
excision and conjunctival autograft is reported to be between 0 and 14.29% (228, 351, 367- 
370). Use of fibrin glue instead of sutures is reported to favourably influence the recurrence 
rate. Although much has been studied and reported in relation to use of autologous grafts 
and fibrin glue (254, 368, 371-379), there is no information on the fate or healing of the 
grafted conjunctival tissue and the changes associated with the donor site. We undertook a 
temporal observational study of the healing of conjunctival autograft and the donor site in 
28 consecutive patients and report our results herein that have implications for clinical 
follow‐up and differentiation from signs of early recurrence. 












The study was conducted in accordance to the declaration of Helsinki. The study was classed 
as a ‘healthcare evaluation project’ and approved by the Clinical Quality, Risk and Safety 
directorate, Nottingham University Hospitals, NHS Trust (project number: 17-206c). 
3.2.2 Patient recruitment 
 
 
Thirty‐two eyes of 28 consecutive patients attending the cornea and ocular surface clinic of 
the Queens Medical Centre, Nottingham were included. All patients had visually or 
cosmetically significant pterygium requiring surgery. 
3.2.3 Clinical intervention and follow up 
 
All thirty two eyes of the 28 patients underwent surgical excision of pterygium using the 
conjunctival autograft technique. 
Surgical procedure 
 
After due consent, surgery was carried out under regional anaesthesia (sub‐Tenon's block) 
or general anaesthesia. A blunt scissors was inserted through the conjunctiva at the neck of 
the pterygium (at limbus) and the head peeled off the corneal surface. The head and neck 
were excised and the corneal surface polished. The conjunctiva covering the body of the 
pterygium was carefully dissected off the underlying fibrovascular tissue and the latter off 
the sclera, up to the medial fornix but anterior to the caruncle. The fibrovascular tissue was 
excised and bleeding points cauterized with a bipolar cautery (Force EZ, Valleylab, USA). 
Donor site: the superior bulbar conjunctiva of the same eye was exposed with a superior 
rectus suture (4/0 silk). The donor conjunctiva, corresponding to the size of the defect 
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created by pterygium excision, was marked with ink (4–6 mm vertically and 5–15 mm 
horizontally) preserving 2 mm of peri‐limbal conjunctiva of the donor site. The donor 
conjunctiva, sparing Tenon's capsule, was undermined with a blunt scissors and excised such 
that the ink marks were included on the epithelial surface. The donor conjunctiva was 
spread epithelial side down, on the cornea and covered with a layer of the thick component 
(fibrinogen, aprotinin, coagulation factor 13) of (Tisseel®, Baxter Healthcare Corporation, 
Berkshire, UK) in a double barrel syringe. The thawed components of each barrel were 
withdrawn separately into 2 ml syringes and glue applied via a Rycroft cannula (Sterimedix, 
Redditch, Worcestershire, UK). The recipient bed was covered with a layer of the thin 
component (thrombin and calcium chloride) of Tisseel®. The donor conjunctiva was flipped 
across to cover the recipient bed and smoothened such that the edges were not rolled. 
Gentle pressure was applied with a dry surgical sponge to approximate the conjunctival 
autograft with the underlying episclera/sclera (scleral bed). Further glue, each component 
sequentially, was applied under the edge of the recipient site conjunctival edges 
(conjunctival bed), and it was approximated to the donor conjunctiva edge as the glue set. 
The posterior part of the conjunctiva at the donor site was undermined, both components 
of glue applied to the surface of exposed Tenon's, and the conjunctiva pulled down to cover 
the defect and approximated to the rim of peri‐limbal conjunctiva. 
Mitomycin‐C was applied as an adjunct in 25 eyes using sponge pieces soaked in 0.04% 
solution and placed between sclera and overlying conjunctiva of the pterygium for 5 min, 
and on the exposed sclera for 2 min. Mitomycin‐C (MMC) was used intraoperatively in all 
patients with recurrent pterygium and patients with Middle‐Eastern and Afro‐Caribbean 
origin undergoing excision of primary pterygium. The eye was then washed with 20 ml of 
balanced salt solution before affixing the donor conjunctiva. 
Postoperative management 
 
All patients were prescribed chloramphenicol eye drops 0.5% (Chloramphenicol minims, 
Bausch & Lomb/Chauvain), instilled four times a day for 2 weeks and prednisolone acetate 
eye drops 0.5% (Predsol minims, Bausch & Lomb/Chauvain), instilled four times a day for 
1 week then tapered to three times a day for 1 week, twice a day for 1 week and then once 
a day for another week. 
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Patients were followed up within the first week and then at weeks 2, 4, and 8. Sixteen 
patients were followed up to 6 months postoperatively. Slit lamp images were taken with a 
Topcon camera SLD701 preoperatively and at each visit. Patients were examined, without 
and with fluorescein staining, for presence of graft, for graft haemorrhage, swelling, 
vascularity/ischaemia and retraction of edges. The graft beds (scleral and conjunctival) and 
the conjunctiva at the donor site were also similarly examined. Fluorescein angiography (FA) 
was performed in four patients within the first week and in one patient 3 months after the 
surgery. 
Anterior segment fluorescein angiography 
 
Anterior segment fluorescein angiography (FA) was performed on five eyes of five patients 
who had pterygium excision and conjunctival autografts. The terms of the study approval 
required that only one angiogram be performed per patient and for five patients only as 
part of an angiography pilot study. Hence, FA was performed at 1 day postoperative for two 
patients, 2 days postoperative for one patient, 3 days postoperative for one patient and at 
3 months postoperative for one patient. 
Procedure of angiography 
 
The angiograms were obtained using the Heidelberg Retina Angiograph, and the degree of 
field of view was chosen according to the size of the conjunctival autograft/vessels. The 
focus was set on +32.00. An initial infrared image of the selected area was taken as baseline. 
Five millilitres of 10% sodium fluorescein were then injected intravenously by cannulating 
the antecubital vein at a rate of 1 millilitre per second. Two single images of the selected 
area were taken at the start and end of the injection. A video recording of 35 seconds 
duration was initiated with the first appearance of the dye, which was usually 12 seconds 
after the start of the injection. After 35 seconds, no images were taken till 1 min elapsed 
from the start of the injection and then a single image was captured every second till 2 min 
elapsed from the start of the injection. At minute 2 from the start of the injection, two 
single images of the selected eye were taken and another two single images were captured 







A total of thirty‐two eyes of 28 patients underwent pterygium excision with autologous 
conjunctival graft affixed with fibrin glue. Patient demographics are shown in Table 3.1. The 
age range was 33–78 years with a mean of 50.8 years and there were 17 males and 11 
females. Twenty‐four cases were unilateral and four were bilateral. Mitomycin‐C (MMC) 
was applied to 25 eyes of 22 patients. Twenty‐seven eyes of 24 patients had primary 
pterygium while five eyes of four patients had recurrent pterygium. None of the primary 
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Table 3.1: Age and sex of patients and laterality of the pterygium. 
 




Within 1 week 
 
The conjunctival autograft was not lost in any eye. About 94% of conjunctival autografts 
showed diffuse or patchy intra-graft haemorrhage (Figure 3.1). Haemorrhage started as 
early as 1 day postoperative. Blood vessels were obscured by the diffuse haemorrhage 
(Figure 3.1). In grafts with patchy haemorrhage, the visible vessels were narrow and/or 
dilated (Figure 3.1). Vascular connections between graft and host bed were not clearly 
visible. All grafts showed variable amount of swelling. The swelling was either due to 
oedema and/or transudation, which appeared as a straw‐coloured accumulation of fluid 
(Figure 3.2).The corneal edge of the conjunctival autograft was overlapping the limbus in all 
patients. About 11% conjunctival autografts showed areas of localized under‐perfusion 
(areas devoid of blood vessels compared to the surrounding perfused conjunctiva in the 
autograft) (Figure 3.3). The episclera under the conjunctival bed of 17% conjunctival 
autografts showed engorged vessels. The conjunctival beds of 89% of conjunctival 
autografts showed congestion and 33% showed haemorrhage (Fig. 3A). The edge of the 
conjunctival beds were swollen with oedema causing the edge to form a narrow hump 
giving it a ‘rolled’ appearance in some sectors as illustrated (Figures 3.1A and 3.1D). 
Fluorescein staining showed no loss of epithelium in any conjunctival autograft. Residual 
fibrin glue at the junction of conjunctival autograft and conjunctival bed, stained brightly 
with fluorescein (Figure 3.4). A separation or gap between the edges of the conjunctival 
autograft and conjunctival bed was seen in 33% of patients. This gap was fully epithelialized 
as evidenced by fluorescein staining. About 12.5% of the patients with a gap showed under‐ 
perfusion of the scleral bed (Figures 3.5 and 3.6). 
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Figure 3.1: Slit lamp anterior segment photographs of the conjunctival autograft within 1 week of 
transplant. 
(A) The conjunctival autograft shows diffuse haemorrhage covering the entire conjunctival autograft and 
obscuring all details posterior to it. The rolled edge of the conjunctival bed is seen closely applied to the 
conjunctival autograft (arrows). (B) The conjunctival autograft shows diffuse haemorrhage, which is 
denser superiorly. The vasculature of the conjunctival autograft is not visible. Inferiorly, accumulation of 
serous (yellowy) fluid is seen. The corneal edge of the conjunctival autograft is encroaching on the limbus. 
The edge of the conjunctival bed is thickened, rolled and also shows patches of haemorrhage. The edges 
of the conjunctival autograft and conjunctival bed have retracted to expose the underlying sclera, with 
sparse episcleral vessels (*). (C) The conjunctival autograft shows patchy haemorrhage and transudation. 
The vasculature of the conjunctival autograft is visible. The conjunctival bed shows retraction. Good 
episcleral vasculature is visible. The corneal edge of the conjunctival autograft is encroaching on the 
limbus. (D) The conjunctival autograft shows a patch of haemorrhage with transudation, inferiorly. The 






Figure 3.2: Slit lamp anterior segment photographs of the conjunctival autograft within 1 week of 
transplant. 
The vasculature of the conjunctival autograft is visible in all photographs. The vessels are of variable 
thickness and some show stagnant columns of blood (arrow). The nasal edge of the conjunctival autograft 
is in close apposition with the conjunctival bed, with no gap in all four cases. (A) The conjunctival 
autograft shows swelling due to oedema. (B) The conjunctival autograft shows swelling due to oedema. 
The conjunctival bed is congested and shows an elevated fold where it apposes the edge of the 
conjunctival 
autograft. (C) The conjunctival autograft shows patchy haemorrhage and diffuse transudation of straw‐ 
coloured fluid which contrasts with the appearance of oedema seen in (A) and (B) above. The corneal 
edge of the conjunctival autograft is encroaching on the limbus. The conjunctival bed is not congested 
but is 
thickened. (D) The conjunctival autograft shows haemorrhage inferiorly with diffuse transudation of 






Figure 3.3: Slit lamp anterior segment photographs of the conjunctival autograft within 1 week of transplant 
(without and with fluorescein staining (2% eye drops). 
(A) The conjunctival autograft shows localized under‐perfused area (outlined), patchy haemorrhage 
with minimal transudation. The conjunctival bed shows areas of congestion. (B) Cobalt blue filter image 
with fluorescein sodium 2% eye drops of (A) showing the outline of conjunctival autograft where 
pooling of dye occurs. The cornea shows an epithelial defect (arrow). (C) The conjunctival autograft 
shows patchy 
haemorrhage and a localized area of under‐perfusion (outlined). (D) Cobalt blue filter image with 









Figure 3.4: Slit lamp anterior segment photographs of the conjunctival autograft within 1 week of transplant 
(without and with fluorescein 2% eye drops). 
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(A) The conjunctival autograft is swollen and shows patchy haemorrhage and transudation. There is 
residual fibrin glue at the junction of the conjunctival autograft and the conjunctival bed (arrow). The 
corneal edge of the conjunctival autograft is encroaching on the limbus. (B) Cobalt blue filter image with 







Figure 3.5: Slit lamp anterior segment photographs images of the conjunctival autograft of a patient from 
1 week of surgery to 6 months (without and with fluorescein 2% eye drops). 
(A) The conjunctival autograft is swollen, haemorrhagic and its nasal edge has retracted from the 
conjunctival bed. The underlying sclera has sparse vessels. (B) Cobalt blue filter image with fluorescein 
sodium 2% eye drops of (A) showing the outline of conjunctival autograft. The exposed underlying sclera 
is epithelialized. A small defect in the healing corneal epithelium is seen. (C) The conjunctival autograft 
showed less swelling, haemorrhage and transudation at 2 weeks postoperative. The corneal edge of the 
conjunctival autograft has retracted from the limbus. (D) The conjunctival autograft swelling has 
resolved, and there is minimal haemorrhage at 1 month postoperative. There is a well‐established 
network of vessels in the conjunctival autograft. Some under‐perfused areas persisted (outlined) but 
small vessels (arrows) are seen to migrate into this area. (E) The conjunctival autograft and conjunctival 
bed have settled completely at 6 months postoperative. The under‐perfusion of the scleral bed has 
resolved. The conjunctival autograft shows multiple reconnections with the bed. (F) Cobalt blue filter 
image with fluorescein sodium 2% eye drops of (E) showing the outline of conjunctival autograft 






Figure 3.6: Slit lamp anterior segment images of the conjunctival autograft of a patient from 1 week of 
transplant to 6 months (without and with fluorescein 2% eye drops). 
(A) (As in Fig. 2B) The conjunctival autograft shows swelling due to oedema. The conjunctival bed is 
congested and shows an elevated fold where it apposes the edge of the conjunctival autograft. (B) Cobalt 
blue filter image with fluorescein sodium 2% eye drops of (A) showing the outline of conjunctival 
autograft. The conjunctival autograft is well apposed to the conjunctival bed. (C) The conjunctival 
autograft shows less swelling and oedema at 2 weeks postoperative. The conjunctival bed shows less 
congestion. (D) The conjunctival autograft shows less swelling at 1 month postoperative. The oedema has 
resolved. (E) The conjunctival autograft and conjunctival bed have settled completely at 2 months 
postoperative. The conjunctival autograft vasculature shows reconnections with the bed (arrows). The 
conjunctival bed fold is less prominent. (F) Cobalt blue filter image with fluorescein sodium 2% eye drops 
of (E) showing that the conjunctival autograft and conjunctival bed have blended almost imperceptibly 




One to two weeks 
 
The haemorrhage was less in all conjunctival autografts and in 13.5% cases had completely 
resolved. This also enabled better visualization of the vessels. The vessels morphology was 
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more varied, being tortuous or straight, narrow or dilated. Vascular connections were 
clearly seen between the conjunctival autograft and conjunctival bed in all patients. About 
60% conjunctival autografts were less swollen while 40% showed no improvement in 
swelling. The corneal edge of 93% had retracted from the limbus, which was now clearly 
visible. The under‐perfused area had not resolved in any of the cases. The episcleral vessels 
(scleral bed) were less engorged. About 80% of conjunctival beds still showed congestion 
but the degree of congestion was less than week one in all congested eyes while the rest of 
the congested eyes has resolved and residual minimal haemorrhage was seen in 27% of 
cases. All beds had several tortuous, straight, narrow or dilated blood vessels 
(Figures 3.5 and 3.6). 
 
Two to four weeks 
 
About 70.5% of conjunctival autografts continued to show minimal haemorrhage, which had 
completely resolved in the rest. All conjunctival autografts demonstrated a well‐formed 
network of blood vessels with well‐established connections with the conjunctival bed. 
Approximately half (47%) showed complete resolution of swelling. Under‐perfusion of 
conjunctival autograft was persistent. The congestion in all conjunctival beds had resolved 
and only 10% showed minimal haemorrhage. At this time point, ‘shunt vessels’ were clearly 
seen in the conjunctival bed (Figure 3.7).The scleral bed in the gap between conjunctival 
autograft and conjunctival bed continued to show under‐perfusion although small vessels 






Figure 3.7: Representative image of the conjunctival autograft of a patient at 1 month postoperative (slit 
lamp image, diffuse illumination). 
The conjunctival autograft shows swelling due to oedema and patchy haemorrhages. There is a 
localized area of under‐perfusion (outlined). The conjunctival bed shows a shunt vessel, the afferent 
starting at the 
black arrow and forming a loop to the efferent (white arrow). No terminal branches are seen from the 




Four to eight weeks 
 
About 16% conjunctival autografts had some remaining haemorrhage. Multiple 
reconnections with the bed were seen in all patients. About 21% conjunctival autografts 
continued to show residual swelling. The under‐perfused areas in the conjunctival 
autografts persisted. Clinically, the junction of the edge of the conjunctival autografts and 
the conjunctival bed was difficult to discern except in those who had developed a gap in one 
or more sector. Under‐perfusion of the scleral bed in the gap persisted. With fluorescein 
staining, the conjunctival autograft‐conjunctival bed junction was clearly outlined with 
pooling of fluorescein in 80% and in cases where there was a gap, the pooling was more 
obvious as a broader outline. About 10% of the conjunctival beds continued to show 
minimal haemorrhage (Figures 3.5 and 3.6). 
Eight weeks up to 6 months 
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All patients had completely settled grafts and beds (Figures 3.5 and 3.6). The conjunctival 
autografts showed no haemorrhage or swelling and all of them had a well‐formed network 
of vessels connected with the beds. Some shunt vessels persisted. The under‐perfusion of 
scleral beds had completely resolved. 
The findings from our temporal observation of ischaemia/under‐perfusion, haemorrhage, 
swelling or gaping at the edge between the conjunctival autograft and conjunctival bed 
were consistent, with no variation in eyes which received adjunct MMC during pterygium 
surgery from those which did not have MMC application. 
Donor site 
 
About 27% of donor sites showed haemorrhage and congestion in the first week, which had 
completely resolved within 8 weeks (Figure 3.8). One patient had telangiectasia, which 
developed at 1 week and persisted thereafter (Figure 3.9). One patient had retraction of the 
conjunctival edge from the limbus with exposed Tenon's capsule, which developed a 
pyogenic granuloma (Figure 3.10). This had settled and epithelialized by the week eight 
follow‐up visit. No other complications were noted. 
 
 
Figure 3.8: Slit lamp anterior segment photograph of the donor site of a patient at 1 week postoperative. 
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The donor site is congested and shows multiple areas of haemorrhages. The superior conjunctiva that 










Figure 3.9: Slit lamp anterior segment photograph of the donor site of a patient at 3 months postoperative. 
The donor site shows an area of aneurysmal/telangiectatic dilation of the vasculature. The lesion was 
noted at 2 weeks postoperative and changed minimally over the follow‐up period. The margins remained 
well‐ defined and the colour did not fade. The probability of this lesion being an intraconjunctival 




Figure 3.10: Slit lamp anterior segment photograph of the donor site of a patient at 2 weeks postoperative. 
The donor site shows pyogenic granuloma associated with an area of conjunctival retraction and 
exposure of Tenon's capsule. 
 
 
3.3.2 Conjunctival autograft angiography 
 
Of the five FA performed, four were within the first 3 days (early FA). All these patients had 
demonstrated graft swelling and haemorrhage at the time of FA (Figure 3.11). At the 3‐ 
month time‐point (late FA), when FA was performed in the fifth patient, the conjunctival 







Figure 3.11: Slit lamp anterior segment photograph and fluorescein angiogram of a conjunctival graft at 
1 day postoperative. 
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(A) Slit lamp anterior segment photograph of the conjunctival autograft of a patient at 1 day 
postoperative. Swelling due to oedema and patchy haemorrhages is seen. (B) Anterior segment 
fluorescein angiogram at 
1 min and 45 seconds. There is hyperfluorescence along the conjunctival bed. Areas of hyperfluorescence 
are also seen on the conjunctival autograft. The dark band does not correspond to the haemorrhage seen 
in 
(A) and is likely to represent an area of non‐perfusion with some masking. 
 
 
Figure 3.12: Anterior segment fluorescein angiogram at 4 min and 10 seconds of the conjunctival 
autograft of a patient at 3 months postoperative. 
A normal vasculature network is clearly visible in the conjunctival autograft. There is no leakage in the 
conjunctival autograft but areas of hyperfluorescence persist along the edge of conjunctival bed which is 
accentuated by light reflection. Long loops of shunt vessels, running parallel to the limbus (arrows) are 
seen at the junction of the conjunctival autograft and the conjunctival bed. 
All early FA showed intense fluorescence along the conjunctival bed early in the passage of 
dye (Figure 3.11).The conjunctival autograft appeared largely non‐perfused or under‐ 
perfused in three of the four grafts. In conjunctival autograft where there was 
haemorrhage, the area of haemorrhage obscured the fluorescence (Figures 3.11 and 3.13) 
but in these conjunctival autografts even areas where there was no haemorrhage showed 
the absence of fluorescence indicating poor or absent circulation (Figure 3.11). In all these 
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early FAs, 0–2 small vascular twigs were seen at some point along the edge of the 
conjunctival bed and multiple fluorescent spots were seen in the underlying scleral bed. One 
of the four early FAs (one‐day postop) showed an extensive network of vessels in the 
conjunctival autograft, unlike the other three (Figure 3.11). Tissue leakage of dye was 
evident as late hyperfluorescence in all conjunctival autografts with early FA indicating a 





Figure 3.13: Image of the conjunctival autograft of a patient at 3 days postoperative (A) Slit lamp diffuse 
anterior segment photograph of conjunctival autograft (B) Anterior segment fluorescein angiogram at 
56 seconds. 
(A) There is an area of diffuse haemorrhage involving almost the entire conjunctival autograft. (B) The 
conjunctival autograft shows a large area of masking corresponding to the diffuse haemorrhage seen in 
(A) obscuring the underlying fluorescence. The conjunctival bed shows intense fluorescence (accentuated 
by the light reflection) due congestion of the conjunctival bed. 
 
 
In the only late FA, the conjunctival bed showed three sites from which feeder vessels 
connected to a well‐established network of vessels in the conjunctival autograft. Some of 
these vessels filled early in the sequence (afferents) and others late (efferents). Two areas in 
the conjunctival autograft remained hypo‐fluorescent for 7 seconds, compared to other 
areas, before the vascular network became visible, suggesting a degree of residual ‘relative 
under‐perfusion’. This conjunctival autograft did not demonstrate any leakage/persistent 
fluorescence, indicating re‐establishment of the blood–tissue barrier. 
 
Disappearance of dye (drainage) from conjunctival bed was earlier than from the 
conjunctival autograft in all cases. One conjunctival autograft showed increased 
fluorescence of the underlying scleral bed rather than of the conjunctival autograft itself. 








Figure 3.14: Anterior segment fluorescein angiogram at 10 seconds of the conjunctival autograft of a patient 
at 2 days postoperative. 
The conjunctival autograft shows increased fluorescence of the underlying scleral bed rather than of the 







Reperfusion injury is a well‐known pathological condition that is characterized by initial 
phase of ischaemia to an organ or tissue which is then followed by restoration of blood 
supply and simultaneous re‐oxygenation. Early reperfusion is essential for the rescue of 
tissue or organ suffering from ischaemia but chronic reperfusion injury can be detrimental 
to the function of the organ (380). The classic example of this is organ transplantation such 
as renal and liver (381). With autologous conjunctival transplants, reperfusion injury was 
clearly manifest but functional implications were less important. 
Our sequential observation of the conjunctival autograft confirmed that the changes 
occurring in the conjunctival autograft were part of the reperfusion injury process. 
Reperfusion injury can start as early as 1 day postoperative in the form of haemorrhage and 
swelling of the graft. Further evidence of this is provided by the FA where the day‐1 
angiogram showed hyperfluorescence of the conjunctival autograft suggesting leakage. 
Harvesting of the free conjunctival autograft severs all vascular and lymphatic connections 
rendering the tissue, including the vessel trunks in it, ischaemic. When the conjunctival 
autograft vessels establish connections with the vessels in the new bed, from both 
surrounding conjunctiva and the episclera, blood flows into the ischaemic vessels of the 
conjunctival autograft. These vessels swell, leak or haemorrhage to give the dramatic clinical 
features seen in the first few postoperative days. Reconnection between the graft and the 
bed starts during the first week. This study indicates that all patients having conjunctival 
autograft will demonstrate patchy or diffuse haemorrhage in the first week and swollen 
grafts due to oedema and/or transudation from the blood vessels. These changes do not 
displace the graft or cause it to fall off; nor do they lead to sloughing of the conjunctival 
autograft epithelium, which remained intact in all cases at all time‐points. By 2 months, 
most of the swelling and haemorrhage had resolved but the conjunctival autograft 
demonstrated under‐perfused areas where the vascular network was poor or ill‐defined. 
However, no necrotic area was noted in any conjunctival autograft suggesting that the areas 
with poorly defined vasculature were receiving adequate oxygen. 
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Changes were also seen in the conjunctival bed surrounding the conjunctival autograft. The 
edge of the conjunctiva was hyperaemic and swollen and haemorrhage was also seen in 
some places. Fibrin glue is known to ‘seal’ vessels and is used for haemostasis (382). 
As fibrin glue was also used to attach the conjunctival bed, it is likely that the clinical picture 
seen, both in the conjunctival bed and the conjunctival autograft was influenced by its 
presence. Fibrin glue has been shown to mechanically interfere with epithelial cell migration 
which proceeds normally once the glue dissolves in 10–14 days (383). The physical presence 
of the glue at the site between the conjunctival autograft and the conjunctival bed could 
also have influenced the re‐establishment of vascular connections. Resolution of the 
oedema of the conjunctival bed corresponded to the appearance of ‘shunt’ vessels that 
were noted to connect severed vessels in the bed. These shunt vessels were seen clinically 
in the conjunctival bed of two eyes. A continuous remodelling of the vasculature occurs in 
the postoperative period as new connections appear and some disappear. Eventually a 
mature vasculature is established which remains permanent. The scleral bed also 
contributes to the re‐vascularization of the conjunctival autograft. These vessels were seen 
as large (relatively thicker) trunks but were sparse and not seen in every case. 
Although the edges of the conjunctival autograft were closely approximated to the 
conjunctival bed intraoperatively, gaps were noted between the edges at places, in some 
cases, in the postoperative period. This represented a retraction of the tissue, exposing the 
sclera/episclera. This exposed area initially stained with fluorescein but was rapidly covered 
by migration of epithelial cells from the conjunctival bed. It is possible that the epithelium 
on the ‘ischaemic’ graft is less likely to respond by proliferation and migration compared to 
the epithelium on the conjunctival bed. These epithelized gaps persisted as thin furrows 
that showed pooling of fluorescein dye. The epithelial migration too could have been 
influenced by the fibrin glue applied (383). 
At 6 months postoperative, all grafts and beds had settled completely and all haemorrhage 
and swelling had resolved indicating complete re‐establishment of vascular and lymphatic 
connections. 
The donor site changes all resolved satisfactorily although complications of telangiectasia 
and pyogenic granuloma were see in one patient each. In the majority, the donor site 
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conjunctiva settled satisfactorily indicating that covering the donor site with conjunctiva and 
use of fibrin glue, restores conjunctival integrity. Exposed tenons can cause pyogenic 
granuloma formation and adequate cover should be ensured to avoid this complication. The 
changes described in the conjunctival autograft are not be confused with conjunctival 
recurrence of pterygium (282). Most recurrence occurs in the first 6 months, which is the 
maximum time taken for all changes in conjunctival autograft to completely resolve. 
Conjunctival recurrence of pterygium precedes corneal involvement and appears as an area 
of focal vascularity and swelling that increases over time as it progresses towards the 
limbus. Re‐perfusion injury on the other hand, although also associated with vascularity and 
swelling, is more diffuse, usually is associated with conjunctival haemorrhage and the 
changes regress with time. 
Fluorescein angiography data were limited on account of the single time‐point and small 
number of patients studied thus no definitive conclusions could be drawn from these 
findings. However, some observations were made that helped to corroborate the clinical 
inferences made above. Reperfusion from the conjunctival and scleral beds was evident. 
Early clearance of dye from the conjunctival bed compared to the conjunctival autograft 
suggests that the lymphatic and efferent vasculature was more efficient in the bed than in 
the conjunctival autograft, which took longer to re‐establish. 
 
 
The small number of patients available to do FFA was a limitation in this study.  The unique thing about this 
study is that it offers explanations to several clinical findings during the healing process of conjunctival 
autografts and the donor bed after pterygium surgical excision which is something that was not fully understood 
before. In the future, more FFAs can be done for a bigger number of patients at more time points after the 
surgery.
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CHAPTER 4: MANAGEMENT OF ACTIVE AND ESTABLISHED 





Corneal neovascularization (NV) is a condition that can result in severe visual impairment 
(42). The normally avascular cornea may vascularize in situations in which a disequilibrium 
between angiogenic and antiangiogenic stimuli leads to a surplus of pro-angiogenic factors 
(such as vascular endothelial growth factor [VEGF], basic fibroblast growth factor [bFGF], 
and matrix metalloproteinases) and a deficiency in antiangiogenic angiostatin, and 
endostatin (56). Corneal NV could occur due to a wide range of infectious, inflammatory, 
degenerative, or traumatic disorders as well as chemical burns, limbal stem cell deficiency 
and prolonged contact lens wear (50, 384). Corneal vascularity is the single most important 
risk factor for graft rejection (200). Grafting onto vascularized corneal beds, which by 
definition are corneas that have NV in 2 or more quadrants or history of previous graft 
rejection, is known as high-risk transplantation because of the frequent occurrence of 
immune rejection (385). Deep vascularisation of the recipient may more than double the 
risk of graft rejection (44) (53). 
Fine needle diathermy (FND) is a surgical procedure that is used in the treatment of corneal 
NV. It is a safe and effective method for corneal vessels occlusion (191). It was described by 
Harminder S Dua in Nottingham (120, 189). Faraj et al, 2014 (120), evaluated the efficacy of 
FND in occlusion of corneal vessels and they concluded that FND was most suitable for active 
old and mature vessels. This has also been confirmed by others (386). In 2015, Vita et al and 
Spiteri N (195) et al did FND successfully under angiographic guidance as they believe 
selective targeting of the afferent vessels is effective in reducing the area of NV while 
applying minimal thermal energy to the limbus. 
It has been shown that vascular endothelial growth factor (VEGF) plays a crucial role in 
corneal NV in different pathological conditions (44). Anti-VEGF agents such as bevacizumab- 
a recombinant humanised monoclonal antibody that binds human VEGF-A isoforms and 
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prevents activation of VEGF receptors-were found to be beneficial in treating corneal 
vessels when injected (167). Anti-VEGF injections are indicated for active young vessels 
(189). Several studies have been conducted to evaluate the efficacy and safety of Avastin 
when used as subconjunctival injections to treat corneal NV (154, 161, 164, 193, 207, 387- 
392). Some of these studies have used Avastin injections as preconditioning treatment 
before keratoplasty to promote corneal graft survival and improve their prognosis. 
It became later known that applying FND can lead to release of endothelial growth factors 
and those will be inhibited from causing further NV by the anti-VEGF agents that will be 
injected subconjunctivally (393). Based on that, several trials were conducted using 
 
combined FND and bevacizumab (192, 193, 394) and Koenig et al, Elbaz et al and Hussein et  
al showed that this combination is a well-tolerated and effective option to regress corneal NV as well as 
giving good results in patients with lipid deposition, children and preconditions the cornea for future 
keratoplasty. 
We retrospectively reviewed 15 patients to compare the effects of FND alone, 
subconjunctival bevacizumab alone and the combined FND and subconjunctival 
bevacizumab injections on the NV and rejection rates in patients who had keratoplasty 





4.2.1 Ethical issues 
 
The work was conducted in accordance to the declaration of Helsinki. The work was classed 
as a ‘healthcare evaluation project’ and approved by the Clinical Quality, Risk and Safety 
directorate, Nottingham University Hospitals, NHS Trust (project number: 17-205c). 
4.2.2 Patients 
 
Patients were seen in routine specialist corneal clinics under the supervision of Professor H 
Dua (consultant ophthalmologist) at a single centre based within the outpatients’ clinic in 
the Ophthalmology department at Queen’s Medical Centre, Nottingham University 
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4.2.3 Clinical intervention and follow up 
 
The medical notes of 15 patients from Feb 2014 till July 2018 were reviewed and clinical and 
surgical information were extracted from the notes. As part of the standard protocol for 
managing patients with corneal NV in the department; visual acuity, pupillary reaction, 
intraocular pressure measurement, anterior segment bio-microscopic examination and 
fundus examination were performed at the first visit. High quality diffuse digital 
standardised imaging of the cornea and vessels were taken with a standard anterior 
segment camera at the first three visits and at the final visit. Visual acuity and intraocular 
pressure were measured at each visit. 
Corneal vessels were examined with respect to stage; number in each quadrant, depth, 
superficial or deep and extent in to the cornea from periphery to centre. Grading of corneal 
 
vascularisation was performed using the corneal NV scoring method that was published by Faraj 
et al (please look page 11 chapter 1). Stages of NV were classified into five categories based 




Figure 4.1: Classification of corneal vessels (47). 
 
(A) Active young: bright red, brush-like vessels invading in to the cornea with interstitial keratitis;(B) 
Active young: bright red vessels emerging from previously mature corneal vessels and invading a 
recurrent herpetic keratitis lesion;(C) Active old: dull red vessels with an active circulation of blood and 
surrounding oedema of the cornea.;(D) Partially regressed: The vessels are dull red with a slow 
circulation and some parts of the complex are less visible or have undergone attrition;(E) Mature, 
relatively large vessels with blood circulation but no established fine network (capillary) of vessels;(F) 
Regressed: Vessels appearing as fine white lines (ghost vessels) displaying the outline of the original 
vessels. The above figures were used as a guideline for the study.  
Severity of vascularisation was ascertained according to their scoring system (Faraj et al, 47) 
which included number of quadrants involved (1–4), depth of involvement 
(superficial=anterior one-third of corneal thickness or deep=posterior two-thirds) and 
location of vessels (peripheral=outer one-third, mid-peripheral=middle third and 
central=central third). A score of 1 was given for each quadrant affected; a score of 1 for 
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superficial vessels and 2 for deep vessels; and a score of 1 for peripheral vessels, 2 for mid-
peripheral vessels and 3 for central vessels. When one quadrant had more than one vessel, 
the score attributed to the worst vessel(s) was counted for that quadrant. Thus, the 
maximum score for any quadrant would be 6 and for the whole cornea 24 (47). 
Patients had 3 different treatment regimens. Group 1 had FND (n=3), group 2 had 
subconjunctival bevacizumab injections (n=4) and group 3 had combined FND and 
subconjunctival bevacizumab (n=8). 
Six patients had corneal transplant surgery. As part of the standard protocol for 
management of patients with corneal NV in the department; all patients were given 
chloramphenicol 0.5% eye drops QID for one month, dexamethasone 0.1% eye drops QID 
for 2 months, then TID for two months and then OD for two months. At 6 months the drops 
were reduced to OD and continued for another six months. 
 
 
As part of the standard protocol for management of patients with corneal NV in the 
department; patients were followed up at two weeks post-treatment and then at 1 month, 
two months and every 3 months till the end of one year. 
FND technique and injection method 
 
Patients received subconjunctival injections of Avastin® around the limbus in the 
quadrant(s) affected (total dose of between 0.2 ml-0.3mlof the 5 mg/0.2 ml solution). The 
subconjunctival injections were administered in a clean room under topical anaesthesia. The 
subconjunctival injections were administered after FND in the same treated quadrants, 
close to the limbus. For fine needle diathermy, the eye was prepared as for extraocular 
surgery and draped. The ground electrode of a monopolar cautery (Covidien Force X) was 
attached to the patient’s leg or abdomen. With topical anaesthesia under an operating 
microscope, a spatulated needle attached to a 10/0 monofilament nylon suture was 
inserted radially at the limbus in the vicinity of the vessel(s) to be cauterised. At a very low 
setting of 1 on the dial, the diathermy probe was brought in contact with the corneal needle 
and switched on until mild blanching of the stroma occurred. Further cautery central to the 
initial application was carried out to occlude the length of the vessel. When several vessels 
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were present close to each other, the needle was inserted into the stroma tangential to the 
limbus and the vessels cauterised in a single pass of the needle. 
Adverse events, epithelial defects and haemorrhage, were recorded if present. For patients 
who underwent keratoplasty, graft clarity (oedema and lipid), evidence of graft rejection 
and recurrence of vascularisation were noted. All patients had the ability to access the 24 
hours on call emergency eye service and contact the investigators for any queries during the 
study period. 
4.2.4 Outcome measurements 
 
Primary outcome measures were decreased corneal neovascularisation. Secondary outcome 
measures were improved/maintained Snellen’s visual acuity, decreased corneal opacity 
related to lipid and reduced episodes of graft rejection (in patients with corneal grafts). 
4.2.5 Statistics and data analysis 
 
Statistical analysis was performed by using GraphPad Prism 8.02 (GraphPad Software La 





We reviewed the notes of 15 patients who fit the criteria. The demographic data and 
procedures for the recruited patients is listed in table 4.1. 
 
 
Table 4.1 Demographic data and procedures done for each case 
at the end of one year. 
 
Keratoconus: KC; Penetrating keratoplasty: PK; Herpes simplex keratitis: HSK; Herpes simplex zoster; Deep anterior lamellar keratoplasty: DALK; Limbal stem cell 
 




































KC with PK graft L FND Active 
Old 
No No 3 0 0.3 0.06 N/A 




No No 12 4 0.04 0.04 N/A 













No Yes (PK) 14 8 CF 0.24 Yes 




Yes No 5 0 0.16 0.1 N/A 









NK stage 3 R Avastin Active 
Old 






51 (F) NK stage 3 R Avastin Active 
old 
No No 9 7 HM HM N/A 
9 73 (F) HSK Left 2×Avastin Active 
young 
No No 18 12 CF 0.92 N/A 
10 68 
(M) 







No Yes (PK) 3 0 CF 0.88 Y 
11 34 
(M) 
Chemical burn L Avastin Active 
Old 
No No 7 3 0.4 0.1  









R FND Active 
Old 











4 0 HM CF Yes 
15 53 
(M) 






12 0 HM 0.2 Yes 
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Fourteen patients had active old NV while 1 patient had active young NV. Of the 15 patients, 
8 were females (50%), and 8 were males (50%). Mean age was 48 years (range was from 22- 
73 years). Ten patients (67%) had 1 treatment session while 5 (33%) had 2 sessions of 
treatment. Three patients had FND, 4 patients had bevacizumab injections and 8 patients 
had combined FND and bevacizumab injections. Six patients had a graft with or after one of 
the 3 treatment options. Five of these grafts were a penetrating keratoplasty (PK) while one 
was a deep anterior lamellar keratoplasty (DALK). Five of the patients with a graft had no 
rejection episodes or failure. Only one patient who had a penetrating graft had an 
endothelial rejection episode 2 months after combined FND and bevacizumab injection and 
was aborted after appropriate treatment. Seventy-three% of the patients had improved 
visual acuity while 27% had stable vision. After treatment, 6 patients had mature NV, 5 
patients had regressed NV and 4 patients had partially regressed NV. Three patients had 
lipid keratopathy. Two of them had remarkable reduction of lipid deposition following 
treatment while one remained the same. Table 4.2 shows the end stage of the NV in each of 
the 3 treatment regimens. The data reported is after one year from the start of treatment. 
Temporal decrease of NV was not analyzed. 





End stage FND Avastin FND and Avastin 
Regressed 1 0 4 
Partially 
regressed 
0 1 3 




There was a mean reduction of 2.33 +/- 2.08 in the clinical scoring of NV in the FND group 
(p=0.1917, paired test, 95% confidence interval (CI) = 2.838-7.504), which was not 
statistically significant. For the Avastin injection group, the mean reduction was 3.25+/- 
2.217 (p= 0.0609, paired test., 95% CI= 0.2783-6.778), which was not statistically significant. 
The mean reduction in the FND and Avastin group was 8.143+/4.14 (p= 0.0020, paired test, 
95% CI= 4.134-11.97), which was statistically significant. None of the patients had adverse 





That is already mentioned in table  4.1 
 
 
Patients 2,5,6  gender, age and laterality is just a co-incidence. 
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Figure 4.2: Slit lamp anterior segment photographs of a patient before treatment (top image) and after 
treatment with FND, Avastin and PK (bottom image). 




Figure 4.3: Slit lamp anterior segment photographs of a patient before treatment (top image) and after 
treatment with FND, Avastin (bottom image). 





Figure 4.4: Slit lamp anterior segment photographs of a patient with lipid keratopathy before treatment (top 
image) and after treatment with FND (bottom image). 
Top image shows superficial superior NV and dense lipid keratopathy. The bottom image shows less lipid 











It is well established that corneal stromal vascularisation is both a risk factor and harbinger 
of rejection in penetrating keratoplasty. Topical steroids have been used to suppress corneal 
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vascularisation and to decrease corneal scarring. However, long term topical use may lead 
to cataract, glaucoma, superinfection and reactivation of herpes simplex virus and they are 
unlikely to cause complete regression of the vessels. There are no current NICE guidelines 
for established corneal neovascularisation. 
The only definitive treatment that is available now is fine needle diathermy which is used as 
a routine for treatment of corneal NV. However, FND itself induces trauma to the vascular 
endothelium that might stimulate further vessel formation. It is hypothesised that if an anti- 
VEGF is combined with FND it will address any surgically induced factor for further 
vascularisation thus reduce the risk of rejection even further (393). 
Several studies were performed where FND was used for corneal NV of different aetiologies 
(120, 189, 191, 386, 395). They reported that FND was a safe and effective method for both 
active and established vessels, can be used before PK to reduce rejection episodes and is 
associated with improvement of vision. However, Thatte et al (191) noted that the 
deposited lipids did not regress any faster by the occlusion of the corneal vessels. This was 
contradicted by Faraj et al (120), who reported that NV regression resulted in gradual 
reduction of lipid keratopathy if present. They also reported that active young vessels were 
usually a sign of underlying continuous pathology which keeps on inducing more 
vascularisation and such eyes will require treatment with anti-VEGF subconjunctival 
injections. 
Combined FND and bevacizumab was also used. Koenig et al (192), used FND combined with 
bevacizumab eye drops as well as bevacizumab injections in some of the eyes. They 
reported good outcomes in terms of regression of the vascularised area and visual acuity 
improvement which was however statistically insignificant with some patients needing a 
second treatment session. They also reported better results in eyes that received injections 
and drops rather than drops therapy alone reported similar results using FND and 
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subconjunctival bevacizumab injections with reduction of lipid deposition (394). However, 
they noted that the management of cases with ongoing inflammatory was much more 
challenging. Elbaz et al (193), reported similar results in children with NV using combined 
FND and bevacizumab subconjunctival injections. 
Many studies used subconjunctival bevacizumab and eye drops to treat NV. They reported 
statistically significant reduction of the calibre of vessels, area of NV (166, 167) (207, 390) 
(387, 396, 397). 
Subconjunctival bevacizumab was also used successfully as an adjunctive treatment in 
vascularized corneas at the time of lamellar and penetrating keratoplasty to reduce the risk 
 
of graft rejection (388, 391). Vassileva et al and Symes et al reported that bevacizumab is an efficient 
and safe additional treatment option for improvement of prognosis in high-risk corneal transplantation 
with pre- and postoperative corneal NV. 
In this retrospective study, there were 3 different treatment regimens. The limitations were 
the small number of patients in each group. The results show that there was a reduction in 
the clinical score of NV in all groups but the FND and Avastin injection group is the only 
group that showed a statistically significant reduction. This is most probably because FND 
occludes all stages of vessels and the VEGF produced by FND trauma to the vascular 
endothelium is blocked by the bevacizumab injections leading to effective and prolonged 
reduction of NV as our patients had a maintained effect for a year after the last treatment. 
Similar to the previous studies, some of our patients required a second session of 
treatment. We had no side effects related to the injections and the FND. Gradual reduction 
of lipid keratopathy was seen in 2 of the 3 patients following treatment. The improvement 
of visual acuity in 73% of the patients was related to the reduction of NV, reduction of lipid 
keratopathy and the reduction of corneal opacity in patients who had grafts. None of the 
patients had worse vision. We noted that patients who did not achieve partial regression or 
regression of vessels had stable, inactive vessels after the treatment which is considered a 
success as these patients had no further progression of NV or lipid deposition. Only one 
patient had an episode of endothelial rejection following treatment with FND and Avastin 
which was controlled by steroid treatment. Based on the results, a combination of anti 
VEGF with FND produces the best outcome of eliminating corneal neovascularisation with 
no reported side effects. Different treatments for HSK patients in this study were given 
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based on the clinical picture with regards to the NV stage and clinical scoring as treatment 
option is based on the NV status and not the aetiology of the NV.  This is because the 
mechanism of corneal angiogenesis is the same for any etiology. The main inducer of NV in 
all etiologies is inflammation. All patients who had HSK in this study were females which 
was a coincidence as HSK almost affects both genders equally. Avastin was used for patients 
with NV secondary to NK as the NV stage was active which is usually a sign of underlying 
continuous pathology which keeps on inducing more vascularisation and such eyes will 
require treatment with anti-VEGF subconjunctival injections. 
 
 
The main limitations in this study was the sample and the fact that data collection was 
retrospective. Future studies with larger sample sizes need to be carried out with longer 
follow-up to ascertain the effect of combined treatment for corneal NV and rejection rates 





CHAPTER 5: AUTOLOGOUS CULTIVATED LIMBAL STEM CELLS 
TRANSPLANTATION FOR RESTORATION OF CORNEAL 
EPITHELIUM IN PATIENTS WITH LIMBAL STEM CELL 






Ex-vivo expansion of limbus derived cells with or without a substrate (collagen, fibrin or 
 
amnion) is an essential option in the surgical management of total limbal stem cell deficiency whether 
unilateral or bilateral. Biopsies are obtained from the unaffected eye or from living related donors and 
are used to extract limbal epithelial cells or can be directly applied as explants on culture plates to 
produce stratified sheets to be used for transplantation (398-400). Excellent results were reported with 
long term follow-up following use of ex-vivo expansion of these stratified sheets 
(401).
 
Oral mucosal cells have been used as potential cells in the treatment of LSCD and it was 
reported that oral mucosal cells can successfully improve vision in patients with LSCD 
obviating the need for immunosuppression (402). Cultivated oral mucosal epithelial 
transplantation (COMET) utilizes a transplanted epithelial sheet which contains stem cells 
that help to reconstruct and sustain the integrity of the corneal surface and is a surgical 
option for bilateral LSCD (403). 
 
Autologous Cultivated Limbal Stem Cell Transplantation (ACLSCT) is an advanced treatment 
for LSCD which utilizes a small limbal-biopsy specimen from the unaffected eye or from a 
normal limbal zone in case of bilateral burns, followed by in vitro expansion to generate a 
sheet of corneal epithelial cells including both differentiated and stem cells. The final 
product is named Holoclar and is a transparent round sheet that consists of 300,000 to 









stem cells as well as differentiated cells and stem cell derived transient amplifying cells. This 
epithelial sheet rests on a supportive fibrin layer and is kept in a nutrient transport medium 
(401,404,405). 
 
This technique has the advantage of being autologous which means that no donor tissue is 
used and no immunosuppression is required. 
Autologous cultivated limbal stem cells (ACLSC) have been obtained using standardized and 
optimized methods since 1998. Since then, ACLSCT was performed on more than 200 
patients with moderate or severe LSCD in several clinical centres in Italy. The acquired 
experience has been reported in independent published studies (401, 404, 405) and in three 
Chiesi-sponsored, retrospective, case-series, non-randomised, non-controlled studies 
(HLSTM01, HLSTM02 and HLSTM04), that gathered all clinical information from all treated 
patients with available source documentation with a follow-up of up to 10 years. 
Specific amendments and improvements in quality and manufacturing have been 
introduced after 2007 to comply with the current legislation and regulations regarding 
Advanced Therapy Medicinal Products (ATMPs), in particular in respect of the quality of the 
reagents (recombinant growth factors, pharmacopoeia-grade reagents) and some excipients 
( the supporting layer of human fibrin for cell attachment). The results of HLSTM04 study 
showed that after the introduction of improvements in quality and manufacturing of ACLSCT 
in 2007, most of the patients with moderate to severe LSCD due to ocular burns, who 
received cultured limbal stem-cell grafts for corneal transplantation, achieved a positive 
clinical outcome with a favourable safety profile. Improved visual acuity was achieved 
despite the majority of study population exhibiting stromal scarring. In addition, clinically- 
and functionally-beneficial effects from Holoclar were observed among patients who failed 
a full restoration of corneal epithelium and who are candidates for Holoclar re-treatment 
and keratoplasty. The data from these retrospective studies demonstrated the efficacy and 
safety of Holoclar for human use and were included as clinical data into the marketing 
authorization application for Holoclar which was filed by Chiesi Farmaceutici S.p.A. in March 
2013 (application EMEA/H/C/2450). 
 
 
Holoclar has been approved by the European Medicines Agency EMA only recently (Committee for 
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Medicinal Products for Human Use (CHMP) meeting 15-18 December 2014). During that meeting, the 
CHMP recommended Holoclar, the first advanced therapy medicinal product containing stem cells for 
usage in the European Union. The CHMP considered that Holoclar provided a first treatment option for 
this eye condition and recommended a conditional marketing authorisation because, although the  
data supplied by the applicant show that the medicine's benefits outweigh its risks, the data was based 
on retrospective studies and were not yet comprehensive. This data has been reported in independent 
published studies (401, 404, 405) and in three Chiesi-sponsored, retrospective, case-series, non-
randomised, non-controlled studies (HLSTM01, HLSTM02 and HLSTM04). Therefore, an additional study 
(Holocore) on the use of Holoclar was conducted and this clinical trial CCD- GPLSCD01-03 has been 
agreed with the regulatory body in order to satisfy the need of additional and more comprehensive data 





5.2.2 Ethical issues  
The study was conducted in accordance to the declaration of Helsinki. All relevant study 
approvals were present before the actual started trial. Chiesi Farmaceutici S.p.A. (the sponsor 
of Holocore study) supplied us with all the relevant documents from the regulatory 
authorities before we started recruiting the patients. (REC reference number: 15/LO/1480). 
5.2.3 Patient recruitment 
 
Holocore is a multinational, multicentre, prospective, open label, uncontrolled clinical trial. 
Queens Medical Centre (Centre number 82602) was one of the 12 sites in 8 countries across 
Europe in which the study was carried out. It was conducted in routine specialist cornea 
clinics under the supervision of Professor Harminder Dua (Consultant Ophthalmologist and 




Subjects had to meet all of the following inclusion criteria to be eligible for enrolment into 
the study: 
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1. Written informed consent prior to any study-related procedures 
 
2. Adult male and female patients (≥18 years old). 
 
3. LSCD secondary to unilateral or bilateral physical or chemical ocular burns, with at least 1- 
2 mm2 of undamaged limbus to harvest stem cells for expansion in culture. LSCD was 
considered for inclusion in the presence of superficial neo-vascularization invading at least 
two corneal quadrants with evidence of central corneal (6mm) involvement (including 
corneal neovascularisation, corneal opacity or corneal dyschromia). 
4. Stability of LSCD, defined by a duration of disease of at least 24 months at the time of the 
screening visit and the presence of continuous epithelial cover by fluorescein staining 
scored as none or trace. 
5. Presence of severe impairment in visual acuity defined by a score of 1/10th or below 
20/200 at the Snellen chart (legal blindness) after best correction (i.e. Best Corrected Visual 
Acuity). 
6. Absence of other clinical contraindications to ACLSC transplantation based upon 
investigators’ judgment. 




The presence of any of the following excluded a subject from study enrolment: 
1. LSCD of mild degree (i.e. below 2 quadrants of neo-vessel invasion without central 
corneal), due to a recent burn (less than 24 months before screening), or secondary to 
medical conditions other than burns (i.e. radiotherapy). 
2. Severe ocular inflammation according to the Efron Grading Scale for Contact Lens 
complications. 
3. Presence of eyelids malposition. 
4. Conjunctival scarring with fornix shortening. 
5. Severe tear secretion deficiency, determined by Schirmer’s test type I (<5 mm/ 5 min). 
 
6. Corneal anaesthesia and conjunctival anaesthesia. 
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7. Active local or systemic infections at the time of screening. 
 
8. Diagnosis of local or systemic neoplastic disease. 
 
9. Congenital diseases (i.e., Aniridia). 
 
10. Bilateral inflammatory diseases (i.e. Stevens-Johnson syndrome, pemphigoid). 
 
11. A pre-existing blindness precluding a functional recovery. 
 
12. Female subjects: pregnant or lactating women and all women physiologically capable of 
becoming pregnant (i.e. women of childbearing potential) unless they were willing to use 
one or more reliable methods of contraception (e.g. oral contraceptives, IUD, tubal ligature). 
Reliable contraception should be maintained throughout the study. 
A urine pregnancy test was performed at the screening visit for all women of childbearing 
potential and repeated before biopsy and treatment. Any postmenopausal women 
(physiologic menopause defined as “12 consecutive months of amenorrhea”) or women 
permanently sterilized (e.g. tubal occlusion, hysterectomy or bilateral salpingectomy) was a 
potential candidate for enrolment into the study 
13. Allergy, sensitivity or intolerance to concomitant drugs or excipients (Hypersensitivity to 
any of the excipients listed in section 6.1 or to bovine serum and murine 3T3-J2 cells). 
14. Contraindications to the local or systemic antibiotics and/ or corticosteroids foreseen by 
the protocol. 
15. Contraindications to the surgical procedure. 
 
16. Clinically significant or unstable concurrent disease or other clinical contraindications to 
stem cell transplantation based upon investigators’ judgment or other concomitant medical 
conditions affecting grafting procedure. 
17. Patients unlikely to comply with the study protocol or unable to understand the nature 
and scope of the study or the possible benefits or unwanted effects of the study procedures 
and treatments. 
18. Participation in another clinical trial where investigational drug was received less than 4 




5.2.4 Clinical Intervention and follow up 
 
Fourteen clinic visits were performed during the study. The study duration period was 19 
months +/- 15 days: 
Five to 6 weeks- screening visit up to biopsy. 
 
Six months roll-in period starting from the biopsy and up to autologous limbal stem cells 
transplant ACLSCT. 
Twelve months from the autologous limbal stem cells transplant ACLSCT up to endpoint 
visit. 
Table 5.1 shows the follow up scheme of HOLOCORE. 
 















Name and code of visit Interpretation 
Visit 0 (V0) Date of recruitment 
Visit 1 (V1) Two weeks from V0 
Visit 2 (V2) Biopsy day (Four weeks 
from V1) 
Visit 3 (V3) Two months after the 
Biopsy 
Visit 4 (V4) Four months after the 
Biopsy 
Visit 5 (V5)   Day -13 +/- 2 
Visit 6 (V6) Transplantation day 
Visit 7 (V7) One day after V6 (done over 
the phone) 
Visit 8 (V8) Four +/- 1 day after V6 
Visit 9 (V9) Two weeks +/- 3 days after 
V6 
Visit 10 (V10) Twenty nine days+/- 5 days 
after V6 
Visit 11 (V11) Three months +/- 14 days 
after V6 




Visit 13 (V13) Nine months +/- days after 
V6 
Visit 14 (V14) End of the study, 1 year +/- 
14 days after V6 
 
 
A) Standard haematology, blood chemistry and infectious assessment 
Standard haematology and biochemistry and infectious assessments were performed at the 
prescribed visits as in at the phlebotomy clinic at Queen Medical Centre and transferred to a 
central laboratory in Germany for analysis. The blood samples for standard haematology 
and blood chemistry were collected in the morning after an overnight fasting (10 hours) at 
screening visit, visit 5 and visit 10. The blood samples for infectious assessments were 
collected at visit 1 and visit 2. The collection was always done after vital signs 
measurements and before any further study assessment. 
The following parameters were assessed: 
Haematology: Red blood cells count, white blood cells count and differential, total 
haemoglobin, hematocrit , platelets count and prothrombin time. 
 
Blood Chemistry: Creatinine, Blood urea nitrogen, fasting serum glucose, Aspartate 
aminotransferase, Alanine aminotransferase, Gamma-glutamyl transpeptidase, total 
bilirubin, albumin, Alkaline phosphatase, sodium, potassium, calcium, and chloride 
electrolytes. 
Infectious Assessment: HAV-Ag, HAV-IgG, HAV-IgM, HBsAg, HBsAb, 
 
HBcAb, HCVAg, HCVAb, HIV1&HIV2 Ab and Ag, Treponema Pallidum Ab, HTLV – Human T 
Lymphotropic Virus-Ag and Ab, HWN -Human West Nile virus- Ab measurement. 
B) Surgical procedures 
 
Holocore study includes obtaining a biopsy from the unaffected eye (or from a normal zone 
in bilateral LSCD cases) then a single administration of Holoclar implant through a dedicated 
surgical procedure of corneal surface scraping and product application. Both the biopsy and 
Holoclar implantation were performed at the Ophthalmology theatre at Queens Medical 
Centre by the same surgeon (Professor Harminder Dua). 
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Biopsy (Visit 2) 
 
The patients had corneal biopsy taken from the unaffected limbus of the contralateral eye 
according to the following multi-steps procedure: 
· Topical anaesthesia was procured with parabulbar anaesthesia with marcaine without and 
adrenaline. 
· Ocular surface lavage was performed with balanced salt solution (BSS). 
 
• A horizontal clear-cornea incision, 2 mm long, was made with a disposable scalpel of 
15 - 30°, just anterior to the limbal vessels. Lamellar dissection in a "pocket" fashion 
using a disk lamellar knife or a crescent blade (the depth was about 50 to 100 μm to 
enable the lifting of the lamella from the corneal limbus) was made from the incision 
extending posterior to the limbus. The conjunctiva at the limbus was then incised to 
expose the posterior limit of the lamellar dissection. The sample was obtained from 
the upper area. 
•Two vertical incisions from each end of the horizontal incision were then made in the 
limbus and adjacent sclera with a disposable scalpel of 15 - 30°. A posterior horizontal 
incision was then made to join the posterior end of the vertical incisions to complete 
the excision of a 2mm piece of limbus. Cautery was not used to coagulate bleeding 
vessels before the tissue sample was removed, in order to avoid damaging the stem 
cells. 
• Biopsy was inserted in the sterile test tube containing the transport medium. 
• The conjunctiva was sutured (tacked down) with 2 nylon 10/0 sutures. 
 
 
Treatment after biopsy 
 
Patients received topical antibiotic prophylaxis with single-dose preservative-free 
levofloxacin, 3-4 drops three times per day for 7 days. 
 
 
Holocalr implantation procedure (Visit 6) 
 
Surgery was performed according to the following procedure: 
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• General anaesthesia was done. 
• Limbal peritomy was done a few millimetres outside the limbus, with proper coagulation. 
The bulbar conjunctiva was freed for about 4-5 mm in order to create a pocket into which 
Holoclar implant was inserted. 
• Pannusectomy for removal of corneal fibrovascular layer of conjunctival origin was done, 
trying to find the cleavage level between the pannus and the cornea for avoiding, when 
possible, keratectomy. 
• Lavage with BSS was done, whilst checking for an absence of consistent blood loss that 
could form blood collections (‘sacks’) under the epithelial graft. 
• Holoclar implant was transferred from the transport container to a suitable dish. Under 
the microscope it was possible to recognize the fibrin "nude" side (smooth and 
translucent) from the cells-seeded side (rough). It is absolutely crucial to place the fibrin 
sheet with the cultivated cells outside and not upside down. 
• Holoclar was allowed to slide onto the recipient’s prepared graft area assisting with BSS 
and slight traction with tweezers at the edge of the graft as necessary. 
• The excess fibrin sheet (Holoclar) was trimmed and the edge covered with the 
conjunctiva applying 2 or 3 stitches (sutures) of Vicryl 8/0. 
• Eyelids were kept closed with Steri-strips. 
 
 
Treatment after administration of Holoclar 
 
 
• Systemic antibiotic treatment: Doxycyclin 100 mg tablets twice per day for 2 weeks. 
 
• Systemic corticosteroid treatment: Prednisone P.O. at a daily dose of 0.5 mg/kg for 2 
weeks after the implant at a daily dose to a maximum of 25 mg for 2 weeks, then tapered 
to 0.25 mg/kg (maximum 12.5 mg) per day for 1 week, to 0.125 mg/kg (maximum 5.0 mg) 
per day for the following week and then stopped. In case of persistent inflammation, the 
corticosteroid treatment was allowed to be maintained or reintroduced. 
110  
• Topical corticosteroid treatment: 2 weeks after surgery, preservative-free dexamethasone 
(dexafree 1 mg/ml PF B&L) eye drops for a total of 4 weeks: 1 drop TID for 2 weeks 
followed by 1 drop bid for 1 week and then 1 drop QID for 1 week. Topical corticosteroid 
can be maintained for longer in case of persistent inflammation according to the judgment 
of the doctor. 
 
 
C) Details of the visits: 
All of the visits and medications received by the patient were recorded in the patient’s 
medical notes as well as in electronic CRF. I was the coordinator of this study. I was 
responsible for performing all the clinical examination during all the visits and 
recording the data on the medical notes as well as doing all correspondence with the 









































































Informed Consent ✓               
Demographic Data ✓               
Inclusion/ Exclusion 
Criteria 
 ✓    ✓ (3)          
Medical History and 
concomitant diseases ✓ 




✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Adverse Events (AE) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Adverse Event of 
Special Interest (AESI) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Physical examination
(5)
 ✓ ✓ ✓ ✓ ✓ ✓ ✓  ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Vital signs  ✓ ✓ ✓ ✓ ✓ ✓  ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Haematology and blood 
chemistry 
 ✓    ✓     ✓     
Infectious Assessment  ✓ ✓             
ECG  ✓    ✓          







































































defects by fluorescein 
staining 
 
✓ ✓ ✓ ✓ ✓ 
    
✓ ✓ ✓ ✓ ✓ 
Superficial corneal neo- 
vascularization 
 ✓ ✓ ✓ ✓ ✓ 
    
✓ ✓ ✓ ✓ ✓ 
Digital photography  ✓ ✓  ✓ ✓     ✓ ✓ ✓ ✓ ✓ 
Best-Corrected Visual 
Acuity 
 ✓  ✓ ✓ ✓ 
    
✓ ✓ ✓ ✓ ✓ 
Ocular tonometry  ✓ ✓ ✓ ✓ ✓     ✓ ✓ ✓ ✓ ✓ 
Slit lamp examination: 
• Corneal endothelium 
• Anterior chamber 
 
✓ ✓ ✓ ✓ ✓ 
  





✓ ✓ ✓ ✓ ✓ 
  
✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Corneal sensitivity  ✓ ✓ ✓ ✓ ✓     ✓ ✓ ✓ ✓ ✓ 
Corneal involvement  ✓ ✓ ✓ ✓ ✓     ✓ ✓ ✓ ✓ ✓ 





































   
✓ 








            
ACLSC grafting 
procedure 






































































Impression cytology       ✓         
Systemic corticosteroid 
treatment 
      ------------- ✓ ----------- Tapering Stop     
Systemic antibiotic 
treatment 
      ------------- ✓ ----------- Stop      
Topic corticosteroid 
treatment 





    




          
ACLSC graft failure 
Check 
              
✓ (8) 
Investigator’s Judgement           ✓ ✓ ✓ ✓ ✓ 










 The study was terminated at this visit 14 for all patients who are judged as a success. 
 
 
5.2.5 Outcome measurements 
 
Efficacy measurements were made in terms of the degree of superficial corneal 
neovascularisation and epithelial defects. Safety measurements were specifically 
investigated with reporting any adverse effects related to the biopsy and Holoclar 
transplantation. Patients had the ability to access the 24 hour on call emergency eye service, 
and at the same time were provided with contact numbers for investigators for any queries 








We were able to recruit 2 patients to this study as these were the only patients that 
met all the eligibility criteria at the time of recruitment. The demographic data for the 
recruited patients is listed in table 5.2. The two recruited patients in this study are 




Table 5.3: Demographic data of HOLOCORE cases. 
 





















Case one (82602-01) 
This patient was a 57 year old gentleman who was recruited on the 7th of February 2017 for 
treatment of the right eye. He had a dense fibrovascular membrane involving the central 
cornea due to an acid chemical burn in 1993. He had severe superficial corneal NV in all 4 
quadrants and his vision was hand movement. The 4 quadrants of the cornea were invaded 
with superficial corneal NV and they extended to the central cornea (Figure 5.1). The visual 
acuity was hand movement. He had normal intraocular pressure in both eyes throughout 
the study (range from 8-12). Schirmer test type I was 10 mm on V1. He had normal corneal 
sensitivity which was assessed by a cotton tip. On V1, the patient had moderate 
photophobia but no pain or burning sensation. His physical examination and vital signs were 
always normal. He was started on Citalopram tablets 20 mg once daily (selective serotonin 
re-uptake inhibitor) because of anxiety related to holocore trial and continued for the whole 
period of the trial. Otherwise, he had no history of any medical conditions. His infectious 
assessment was always normal. The biopsy was done on 30th of May 2017. The biopsy was 














1 82602-01 57 (M) Acid 
chemical 
burn 
07/02/2017 Right   19/12/2018 
2 82602-02 27 (F) Chemical 
burn 
(Unknown) 
08/02/2017 Left 19/12/2018 
19 
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medium. The standard operating procedures were followed carefully and the biopsy was 
shipped on the same day to Holostem (The site where the biopsy will be processed into 
Holoclar). The patient was prescribed preservative-free levofloxacin eye drops, three times 
per day for 1 week. Conjunctiva was closed using 2 sutures. The patient presented to the 
eye casualty 2 days after the biopsy procedure with pain which was due to a broken suture 
and was removed. The other suture was removed 2 weeks after the biopsy procedure. The 
wound was healing well underneath. There were no adverse events. The holoclar implant 
was performed on the 6th of December 2017. Holoclar was delivered on the same day to the 
hospital inside a sterile, plastic Petri dish which was placed in a secondary container that 
was only removed in the operating theatre. The surgery was done under general 
anaesthesia. The surgery was successful and Holocolar was in place. The patient was started 
on the treatment mentioned before. On V8, the ocular bandage was removed and replaced 
with new bandage, Steri-strips and shield. He continued on Doxycycline tablets, 25 mgs of 
prednisolone tablets. On V9, the ocular bandage was removed. The vision was not recorded 
on that visit. The patient had mild burning sensation and photophobia but no pain. He was 
asked to stop doxycycline, taper Prednisolone to 12.5 mgs and to start dexafree eye drops 
TID. There were no adverse events. On V10, the vision was counting fingers. On 
examination, he had marked limbal and conjunctival hyperaemia with an epithelial defect (> 
2mm) (Figure 5.2). He had a deep central corneal opacity. The anterior chamber was deep 
and quite. He was prescribed levofloxacin 5mg/ml eye drops QID. Dexafree eye drops were 
tapered by 1 drop every week. He was seen two weeks later. His vision was still counting 
fingers and he had moderate pain and photophobia. The epithelial defect was much larger 
and was involving the centre of the cornea (Figure 5.3). A bandage contact lens (BCL) was 
inserted and Celluvisc 0.5% eye drops QID were prescribed in addition to the levofloxacin 
eye drops that he was using. It was decided that the patient should be withdrawn from the 
trial and the epithelial defect was reported to Chiesi as a serious advert event. He was listed 
for penetrating keratoplasty with autolimbal stem cell transplant. The patient had a 
persistent epithelial defect for 5 months despite eyelid taping with Steri-strips so a decision 
was took to list him for Omnigen transplant. During these 5 months he was on levofloxacin 
preservative free eye drops QID, predsol preservative free eye drops 0.5% and Visuxl 6 times 
per day. The Omnigen was transplanted on 20th June 2018 and sutured. A BCL was inserted. 
Gradually over 3 months, the eye became more comfortable. During that time the patient 
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was seen frequently and the BCL was replaced until the epithelial defect healed completely 
(Figure 5.4). The final vision was hand movement and there were superficial NV in all 
quadrants involving the corneal centre. The patient is currently on the waiting list for 




Figure 5.1: Slit lamp anterior segment photographs of Case 1 on V1. 
 




Figure 5.2: Cobalt blue filter image with fluorescein sodium 2% eye drops of Case 1 on V10. 
 




Figure 5.3: Cobalt blue filter image with fluorescein sodium 2% eye drops of Case 1 2 weeks after V10. 
 
Enlargement of epithelial defect to involve the central cornea. 
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Figure 5.4: Slit lamp anterior segment photographs of Case 1 9 months on V1. 
 





Case two (82602-02) 
 
This patient was a 27 year old lady who was recruited on the 8th of March 2017 for 
treatment of the left eye. She had dense fibrovascular pannus involving the central cornea 
due to an assault chemical injury in 2011. The 4 quadrants of the cornea were invaded with 
superficial corneal NV and they extended to the central cornea (Figure 5.5). The visual acuity 
was hand movement. She had normal ocular pressure in both eyes throughout the study 
(range from 12-15 mmHg). The anterior chamber was always visible and it was always deep 
with no cells or abnormal contents. Schirmer test type I was 10 mm on V1 and dropped to 
6mm on V14. She had corneal anaesthesia which was assessed using a cotton tip. On V1, the 
patient had moderate photophobia but no pain or burning sensation. Her physical 
examination and vital signs were always normal and she was not on any concomitant 
medications and had no history of any medical conditions. Her infectious assessment was 
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always normal apart from high levels of anti-HBs and positive values for HBc IgG Ab for 
hepatitis B virus which was due to previous hepatitis B vaccination with booster doses. Her 
pregnancy test was always negative. The biopsy was done on the 30th of May 2017. The 
biopsy was taken from the superior limbus of the right eye. The biopsy was placed in a 
sterile tube containing the transport medium. The standard operating procedures were 
followed carefully and the biopsy was shipped on the same day to Holostem. The patient 
was prescribed preservative-free levofloxacin eye drops, three times per day for 1 week. 
Conjunctiva was closed using 2 sutures which were removed after the biopsy procedure. 
The wound was healing well underneath. There were no adverse events. The holoclar 
implant was performed on the 7th of February 2018. Holoclar was delivered on the same day 
to the hospital inside a sterile, plastic Petri dish which was placed in a secondary container 
that was only removed in the operating theatre. The surgery was done under general 
anaesthesia. The surgery was successful and Holocolar was in place. The patient was started 
on the treatment as per protocol. On V8, the ocular bandage was removed and replaced 
with new bandage, Steri-strips and shield. The patient had moderate limbal and bulbar 
hyperaemia. She continued on Doxycycline tablets, 25 mgs of prednisolone tablets and 
tapering doses of dexafree eye drops. On V9, the ocular bandage was removed. The patient 
had no burning, no pain and no photophobia. The vision was hand movement. On 
examination, there were intra-corneal haemorrhages, congested conjunctiva with chemosis 
and superficial corneal NV. There were no epithelial defects. She was asked to stop 
doxycycline, taper Prednisolone to 12.5 mgs and to start dexafree eye drops TID. There  
were no adverse events. On V10, the patient reported that she has noted a remarkable 
improvement of vision since she last had the chemical injury. Her vision was 3/60 on Snellen 
chart (+1.30 logMAR). On examination, there was less limbal and conjunctival hyperaemia 
compared to V8 and V9. There was also less superficial corneal NV in all 4 quadrants, 
corneal opacification and less intracorneal haemorrhage (Figure 5.6). There were no 
epithelial defects. She was asked to stop the Prednisolone tablets and to continue tapering 
the dexafree eye drops for 2 more weeks. On V11, the patient had marked limbal and bulbar 
hyperaemia. There were more superficial NV superiorly, temporally and inferiorly and a 
nasal conjunctival encroachment on the cornea, but no epithelial defects (Figure 5.7). She 
was prescribed dexafree 1mg/ml eye drops QID. We saw her after 2 weeks. There was 
remarkable partial regression of the superficial NV in the superior and temporal quadrants 
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as well as regression of the nasal conjunctival growth. The inferior vessels regressed 
completely. There was also less bulbar and limbal hyperaemia (Figure 5.8). The dexafree 
drops were tapered to bid. On V12, there were very fine vessels superiorly and temporally 
and the nasal vessels were inactive and stable (Figure 5.9). On V13 and V14, the patient had 
stable inactive NV in 3 quadrants with no epithelial defects. The case was considered a 
success as she had no epithelial defects at any visits after the implant (V6) and mild degree 
of superficial NV at the end of the study (V14). She has been added to the waiting list for a 




Figure 5.5: Slit-lamp anterior segment photograph of Case 2 at V1. 
 
Fibrovascular pannus with superficial NV in all four quadrants and central corneal opacity. 
123  
 
Figure 5.6: Slit-lamp anterior segment photograph of Case 2 at V10. 
 
Intracorneal haemorrhages and superficial NV. 
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Figure 5.7: Slit-lamp anterior segment photograph of Case 2 at V11. 
 
Limbal and bulbar hyperaemia with marked superficial NV in superior, inferior and temporal 




Figure 5.8: Slit-lamp anterior segment photograph of Case 2 two weeks after V11. 
 
Less limbal and conjunctival hyperaemia compared to Figure 5.3 (V11). Less active vessels nasally. 
Inferior vessels regressed. 
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Figure 5.9: Slit-lamp anterior segment photograph of Case 2 at V12. 
 






We recruited 2 patients as part of the Holocore study. Case 2 was a success and case 1 was 
considered a failure as it did not achieve the outcomes of the study which were the 
reduction of the degree of superficial corneal neovascularisation and absence of epithelial 
defects. Case 1 is currently on the waiting list for penetrating keratoplasty and autolimbal 
stem cell transplant. We could not ascertain the reason for the failure as the patient had no 
underlying systemic or local causes such as blepharitis, lid malposition, infections, blinking 
or exposure problems that could explain the failure of the implant. Another study centre 
reported a similar case where the patient suffered from persistent epithelial defect in 
addition to corneal melting and the development of a descemetocele and they attributed 
this to the Holoclar implant. Case 2 is on the waiting list for penetrating keratoplasty as she 
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had residual central deep corneal opacity. Recently, NICE has approved Holoclar as an 
option in people with moderate to severe limbal stem cell deficiency after eye burns, only if 
it is used to treat 1 eye and people have already had a conjunctival limbal autograft or if 
there is not enough tissue for a conjunctival limbal autograft. 
Scholz et al (406), evaluated the visual acuity and graft success in 34 eyes with LSCD due to 
chemical and thermal burns using autologous transplantation of ex vivo on human aminiotic 
membrane -cultured and expanded limbus epithelium. They reported stable corneal surface 
in 75.4% of the eyes. Visual acuity increased significantly in 40 (65.6%) eyes, was stable in 
19.7% of the eyes and decreased in 14.8% of the eyes. They considered this method to be 
safe and successful on the long term. Shimazaki et al (407) transplanted cultivated human 
limbal epithelium on aminiotic membrane for 13 eyes with severe LSCD and achieved 
corneal epithelialisation in 46.2% of the eyes. 
Two long-term studies have been published about simple limbal epithelial transplantation 
(SLET). A study by Basu et al (408) reported long-term clinical outcomes of autologous SLET 
on a population of 125 patients suffering from unilateral LSCD. Seventy-six percent of eyes 
maintained a successful outcome with survival probability of 80% after 1 year. Progressive 
corneal conjunctivalization was recorded in 18.4% of the eyes in this study. 
Another retrospective, multicentre study with 6-month follow-up on 68 eyes showed the 
success of SLET in 83.8% of the cases with survival probability greater than 80% after 1 year 
(409). 
The main limitation of HOLOCORE is the method of assessment of the severity of LSCD 
which was based on only the extent of corneal neovascularization and corneal opacity. 
There was no impression cytology or IVCM performed to assess the quality of epithelium 
on the corneal surface.  
Further trials need to be conducted to compare the results of Holoclar and other exvivo 
methods for expansion of limbus derived cells with regards to efficacy and safety. 
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CHAPTER 6: CORRELATION BETWEEN DIABETIC CORNEAL 





The prevalence of diabetes mellitus (DM) has continued to increase across the world. As at 
2013, 382 million people have diabetes worldwide (410). Type 2 DM makes up about 90% 
of the cases. This equated to 8.3% of the adult population with equal rates in women and 
men (411). Diabetes can affect any ocular tissue. Diabetic retinopathy (DR) is the 
commonest complication of diabetes (412) and meets the World Health Organization 
(WHO) criteria of suitability for screening (413). It is the most significant ocular 
complication of diabetes and is a major cause of vision loss worldwide (318). Approximately 
one third of people with diabetes have DR, and a third of the DR patients may have sight- 
threatening DR, defined as proliferative diabetic retinopathy (PDR) or clinically significant 
macular oedema (DMO) (318). The natural history of DR is relatively well understood, with 
recognizable stages. Major risk factors for developing DR include duration of diabetes (414, 
415), severity of hyperglycaemia (416, 417), hypertension (418) and dyslipidaemia (419). 
Once sight-threatening DR is present, progression is the norm and complications are 
unpredictable. Twenty years after diagnosis, almost all people with Type 1 DM and 60% of 
people with Type 2 DM will have some degree of diabetic DR (414, 415). Recently, diabetic 
retinal neurodegeneration (DRN) has been described, where progressive neuronal changes 
occur in the inner retina before or in the absence of clinically visible microvascular 
abnormalities (318, 420-422) and may contribute to DR (421, 423-425). OCT studies of 
diabetic retinal neuropathy (in eyes without DR) have been reported by several 
investigators (426-430). 
 
Other ocular complications including keratopathy, glaucoma and cataracts may be 
associated with diabetes (431). The diabetic cornea suffers from cellular dysfunction and 
dysfunctional repair mechanisms, which manifests as recurrent erosions, delayed wound 
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healing ulcers, and oedema. In addition and undoubtedly related to epithelial dysfunction, 
alterations in epithelial basement membrane occur. 
 
More recently, diabetic corneal neuropathy, has been reported as resulting in loss of 
corneal sensation and innervations (432-435) which may be related to corneal epithelial 
defects. Progressive reduction in corneal sensitivity and increasing corneal nerve 
degeneration has been linked with, and may occur before diabetic neuropathy elsewhere 
in the body (433). In-vivo confocal microscopy (IVCM) (a rapid and non-invasive new tool 
to examine sub-epithelial and stromal corneal nerves) has demonstrated a decrease in 
nerve fibre bundles (436), nerve beadings, and nerve branching patterns as well as an 
increase in nerve fibre tortuosity (437), and abnormal stromal nerves (438) in diabetic 
patients. 
 
Some studies have shown the involvement of corneal sub-basal nerve plexus in diabetes 
and their marked reduction with increasing severity of DR and neuropathy using IVCM (436, 
439). These studies also showed alterations in basal epithelial cell density in different 
retinopathy stages, and demonstrated that reduced density in basal epithelial cell is 
correlated with changes in innervations (436). 
 
A few studies have reported on the effect of laser photocoagulation on sub-basal nerve 
plexus in patients with diabetic retinopathy (440, 441). Anti-vascular endothelial growth 
factor (anti-VEGF) drugs have been introduced as treatments for diabetic macular oedema 
(DMO) (442-444). It is known that VEGF is neuroprotective (445, 446). It is, therefore, 
theoretically possible that intraocular innervation may be affected by multiple intravitreal 
injections of anti-VEGFs. In addition, a few studies have reported on the effect of anti-VEGF 
on corneal nerves in humans and animals (447-450). 
 
However, to date, the author is unaware of any studies that have evaluated corneal 
innervation following anti-VEGF therapy in a large number of diabetic eyes at different 
stages of DR. There is a further paucity of data on how the corneal nerve parameters in 







6.2.1 Ethical issues 
 
The study was conducted in accordance to the Declaration of Helsinki (Version 5, 2000). 
The study proposal with the relevant forms and documents were approved by the 
Nottingham Research Ethics Service Committee II, the Health Research Authority HRA and 
local NHS (Nottingham University Hospitals [NUH] NHS Trust) Research and Innovation 
authorities (REC reference Number: 15/SW/0186). 
The ethical approval application process involved the submission of the project proposal 
and completed IRAS form to all parties (Research Ethics Committee, NUH NHS trust R&I 
and HRA), the ethics committee reviewed the application on 6th July 2015 and was 
approved on 11th August 2015. One substantial amendment was applied for and was 
approved. The first patient was recruited on 23rd June 2016. 
6.2.2 Patient recruitment 
 
This single centre prospective longitudinal study included the identification of 86 patients. 
The non-diabetic and diabetic patients with type 1 and 2 were recruited from eye clinics at 
Queen’s Medical Centre, NUH Trust, Nottingham. 
 
 
Participants were recruited from specialist macula clinics, diabetic clinics and diabetic 
screening clinics at the Queen’s Medical Centre, NUH Trust, Nottingham under the 
supervision of Mr Winfried Amoaku (Consultant Ophthalmologist). Based on the diagnostic 
criteria and stage classification of DR, the patients were divided into the following 5 groups: 
Non-diabetic patients (control), diabetic patients with no diabetic retinopathy (DR), Non-
proliferative DR (NPDR) and Proliferative DR (PDR) patients including those who have and 
have not received Anti-VEGF injections and/or retinal laser photocoagulation. Twenty- 
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three patients were recruited into the control group, 24 patients in the group of diabetic 
patients with no DR, 27 patients in the NPDR group, and 12 patients in the PDR group. 
 
 
Control group inclusion criteria: 
- Patients over the age of 18 
-Patients with no diabetes 
-Able to consent 
 
 
Control group exclusion criteria: 
-Patients under age of 18 
-Patients unable or unwilling to provide informed consent 
-Any other known cause of neuropathy e.g. herpes keratitis 
-History of corneal trauma or surgery 
-Contact lens wearers 
 
 
Diabetic groups inclusion criteria: 
-Patients over the age of 18 
-Patients with type 1 or type 2 diabetes 
-Patients who have received retinal laser photocoagulation or intravitreal injections 
- Able to consent 
 
 
Diabetic group exclusion criteria: 
-Patients under age of 18 
-Patients unable or unwilling to provide informed consent 
-Any other known cause of neuropathy e.g. herpes keratitis 
-History of corneal trauma or surgery 
-Contact lens wearers 
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6.2.3 Clinical intervention and follow up 
 
Each participant attended one research session. All participants and groups had identical 
processes and procedures. A full ophthalmological examination was undertaken for all 
patients. 
Relevant ophthalmic history was obtained. Information was collected on diabetes duration, 
hypertension state, renal problems and smoking. Visual acuity with glasses and pinhole (best 
habitual) was measured using ETDRS LogMAR charts (for both literate and illiterate) followed 
by assessment of pupil reaction. Corneal sensitivity was assessed with Cochet Bonnet 
esthesiometer (Luneau, Paris, France) was used to assess the sensation of the corneal nerves. 
A 0.08-mm monofilament was used to gently touch the inferior portion of the cornea in the 
vertical direction. The filament length was sequentially reduced in 5-mm steps, starting from 
60 mm, until a positive response (verbal or a blink) occurred. The length of the monofilament 
at the time of response was recorded as the corneal sensitivity threshold and graded on a 
scale from 10 to 60. Anterior segment biomicroscopic examination, intraocular pressure (IOP) 
measurement with the Goldmann applanation tonometer, and fundal examination after pupil 
dilatation were performed. 
Retinal stereo photographs were obtained in 4 ETDRS fields using the Topcon TRC 50IA 
camera. DR severity was based on clinical examination and the colour photographic grading 
by trained ophthalmologists according to the International DR Classification (modified from 
ETDRS classification). Corneal nerves were examined and quantified by in IVCM in all patients 
(with the Heidelberg Retina Tomogram II-Rostock Cornea Module; HRTII-RCM; Heidelberg 
Engineering GmbH, Heidelberg, Germany). This is a laser scanning confocal microscope that 
uses a class I diode laser (670-nm wavelength) with a 63× water-immersion lens. IVCM was 
performed under topical anaesthesia with Guttae Proxymetacaine 0.5% (B&L, UK). A digital 
camera mounted on a side arm furnished a lateral view of the eye and objective lens to 
monitor the position of the objective lens on the surface of the eye. A drop of polyacrylic gel 
(Carbomer 0.2% eye gel, Blumont, UK) was used as coupling medium between the contact 
cap and objective lens of the microscope. 
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The IVCM images were then analyzed on a special software for analyzing corneal nerves (Image J, LOCI, 
University of Wisconsin). This software measures 4 main parameters for corneal nerves which are nerve 
fibre density and that is defined as the number of main nerves per frame, the nerve branch density which 
is the number of main branches per frame, the nerve fibre length which is the total length of all nerves 
per frame and the nerve fibre tortuosity which is the main nerves per frame.  
Three IVCM frames (the clearest images) were selected from among hundreds of scans for 
each eye. To analyze the image, the parameter that needs to be measure was selected from the 
metric box on the software. The density and length of the sub-basal nerves in each of the three 
frames was measured the using the tracing in analysis tool. The average was calculated and 
so for each eye two values were calculated: the density and length of sub-basal nerves in that 
eye. 
Patients were provided with contact numbers for investigators for any queries, and access 
the 24 hour on call emergency eye service, during the study period. 
 
Figure 6.1: IVCM image of a left eye of a patient showing sub-basal corneal nerves (depth 167 microns) of 





Figure 6.2: IVCM image of a left eye of a patient showing sub-basal corneal nerves (depth 62 microns) of 
reduced length and density. 
6.2.4 Outcome measurements 
 
The outcome measure was to detect and grade the changes in corneal nerves in correlation 
with different stages of diabetic retinopathy. 
Data will be captured using Microsoft Office Access and cleaned using Excel. Analysis will be 
done using statistical package for social sciences (SPSS Version 24.0.). Continuous numerical 
data will be presented as Mean and Standard deviation (SD) and categorical data as 
percentages (%). 
6.2.5 Statistics and data analysis 
 
Statistical analysis was performed with SPSS software version 24.0 (SPSS Inc, Chicago, 
Illinois, USA). The statistical analysis was carried out on corneal nerve parameter (length and 
density) between the control group, NPDR, PDR and diabetics with no retinopathy groups. 
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Normality of the data was tested between the different groups using the non-parametric 
test Kolmogorov-Smirnov as the groups were not age and co-morbidity matched. The non- 
parametric Mann-Whitney test and Kruskal-Wallis test were subsequently used to 
determine differences in corneal nerve parameters between the different groups. 







6.3.1 Recruitment and Cases 
 
A total of 86 patients were recruited into this study. Of the 86 patients, 35 were females and 





Table 6.1 Demographics of study participants 
 














Sex (F, M) 7, 16 13, 11 10, 17 5, 7 
Diabetes 
Type 
N/A 23 type 2 
1 type 1 
25 type 1 
2 type 2 
8 type1 











Smoker 0 2 1 0 
HTN 0 10 7 4 
Renal 
problems 
0 1 2 2 
 
 
A) Combining both eyes in each group: 
 
 
Data from both eyes for each patient were combined for analysis of nerve length and 
density parameters for the control, NPDR, PDR and diabetics with no diabetic retinopathy as 
there was no statistically significant difference between nerve length and density between 2 
in all of the above mentioned groups. Tables 6.2-6.9 show the significance level of each of 
the above mentioned groups. Mann- Whitney test was used for all groups. 
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Table 6.2: p-value of statistical test for combining nerve length and nerve density for both eyes in in Control, NPDR, PDR and 





Null Hypothesis  Significance Decision 
Combining both eyes in nerve length of 
control group (same across all categories 
of eyes) 
.783 Retain the null hypothesis 
Combining both eyes in nerve density of 
control group  
.767 Retain the null hypothesis 
Combining both eyes in nerve length of 
NPDR group 
.406 Retain the null hypothesis 
Combining both eyes in nerve density of 
NPDR group 
.356 Retain the null hypothesis 
Combining both eyes in nerve length for 
PDR group 
.321 Retain the null hypothesis 
Combining both eyes in nerve density of 
PDR group 
.314 Retain the null hypothesis 
Combining both eyes in nerve length of 
diabetics with no retinopathy group  
.918 Retain the null hypothesis 
Combining both eyes in nerve density of 
diabetics with no retinopathy group 
.869 Retain the null hypothesis 
 




Group  Normal distribution 
NPDR group nerve length Not normally distributed 
Control group nerve length Normally distributed 
PDR group nerve length Normally distributed 
Diabetics with no retinopathy group nerve length Not normally distributed 
NPDR group nerve density Normally distributed 
Control group nerve density Normally distributed 
PDR group nerve density Normally distributed 








B) Comparing different groups: 
 Table 6.4: p-value of statistical test for comparing  nerve length and nerve density  in Control, NPDR, PDR and diabetics 
with no retinopathy groups 
 
 
C) The effect of laser and intravitreal injection on nerve length and density in NPDR and PDR 
groups: 
 





Non-parametric Mann- Whitney test was applied to compare the nerve length of laser/ non- 
laser NPDR groups. The p-value = 0.41. Therefore, laser treatment had no significant effect 





Group Test used p-value Significance 
Control vs NPDR nerve 
length 
Mann-Whitney 0.007 Significantly different 
Control vs NPDR nerve 
density 
Mann-Whitney <0.001 Significantly different 
Control vs PDR nerve 
length 
Mann-Whitney <0.0001 Significantly different 
Control vs PDR nerve 
density 
Mann-Whitney <0.0001 Significantly different 
NPDR vs diabetics with no 
retinopathy nerve length 
Mann-Whitney 0.84 No significant difference 
NPDR vs diabetics with no 
retinopathy nerve length 
Mann-Whitney 0.84 No significant difference 
PDR vs diabetics with no 
retinopathy nerve length 
Kruskal-Wallis 0.020 No significant difference 
PDR vs diabetics with no 
retinopathy nerve density 
Kruskal-Wallis 0.019 No significant difference 
NPDR vs PDR nerve length Kruskal-Wallis 0.048 No significant difference 




Figure 6.3: Box plot showing insignificant difference in nerve length between NPDR eyes that did not 
receive laser treatment and NPDR eyes that received laser treatment. 0:group that did not receive laser, 1: 
group that received laser.  
 
 
2. Focal and macular grid laser has effect on NPDR-density (no/mm2) (No) both eyes 
considered combined 
 
Non-parametric Mann-Whitney test was applied to compare the nerve density of laser/ non- 
laser NPDR groups. The p-value = 0.36. Therefore, laser treatment had no significant effect on 




Figure 6.4: Box plot showing insignificant difference in nerve density between NPDR eyes that did not 
receive laser treatment and NPDR eyes have received laser treatment. 0: group that did not receive laser, 1: 






3. Anti-VEGF Injection has effect on NPDR-length (mm/mm2) (yes) both eyes considered combined 
 
Non-parametric Mann-Whitney test was applied to compare the nerve length of injection/ 
non-injection NPDR groups. The p-value = 0.046. Therefore, anti-VEGF injections had a 






Figure 6.5: Box plot showing significant difference in nerve length between NPDR eyes that did not receive 









4. Anti-VEGF Injection has effect on NPDR-density (no/mm2) (yes) both eyes 
considered combined 
Non-parametric Mann-Whitney test was applied to compare the nerve density of injection/ 
non-injection NPDR groups. The p-value = 0.016. Therefore, anti-VEGF injections had a 
significant effect on the nerve density in the NPDR group (Figure 6.4). 
 
 
Figure 6.6: Box plot showing significant difference in nerve density between NPDR eyes that did not receive 
injections and NPDR eyes that received injections. 0:group that did not receive injections, 1: group that 





5. PASCAL laser has effect on PDR-length (mm/mm2) (No) both eyes considered combined 
 
Non-parametric Mann-Whitney test was applied to compare the nerve density of laser/ non- 
laser PDR groups. The p-value = 0.32. Therefore, laser treatment had no significant effect on 




Figure 6.7: Box plot showing insignificant difference in nerve length between NDR eyes that did not receive 
laser treatment and NPDR eyes that received laser treatment. 0:group that did not receive laser, 1: group 





6. PASCAL laser has effect on PDR-density (no/mm2) (No) both eyes considered combined 
 
Non-parametric Mann-Whitney test was applied to compare the nerve density of laser/ non- 
laser PDR groups. The p-value = 0.22. Therefore, laser treatment had no significant effect on 







Figure 6.8: Box plot showing insignificant difference in nerve density between PDR eyes that did not receive 




7. Anti-VEGF Injection has effect on PDR-length (mm/mm2) (No) both eyes considered combined 
 
Non-parametric test Mann-Whitney test was applied to compare the nerve length of 
injection/ non-injection PDR groups. The p-value = 0.26. Therefore, anti-VEGF injections had 




Figure 6.9: Box plot showing insignificant difference in nerve length between PDR eyes that did not receive 
injections and PDR eyes that received injections. 0:group that did not receive injections, 1: group that 





8. Anti-VEGF Injection has effect on PDR-density (no/mm2) (No) both eyes considered combined 
 
Non-parametric Mann-Whitney test was applied to compare the nerve length of injection/ 
non-injection PDR groups. The p-value = 0.22. Therefore, anti-VEGF injections had no 






Figure 6.10: Box plot showing insignificant difference in nerve density between PDR eyes that did not 
receive injections and PDR eyes that received injections. 0:group that did not receive injections, 1: group 





The results of the study are summarised in Table 6.10. The length and density of fibres of 
the sub-basal nerve plexus are significantly lower in the NPDR and PDR groups compared to 
the control group. There was no significant difference between the nerve length and density 
in the NPDR and diabetic patients with no retinopathy groups. The nerve length and density 
of the diabetic patients with no retinopathy group are significantly lower than those of the 
PDR group. The nerve length and density of the NPDR group were significantly lower than 
those in the PDR group. 
 
The PASCAL laser treatment had no significant effect on the corneal nerve length and 
density in both the NPDR and PDR groups. Anti-VEGF treatment had a significant reduction 
of corneal nerve length and density of the NPDR group but not the PDR group. 
 
 
Aflibercept and ranibizumab were the anti-VEGF drugs used in the current study. The 
average number of intravitreal injections of anti-VEGF in NPDR group was 4.3, and 2.8 in the 
PDR eyes group. 
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Table 6.4: Features of the sub-basal plexus nerves in the study participants and corneal nerve sensitivity 
 
Parameters Length (mm) Density (mm/mm2) Corneal 
sensitivity 
Control Mean +/- SD: 
2.278+/- 0.89 
Range: 0.8- 4.2 




NPDR Mean +/- SD: 
1.5802+/-0.71 
Range: 0.2- 3.4 
Mean: 10.245+/- 4.38 
Range: 1.2- 21.5 
Mean: 55.4 
Range: 25-60 
PDR Mean: 1.241+/-0.65 
Range: 0.5- 2.7 
Mean: 7.745+/- 3.40 
Range: 2.9- 16.1 
Mean: 50 
Range: 25-60 
Diabetics with no 
retinopathy 
Mean: 1.635+/- 0.70 
Range: 0.6- 3.1 
Mean: 10.185+/- 4.24 













Confocal microscopy is a non- invasive method for quantifying corneal nerve length and 
density. Studies have shown that there is a marked reduction of the sub-basal plexus nerve 
density in patients with DR which increased with the increasing severity of DR as well as 
decreased corneal sensitivity (435, 436, 439, 451). The results from this study showed a 
significant difference between the sub-basal plexus nerve length and density in diabetic 
eyes with different stages of retinopathy compared to control eyes, and support findings 
from previous studies. Similarly, there were differences in corneal nerve parameters 
between NPDR eyes when compared to PDR eyes, and PDR eyes when compared to diabetic 
eyes with no retinopathy. However, there was no significant difference in corneal nerve 
parameters between the NPDR eyes and eyes of diabetics with no retinopathy. These 
findings suggest that neuronal changes in the cornea precede the development of clinical 
DR, and may coincide with development of retinal neuropathy as previously described (318, 
420-422). 
  
Nerve branching is one of the parameters measured in some previous studies, but was found 
to be unpredictable as nerve fibre branches were sometimes difficult to grade, as for 
 
example, a single nerve branch could be easily interpreted as two fibres without branches 
(441). Tortuosity was another measurement used in some studies but the subjective (438, 
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440) and objective grading methods (452, 453) that have been used for quantification were 
not repeatable or comparable. For these reasons, the sub-basal nerve length and density 
were thought to be the most accurate parameters to compare between the different groups 
in this study. 
The results from this study have shown that PASCAL laser treatment, whether focal, macular 
grid or PRP did not lead to significant changes in the length and density of the sub-basal 
corneal nerve plexus in NPDR and PDR eyes. Misra et al (441), reported the same as they 
found no significant difference in nerve density between 19 PDR eyes that had no PRP 
compared to 19 PDR eyes that had PRP. They did not specify the type of laser equipment 
that was used. They suggested that the decreased nerve density found in their study was 
due to diabetes rather than the laser treatment. 
De cilla et al (440) recruited 50 patients with DR and 50 normal control subjects. They studied 
the effect of argon laser PRP on the corneal sub-basal nerve plexus of 14 patients with PDR 
who had argon laser and compared them to 13 patients who had PDR but did not receive any 
laser treatment. They used IVCM to quantify the number of nerves, tortuosity and fibre 
reflectivity. Contrary to results from this study, they reported significant reduction of sub- 
basal nerve plexus number in the laser treated group compared to the non-treated group. 
Similar to results from the present study, they reported significant differences between the 
PDR and NPDR eyes  and diabetic eyes  (NPDR and  PDR)  when  compared to normal control 
  
eyes. The results from the present study might be different from those from De Cilla et. al. as 
the PASCAL laser was used in the present study (Synthesis 577 nm, Topcon, Essebaan, 
Netherlands) which is a frequency-doubled (Nd:YAG) solid-state laser rather than argon. The 
number of laser burns might be another factor of difference. The other possible reason might 
 
be that De Cilla et. al. study included patients who had previous cataract surgery which is known to 
have damaging effect on corneal nerves. Schiodte et al (454) suggested that the argon laser 
might be causing damage to the short ciliary nerves as they cross the suprachoroidal space 
having left the ciliary ganglion on their way to the ciliary body and iris. However, corneal 
innervation is generally derived from the long ciliary nerves, rather than the short ciliaries. 
In this study, the corneal sensitivity worsened with the increasing severity of the diabetic 
retinopathy. 
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VEGF was reported to be an essential player in nerve growth. VEGF and its receptor are 
expressed by neurons and they are responsible for promoting neurotrophic and 
neuroprotective activities (445, 455, 456). These activities include protection of neurons 
from hypoxia-induced death, expansion of cortical neurones and stimulation of outgrowth 
of axons in peripheral neurons (457). One study reported that systemic inhibition of VEGF 
with bevacizumab may cause apoptosis in retinal neurons (458). 
Studies were carried out to investigate the influence of VEGF on promoting corneal nerve 
regeneration and repair. VEGF was found to have established trophic effects on nerve 
growth including studies of neurite outgrowth of trigeminal ganglion cultures (455, 459- 
463). Li et al, investigated the contribution of acute inflammation to sensory nerve 
regeneration in the murine cornea using a model of corneal abrasion that removes the 
stratified epithelium and sub-basal nerve plexus (464). Their results showed that VEGF is 
necessary for efficient corneal nerve repair following epithelial abrasion. 
Results from this study showed that anti-VEGF injections have an effect on the sub-basal 
nerve plexus length and density in eyes with NPDR. This effect may be due to the role that 
VEGF plays in nerve growth. The non-significant corneal nerve changes in eyes with PDR 
maybe that the decreased nerve density and length are due to the effect of the long- 
standing diabetes rather than the injections. Another possibility is that the average number 
of injections in the NPDR was greater than in PDR eyes. Goldhardt et al (450) carried out a 
retrospective study and compared between eyes in 39 patients who had anti-VEGF in one 
eye only and the fellow eye. They also compared corneal nerve parameters between 50 
eyes of 50 individuals who had anti-VEGF and 80 individuals with no history of injections. 
That study only included 8 diabetic patients among the 89 patients; the other cases included 
 
retinal vein occlusion, wet age-related macular degeneration and other mixed aetiologies and  
did not specify the degree of retinopathy in the 8 diabetic patients. They reported 
reduced corneal nerve length and density in all eyes that received injections regardless of 
the indication for the injection. 
 
Bock et al (447) used bevacizumab eye drops to treat corneal neovascularisation in murine 
corneas. They measured the corneal nerve density following treatment with the drops.The findings 
showed that the nerves were not affected by the treatment and this may imply Anti-VEGf drops might 
be a safer option than injections . 
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However, a direct comparison in a randomised study will be required for confirmation of the 
hypothesis. 
The current study was prospective, and showed that PASCAL is a safe modality of treatment 
for patients who need focal, macular grid or PRP laser treatment. It also shows that anti-VEGF 
injections might be implicated in the damage of corneal nerves seen in diabetic eyes especially 
at the NPDR stage. In eyes with PDR, it is most probable that the long-standing diabetes rather 
than the laser treatment or anti-VEGF injections are responsible for reduced corneal nerve 
parameters. However, higher numbers of anti-VEGF injections might play role in the extent of 




CHAPTER 7: SUMMARY AND CONCLUSIONS 
 
Ocular neovascularisation is an important feature in the pathophysiology of many vision- 
threatening conditions including corneal vascularisation and diabetic retinopathy. 
The cornea is the transparent part of the eye and is responsible for the majority of its 
refractive power. The cornea is normally an avascular structure, but may vascularize in 
situations in which a disequilibrium between angiogenic and antiangiogenic stimuli occurs. 
Such vascularisation leads to oedema, further inflammation and eventually scar formation 
resulting in severe visual impairment if uncontrolled. Vascularisation is the single most 
important risk for corneal graft rejection. Treatments for corneal vascularisation have been 
ineffective to date. 
Treatments for corneal vascularisation (NV) have been ineffective to date. As part of this 
project, fifteen patients with corneal vascularisation resulting from different pathologies who 
had fine needle diathermy (FND) only, subconjunctival injection of bevacizumab (Avastin, 
Roche) only, or a combination of both modalities were studied. The corneal vessels were 
graded using the scoring system published by Faraj et al at Queens Medical Centre, 
Nottingham University hospitals. The study results showed that the only statistically 
significant method of reduction of corneal NV was the combined FND and bevacizumab 
injections. This is most probably due to the fact that FND induces trauma which stimulates 
the release of vascular endothelial growth factor (VEGF). Anti-VEGF injections are thus 
required to block these factors and prevent further NV formation following FND. Both FND 
and bevacizumab injections had no significant complications. A randomised control trial with 
a larger number of patients is required to establish this combined method of treatment as the 
number one option for managing corneal NV especially in patients with NV undergoing 
keratoplasty. 
In another study (HOLOCORE), Holoclar - a sheet of autologous cultivated limbal stem cells 
was used to treat patients with moderate to severe limbal stem cell deficiency complicated 
by deep and superficial corneal vascularisation. This work was part of a global multi-centre 
study. Two patients with unilateral chemical burns with moderate corneal vascularisation 
150  
were recruited from Nottingham. One patient failed with treatment in HOLOCORE, and had 
persistent epithelial defect which was managed with aminiotic membrane transplant. The 
reason of the failure was not clear but could have been related to the age of the patient, the 
condition of the cornea and conjunctiva or the corneal nerves status after the chemical burn. 
The other chemical burn case successfully treated and was listed for a penetrating 
keratoplasty due to residual deep central corneal scar. There are other studies which have 
used autologous transplantation of ex vivo cultivated cells on human aminiotic membrane 
and simple limbal epithelial transplantation (SLET), which reported safe and successful 
outcomes in the majority of the cases on the long term (406-409). NICE has approved Holoclar 
as an option but only if it is used to treat 1 eye in a patient who have already had a conjunctival 
limbal autograft or if there is not enough tissue in the healthy eye for a conjunctival limbal 
autograft. Further trials need to be conducted to compare the results of Holoclar and other 
ex vivo methods for expansion of limbus derived cells with regards to efficacy and safety. 
Pterygium is a potentially sight threatening condition and is composed of wing shaped fleshy 
fibrous and vascular tissue that grows towards the cornea. Two studies were carried to 
investigate the medical management and healing of primary and recurrent pterygium. In the 
first study (REPEAT), 20 patients with primary and recurrent were recruited and treated with 
combined subconjunctival injections of 5 fluorouracil (5FU) and Avastin. Tissue was obtained 
by surgical excision of primary pterygium from 4 eyes who received injections and 3 eyes with 
primary pterygium who did not receive injections (control) and subjected to 
immunohistological examination for beta fibroblast growth factor (bFGF), vascular 
endothelial growth factor (VEGF), epidermal growth factor (EGF), von-Willebrand factor 
(vWF), lymphatic vessel endothelial hyaluronan receptor (LYVE-1) and collagen-I. All of the 
patients had arrest of progression of their pterygia, as well as reduction in the clinical grade, 
thickness and vascularity of the pterygium. This is related to the effect of agents on 
fibroblasts, collagen, and vascular tissues. There was also a reduction of all the above 
mentioned molecules on immunohistochemical study in the injected samples compared to 
the control samples. Fifty six percent of the patients were happy with their eyes being less 
red and irritated and refrained from further surgery. Four patients subsequently decided to 
proceed with surgical excision for cosmetic reasons. Astigmatism was found to be increased 
in 67% of the treated patients which could be related to the retraction of the fibrotic tissue 
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post-injection exerting a greater force on the cornea inducing further deformation. This is the 
first time both 5FU and Avastin were combined to treat pterygia. Other studies that used 
either 5FU or bevacizumab alone (234, 236, 273) concluded that improvements in 
appearance, colour and surface area of pterygium could be safely achieved with their 
regimen. However, Avastin on its own was not very effective to halt progression. The results 
of injecting 5 FU on its own in primary and recurrent pterygia are very similar to the results of 
REPEAT study (234, 282). As such, 5FU on its own might be used in primary or recurrent 
pterygium. However, this study found that intraoperative bleeding was much less in eyes 
treated with the combination regime compared to un-injected eyes. This is most probably 
related to the use of Avastin which reduced vascularity of the membranes. Combined 
intralesional injection of Avastin and 5FU was found to be safe and viable option in the 
management of pterygium on its own or as an adjuvant with surgical excision. Longer follow 
up is needed to ascertain whether this will reduce the recurrence rate following excision. 
In the second study, 32 eyes of 28 patients underwent pterygium surgery for primary and 
recurrent pterygia. The healing of the conjunctival autografts was temporally studied 
following the surgery. The changes that occurred in the autoconjunctival grafts were part of 
the reperfusion injury process which can start as early as 1 day postoperative in the form of 
haemorrhage and swelling of the graft. These changes were evidenced by fluorescein 
angiography which was performed in 5 patients in the study. Harvesting of the free 
conjunctival autograft severs all vascular and lymphatic connections rendering the tissue 
ischaemic. When the conjunctival autograft vessels establish connections with the episcleral 
vessels in the new host bed, blood flows into the ischaemic vessels of the conjunctival 
autograft so they recanalize, swell and leak, giving dramatic clinical features seen in the first 
few postoperative days. Reconnection between the graft and the bed starts during the first 
week. All patients having conjunctival autograft will demonstrate patchy or diffuse 
haemorrhage and swollen grafts due to oedema and/or transudation from the blood vessels 
in the first week. All the grafts remained in place and the conjunctival autograft epithelium 
remained intact in all cases at all time‐points. At 2 months, most of the swelling and 
haemorrhage had resolved but the conjunctival autograft demonstrated under‐perfused 
areas where the vascular network was poor or ill‐defined. Changes were also seen in the 
conjunctival bed surrounding the conjunctival autograft in the form of hyperaemia and 
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scattered haemorrhages. Fibrin glue used to fix the graft, was shown to have an influence on 
the clinical picture seen both in the conjunctival bed and the conjunctival autograft as it 
mechanically interfered with epithelial cell migration which proceeds normally once the glue 
dissolves in 10-14 days. Donor site complications were only seen in 2 eyes in the form of 
telangectasia and pyogenic granuloma. This study showed that reperfusion injury occurs in 
the autoconjunctival graft and is an essential feature of early healing. The changes described 
in the conjunctival autograft should not be confused with conjunctival recurrence of 
pterygium. Patients should be assured that the dramatic clinical picture seen in the early post- 
operative is actually a sign of healing and will steadily decline over time. 
Ocular neovascularisation also includes retinal neovascularisation which can occur as a result 
of diabetic retinopathy (DR). DR is the leading cause of loss of vision in the working age 
population in the developed world,and is fast gaining importance in the low and middle 
income countries. Diabetes affects all ocular tissues, although most significant visual loss 
results from the retinopathy. Clinically, DR is characterized by the formation of 
microaneurysms, exudates in the outer plexiform layer, retinal haemorrhages, cotton wool 
spots and retinal vascular calibre changes in the NPDR stage. Recent evidence indicates that 
diabetic retinal neuropathy is an important consequence of diabetes, which precedes clinical 
DR. Neovascularisation of the retina (PDR) and iris (iris neovascularisation/rubeosis iridis) 
occur at the later stages of DR,and are attributed to retinal ischaemia. Retinal 
neovascularisation may result in bleeding from the fragile vessels leading to pre-retinal and 
vitreous haemorrhage. Further changes may result in fibrous tissue formation and traction 
retinal detachment. The effect of anti-VEGF and PASCAL laser treatment whether in the form 
of panretinal photocoagulation (PRP), focal or macular has not been widely investigated. 
This study on diabetics aimed to show the correlation between DR and retinal neuropathy, 
corneal neuropathy and corneal sensitivity. The study was able to show that the corneal and 
retinal neuropathy precedes the DR (vascular) changes as there was no significant difference 
in the corneal nerve parameters between the non-proliferative diabetic retinopathy eyes 
(NPDR) and eyes of diabetics with no retinopathy, and confirms findings from previous studies 
(318, 420-422). The study, addition, showed that both corneal sensitivity and corneal 
neuropathy worsen as the DR becomes more advanced. The study, further, demonstrated 
that PASCAL laser is a safe option for treating different stages of retinopathy. Anti-VEGF 
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injections were found to be associated some potentially damaging effect especially in NPDR 
eyes rather than PDR eyes, as corneal sensitivity was significantly reduced. On the contrary, 
in eyes with PDR, the corneal neuropathy is most probably due to the long-standing diabetes. 
The number of injections might be another factor. 
The main limitations of this study on diabetic eyes is the inclusion of a small number of eyes 
within the PDR group and the short follow up visits. Furthermore, information from patient 
records on the details of the laser sessions for patients in NPDR and PDR groups were 
incomplete. Further longitudinal studies are needed, with a larger number of PDR eyes and 
with longer follow up on the same patients before and after PRP and anti-VEGF injections. 
This thesis has investigated vascularisation and its modulation in the cornea and retina in 
different eye diseases. Further studies on the different mechanisms and therapies will be 
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